Imaging in neurological and vascular brain diseases (SPECT and SPECT/CT) by Lucena, Filipa et al.
Produced with the kind Support of
Brain Imaging  
A Technologist’s Guide
Publications · Brochures
Fragoso Costa, Pedro (Oldenburg)
Santos, Andrea (Lisbon)
Vidovič, Borut (Munich)
Contributors
Arbizu Lostao, Javier
Barthel, Henryk
Boehm, Torsten
Calapaquí-Terán, Adriana
Delgado-Bolton, Roberto
Garibotto, Valentina
Grmek, Marko
Hackett, Elizabeth
Hoffmann, Karl Titus
Law, Ian
Lucena, Filipa
Morbelli, Silvia
Pagani, Marco 
Payoux, Pierre
Pepe, Giovanna
Peștean, Claudiu
Sabri, Osama
Sočan, Aljaž 
Sousa, Eva
Testanera, Giorgio
Tiepolt, Solveig
van de Giessen, Elsmarieke 
Vaz, Tânia
Werner, Peter
Editors
EA
NM
3
Foreword 4
Introduction 5
Andrea Santos, Pedro Fragoso Costa
Chapter 1 
Anatomy, Physiology and Pathology 6
Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux
Chapter 2
 Tracers for Brain Imaging 12
Aljaz Socan 
Chapter 3 
SPECT and SPECT/CT in Oncological Brain Imaging (*) 26
Elizabeth C. Hackett
Chapter 4 
Imaging in Oncological Brain Diseases: PET/CT 33
Giorgio Testanera and Giovanna Pepe 
Chapter 5 
Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT)  54
Filipa Lucena, Eva Sousa and Tânia F. Vaz
Chapter 6  
Imaging in Neurological and Vascular Brain Diseases (PET/CT)  72
Ian Law, Valentina Garibotto and Marco Pagani
Chapter 7 
PET/CT in Radiotherapy Planning of Brain Tumours  92
Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu 
Chapter 8 
PET/MRI for Brain Imaging 100
Peter Werner , Torsten Boehm, Solveig Tiepolt,  
Henryk Barthel, Karl T. Hoffmann and Osama Sabri 
Chapter 9 
Brain Death 110
Marko Grmek
Chapter 10 
Health Care in Patients with Neurological Disorders 116
Claudiu Peștean 
Imprint 126
(*) Article was written with the kind support  
of and in cooperation with: 
Contents
Pr
in
te
d 
in
 a
cc
or
da
nc
e 
w
ith
 th
e 
Au
st
ria
n 
Ec
o-
La
be
l f
or
 p
rin
te
d 
m
at
te
rs
.
4During the past two decades the European 
Association of Nuclear Medicine (EANM) has 
become a leading institution for research 
and education in all aspects of nuclear med-
icine (NM), including tracer development, 
scanning technology and multimodality and 
hybrid imaging. Within the last 5 years, the 
EANM has followed the “Go Clinical” motto, 
with the intention of advancing the role 
of NM into clinical and research protocols. 
This challenge was accepted by the EANM 
Technologist Committee (TC), which has 
attempted to ensure that technologists’ 
education, research and daily practice have 
a strong clinical impact. This intention is also 
reflected in the decision to dedicate the 
Technologist Guide 2015 to brain imaging.
EANM Technologist guides are developed 
and printed on a yearly basis for presenta-
tion at the EANM Annual Congress. They 
are specifically aimed at NM technologists, 
radiographers and all other healthcare pro-
fessionals working or intending to work in a 
nuclear medicine department. 
After dedicating three books specifically to 
PET/CT, we have focussed on specific clini-
cal fields in which NM has a strong impact 
on clinical procedures, such as myocardial 
perfusion imaging and brain imaging. Brain 
imaging was strongly influenced by the 
PET/CT revolution and is now also a field 
of high interest for radiopharmaceutical 
research, thanks to the development of 
11C tracers, somatostatin analogues and 
amyloid-based tracers, which are rapidly 
becoming standards as diagnostic tools. 
Following its recent development, PET/MRI 
has also found many suitable clinical ap-
plications in brain imaging that have helped 
this new hybrid technique to find a role in 
clinical practice and research protocols.
I would like to thank all those who have 
contributed to this project as authors and 
reviewers, without whom the book would 
not have been possible. I would also like to 
thank SNMMITS (Society of Nuclear Medi-
cine and Molecular Imaging Technologist 
Section) and the EANM Neuroimaging 
Committee for their help and high-quality 
contributions.
Special thanks are due to Pedro Fragoso 
Costa, Andrea Santos and Borut Vidovic for 
their incredible enthusiasm and compe-
tence in dealing with the editorial duties 
and organisational work. Finally I remain ex-
tremely grateful to the EANM Board, EANM 
Executive Office, Technologist Committee 
and all the EANM committees involved in 
the project.
With my warmest regards,
Giorgio Testanera 
Chair, EANM Technologist Committee
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Neurological disorders are already affecting 
hundreds of millions of people worldwide, of 
whom more than 50 million suffer from epi-
lepsy and around 35.6 million have Alzheim-
er’s disease or other dementias. Furthermore, 
greater life expectancy and the overall ageing 
of the general population in both developed 
and developing countries will contribute to 
continued increases in the prevalence of many 
chronic and progressive physical and mental 
conditions, including neurological disorders [1].
Diagnostic nuclear medicine investigations 
have evolved from being a research modality 
in the evaluation of function and disease of 
the central nervous system to an established 
clinical tool in neurology. During recent years, 
new technologies and techniques have been 
developed in order to improve the quality of 
the images acquired, thereby enhancing the 
clinical impact of these techniques. More-
over, radiopharmaceutical development 
has allowed SPECT and PET imaging to be-
come increasingly acute and to cover more 
pathologies. From metabolism to perfusion, 
brain function has been studied in a variety 
of conditions, including dementia, epilepsy, 
movement disorders and brain tumours. 
These advances represent a challenge for tech-
nologists, given that each new technique and 
piece of equipment requires optimisation of 
protocol design. In the neuroimaging context, 
technologists also play a key role in patient 
care, which can be particularly challenging ow-
ing to the inability of patients suffering from 
neurological disorders to cooperate and also 
the demanding nature of the examinations.  
In this book, we begin by describing the 
brain’s anatomy, physiology and pathology 
(Chapter 1). After this, tracers for brain imaging 
are discussed (Chapter 2). The following two 
chapters provide an overview on the imaging 
of oncological disease by means of SPECT or 
SPECT/CT and PET/CT techniques (Chapters 3 
and 4). Imaging in neurological and vascular 
brain diseases is also analysed, focussing first 
on SPECT and SPECT/CT technology and 
then on PET/CT (Chapters 5 and 6). The use of 
PET/CT in brain tumour radiotherapy planning 
is discussed in Chapter 7. The application of 
the emerging technology of PET/MRI for brain 
imaging is approached in Chapter 8. Brain im-
aging in the case of suspicion of brain death 
is described in Chapter 9. The final chapter is 
devoted to the special health care and surveil-
lance needs of patients affected by neurologi-
cal disorders. This extended overview of neu-
roimaging techniques and the clinical state 
of art will provide a valuable tool to all clinical 
staff, including not only technologists but also 
physicians, physicists and students interested 
in this particular field.
The EANM Technologist Committee would 
like to thank all the authors who have kindly 
offered their time and expertise, which have 
been fundamental to the creation of this book.
Andrea Santos 
Pedro Fragoso Costa
Reference:
1. Neurological disorders: Public health challenges. 
Geneva: World Health Organisation, 2006.
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Anatomy, Physiology and Pathology
Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux
The brain serves many important functions, 
including movements, thoughts, learning, 
memory, language, integration and inter-
pretation of our senses, and critical functions 
such as respiration. To understand imaging 
of the brain it is essential to have knowledge 
of the anatomy and its normal function. This 
chapter provides an overview and describes 
several common brain pathologies.
Anatomy
Brain structures
The brain consists of three major structures: the 
brainstem, cerebellum and cerebrum (Fig. 1). 
The brainstem is the lower structure of the 
brain, extending into the spinal cord at the 
point where it leaves the skull. It is an impor-
tant relay station and consists of the midbrain, 
pons and medulla oblongata. The medulla 
oblongata is important for primitive functions 
like respiration, blood pressure and heart rate. 
Figure 1: The human brain 
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The cerebellum is located at the back of the 
brain and is divided into two hemispheres 
(left and right). It is important for coordination 
and timing of movement. The cerebrum is the 
largest structure of the brain and is also divid-
ed into left and right hemispheres, which are 
connected through the corpus callosum. The 
cerebrum is covered with the cerebral cortex 
that is folded into gyri and sulci to increase its 
surface. The cerebral cortex can be divided 
into four lobes: frontal, parietal, temporal and 
occipital. The frontal lobes are located in the 
front of the brain and include the primary mo-
tor cortex and prefrontal cortex, which is im-
portant for cognitive and executive functions. 
The temporal lobes are located on both sides 
of the brain and contain the auditory cortex. 
On the medial sides of the temporal lobes are 
the hippocampus, important for memory for-
mation, and the amygdala, involved in emo-
tions. The occipital lobes are at the back of the 
brain and are essential for processing visual 
information. The parietal lobes are located 
in between the frontal and occipital lobes; 
they include the somatosensory cortex and 
are involved in integrating sensory informa-
tion to form a perception. The basal ganglia 
are located subcortically, close to the centre 
of the cerebrum. They play an important role 
in controlling and regulating activities of the 
motor system and in motivation and habitu-
ation. A major structure of the basal ganglia 
is the striatum, which is involved in the plan-
ning and modulation of movement pathways, 
but is also part of the cognitive processes in-
volving executive function, such as working 
memory. The thalamus is located superior to 
the midbrain, near the centre of the brain. This 
is an important relay station for signals to the 
cerebral cortex, including motor and sensory 
signals, but it is also involved in sleep/wakeful-
Chapter 1     Anatomy, Physiology and Pathology
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ness and consciousness. Below the thalamus 
lies the hypothalamus, which is connected to 
the pituitary gland. The hypothalamus is con-
sidered to be the link between the nervous 
system and the endocrine system, regulating 
appetite, electrolyte balance and body tem-
perature. The two major components of the 
brain structures are grey and white matter. 
Grey matter largely consists of neuronal cell 
bodies and white matter is white because of 
the large number of myelinated axons.
Meninges and cerebrospinal fluid 
The brain and spinal cord are enveloped and 
protected by the meninges, which consist 
of three layers: dura mater, arachnoid mater 
and pia mater. The space in between the pia 
mater and the arachnoid mater is termed the 
subarachnoid space, which is filled with ce-
rebrospinal fluid (CSF). CSF is produced from 
arterial blood by the choroid plexuses. There 
it is filtered through the blood-brain barrier, 
which protects the brain from infections and 
toxins. The CSF flows through the ventricu-
lar system, consisting of the lateral ventricles 
and third and fourth ventricles.
Cerebral vasculature
Two pairs of arteries provide the arterial blood 
supply of the brain: the internal carotid arter-
ies in the neck and the vertebral arteries. They 
are interconnected through the circle of Wil-
lis, which ensures a back-up circulation in the 
event of dysfunction of one of the arteries. The 
three main pairs of arteries that branch off from 
the circle of Willis and supply the cerebrum 
with arterial blood are the anterior, middle and 
posterior cerebral arteries. The venous drainage 
consists of the venous sinuses in the dura mater 
and of veins inside the deep structures of the 
brain, which join behind the midbrain and then 
drain into the sinus system. The sinus drainage 
connects to the jugular veins in the neck.
Physiology
Cell types
Two main types of cell compose the brain: 
neurons and glial cells. Neurons transmit 
nerve signals to and from the brain over 
long distances. They consist of a cell body 
(or soma) with branching dendrites (signal 
receivers) and a projection called an axon, 
which conducts the nerve signal and trans-
mits it across a synapse (Fig. 2).  
Figure 2: Propagation of a signal down an 
axon to the cell body and dendrites of the 
next cell
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8Neurons can be classified according to the 
number of extensions deriving from the 
neuron’s cell body (bipolar, pseudo-unipolar, 
multipolar) or according to the direction in 
which they send information (afferent/sen-
sory, efferent/motor and interneuron).
Glial cells have supportive functions in that 
they help to define synaptic contacts and to 
maintain the signalling abilities of neurons, 
but they do not participate directly in elec-
trical signalling. There are three types of glial 
cell in the mature central nervous system: 
astrocytes, oligodendrocytes and microglial 
cells.
Metabolism, neurotransmitters and 
transporters 
The brain relies entirely on glucose for its en-
ergy supply and uses approximately 20% of 
the body’s total energy requirements. Mea-
surements of glucose consumption reflect 
the amount of brain activity in the various re-
gions of the brain and allow us to learn more 
about how the brain works. 
Neurotransmitters are the chemicals which 
allow the transmission of signals from one 
neuron to the next across the synaptic cleft. 
Acetylcholine is responsible for muscle 
stimulation and has been found in the auto-
nomic nervous system and sensory neurons. 
The cholinergic system modulates cognitive 
performance and gait stability and has been 
linked with cognitive/motor dysfunction in 
several neurodegenerative diseases. Nor-
epinephrine or noradrenaline is prevalent in 
the sympathetic nervous system. The nor-
adrenergic system effects are alertness and 
arousal and influences on the reward system. 
Dopamine is an inhibitory neurotransmit-
ter involved in the control of locomotion, 
cognition, affect and neuroendocrine secre-
tion. Dopamine deficiency results in Parkin-
son’s disease. GABA (γ-aminobutyric acid) is 
the main inhibitory neurotransmitter in the 
human central nervous system. The GAB-
Aergic system is the target of many drugs 
and substances including benzodiazepine, 
alcohol and barbiturates. Glutamate is the 
most common neurotransmitter in the CNS 
and is involved in most aspects of normal 
brain function, including cognition, mem-
ory and learning. Serotonin is an inhibitory 
neurotransmitter that has been found to be 
intimately involved in emotion, mood, ap-
petite and sleep. Modulation of serotonin at 
synapses is thought to be a major action of 
several classes of pharmacological antide-
pressant.
Neurotransmitter transporters are a class of 
membrane transport proteins that span the 
cellular membranes of neurons. A variety of 
neurotransmitter re-uptake transporters are 
pharmacotherapeutic targets for modulating 
the synaptic neurotransmitter concentration, 
and therefore neurotransmission. Among 
neurotransmitter transporters, the dopamine 
transporter (DAT) has a crucial role for nucle-
ar imaging of the dopaminergic system. DAT 
pumps dopamine out of the synapse back 
into cytosol, from which other transporters 
sequester dopamine and noradrenaline into 
Chapter 1     Anatomy, Physiology and Pathology
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vesicles for later storage and release. 
Pathology
Neurodegenerative disease
Alzheimer’s disease (AD) is the most com-
mon cause of dementia among older people. 
Dementia is the loss of memory and other 
intellectual functions of sufficient sever-
ity to cause problems in patients’ abilities to 
perform their usual personal, social or occu-
pational activities. AD is pathologically char-
acterised by the presence of plaques com-
posed of amyloid-beta peptides and neuro-
fibrillary tangles containing phosphorylated 
tau [1]. Enzymatic cleavage of amyloid-beta 
peptides is considered to play an important 
pathogenetic role in AD (likely occurring sev-
eral years before clinical manifestations) [1]. 
The ongoing challenge is the distinction of 
slight cognitive deficit which precedes AD 
dementia from normal aging. Mild cognitive 
impairment (MCI) refers to a subtle but mea-
surable cognitive decline in the absence of 
dementia and those affected include both 
subjects who remain stable over time and 
patients who become demented due to 
underlying neurodegenerative aetiologies, 
including AD [2]. Imaging and CSF biomark-
ers allow the identification of probable AD 
among MCI patients with a typical gradual 
and progressive (isolated or not) episodic 
memory impairment [3]. 
Dementia with Lewy bodies (DLB) is a degen-
erative dementia of unknown aetiology. It is 
the second most common form of dementia. 
Deficits in attention and executive function 
are central features. Fluctuating cognition, 
visual hallucination and spontaneous fea-
tures of parkinsonism are typical. Finally, REM 
sleep behaviour disorder, severe sensitiv-
ity to neuroleptics and low dopamine trans-
porter uptake in the basal ganglia as seen 
on SPECT/PET imaging scans are suggestive 
features [4].
Frontotemporal degeneration (FTD) refers to 
a group of diseases involving the temporal 
and/or frontal lobes. FTD is also commonly 
referred to as frontotemporal dementia and 
occurs most frequently in persons under 
the age of 65. FTD has a heterogeneous 
spectrum, with behavioural, cognitive or lan-
guage changes [5]. 
Parkinson’s disease (PD) is an idiopathic de-
generative disease which results from the 
death of dopamine-generating cells in the 
substantia nigra. PD usually affects people 
over the age of 50.  Symptoms of PD are rest-
ing tremor, rigidity, bradykinesia and postural 
instability. Onset of symptoms is gradual and 
typically asymmetrical [6]. 
Cerebrovascular disease 
Cerebrovascular disease (CVD) refers to a 
group of conditions that impair the circula-
tion of blood to the brain, causing limited 
or no blood flow to affected areas. Clinical 
symptoms depend on the location and ex-
tent of cerebral tissue affected. CVDs are 
subdivided into ischaemic events and ce-
rebral haemorrhages. Ischaemic events are 
further classified according to the duration 
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of symptoms (transient ischaemic attacks 
last more than a few minutes and less than 
24 h; ischaemic stroke lasts more than 24 h 
and may be progressive stable, or resolving. 
In some cases a number of small strokes or 
a large stroke may cause so-called vascular 
dementia (the second most common form 
of dementia after AD) [7].
Brain tumours
Primary brain tumours are classified accord-
ing to the type of tissue in which they arise 
[8]. The most common brain tumours are 
gliomas, which begin in the glial (supportive) 
tissue. There are several types of glioma, in-
cluding astrocytomas, oligodendrogliomas 
and ependymomas. Other types of brain 
tumour that do not begin in glial tissue are 
meningiomas, schwannomas, craniopha-
ryngiomas, germ cell tumours and pineal 
region tumours. Cerebral secondary tumours 
are metastatic tumours originating in other 
organs and are more common than primary 
ones (8).
Brain inflammation and infections
Encephalitis refers to a diffuse brain paren-
chymal inflammation mainly due to viral 
infections. Meningitis is an inflammation 
of meninges surrounding both brain and 
spinal cord. It can be caused by viral, bacte-
rial and fungal infections. Symptoms include 
headache, fever, confusion, drowsiness and 
fatigue, and in some cases seizures or con-
vulsions, hallucinations, stroke, haemorrhag-
ing and memory problems occur [9].
Epilepsy 
Epilepsy is characterised by sudden recurrent 
episodes of sensory disturbance, loss of con-
sciousness or convulsions, associated with 
abnormal electrical activity in the brain caus-
ing seizure (a transient occurrence of signs 
and symptoms due to abnormal excessive or 
synchronous neuronal activity) [10]. Seizures 
can be focal or generalised. The cause of 
most cases of epilepsy is unknown (“crypto-
genic”) although some people develop epi-
lepsy as the result of brain injury, stroke, brain 
tumour or substance abuse. 
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Introduction
Positron emission tomography (PET) and 
single-photon emission computed tomogra-
phy (SPECT) imaging use positron- and gam-
ma-emitting radioisotopes that can easily be 
incorporated into biological molecules and 
thus allow the measurement of functional 
parameters (physiological and/or pharma-
cological interactions) of tissue rather than 
just providing the anatomical definition of 
structures. Both techniques are exceptionally 
sensitive (PET more so than SPECT); they can 
detect picomolar or even femtomolar con-
centrations of radiolabelled compounds and 
enable the dynamic acquisition of relatively 
fast kinetics (of the order of seconds for PET). 
With these properties, PET/SPECT can facili-
tate the quantitative measurement of rapid 
physiological/pharmacological processes of 
biomolecules in the living brain, for example 
[1]. The increase in neurological applications 
of PET/SPECT over the past decade has been 
greatly aided by the significant improve-
ments in data acquisition (hardware technol-
ogy) and data quantification (model-based 
methodology) and by the vastly growing 
number of available PET/SPECT metabolic ra-
diotracers and receptor-specific radioligands. 
Table 1 lists the more common PET/SPECT ra-
diotracers/ligands and their intended targets 
in clinical neurology [1,2].
For the tracer (radiopharmaceutical) to be 
able to enter the CNS (brain), it is a prereq-
uisite that it possesses the capacity (suit-
able physiochemical properties) to cross the 
blood-brain barrier (BBB), whether by free 
diffusion or by specific transport mecha-
nisms. Depending on the brain target of the 
imaging and the attendant required tracer 
properties, tracers for brain imaging can be 
divided into several groups: regional cerebral 
blood flow (rCBF) tracers, metabolic tracers, 
tracers targeting neurotransmission and re-
ceptors, tracers targeting amyloid and tracers 
for brain tumour imaging.
rCBF tracers
In order to be used for the measurement 
of brain perfusion, the radiopharmaceutical 
must possess certain physiological proper-
ties. In addition to being able to cross the 
BBB, their extraction must approximate unity 
and must be independent of blood flow; as a 
consequence their initial distribution will be 
proportional to rCBF. They also must be re-
tained within the brain in their initial distribu-
tion for sufficiently long to enable diagnostic 
images to be obtained [3]. Ideally, tracer up-
take should show no redistribution, so that 
the initial uptake, reflecting rCBF at a fast 
time window after injection, will remain al-
most unchanged for several hours. The result 
is images independent of variations in rCBF 
after the fixation time. Two tracers are cur-
rently used for evaluation of rCBF in routine 
clinical practice: 99mTc-HMPAO (hexamethyl 
propylene amine oxime, exametazime, 
Ceretec®) and 99mTc-ECD (ethyl cysteine di-
mer, bicisate, Neurolite®); these are discussed 
further below. Other available tracers such as 
123I-IMP and H2
15O are still used mainly for re-
search purposes.
Chapter 2
Tracers for Brain Imaging
Aljaz Socan 
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Brain perfusion SPECT using 99mTc-labelled 
radiopharmaceuticals
SPECT is a technique that produces topo-
graphic images of the three-dimensional 
distribution of a radiopharmaceutical. Ap-
plied to the brain, it can be used to mea-
sure regional cerebral perfusion [3]. The two 
tracers most widely used in brain SPECT in 
the EU, 99mTc-HMPAO and 99mTc-ECD, differ in 
terms of their in vitro stability, uptake mech-
anism, cerebral distribution and dosimetry; 
nevertheless, their kinetic properties are 
very similar. They enter the brain cells ow-
ing to their lipophilicity and then remain 
there as a consequence of their metabolic 
conversion into hydrophilic compounds. In 
the case of ECD, the stable lipophilic com-
plex crosses the BBB by passive diffusion. 
Its localisation in the brain depends upon 
both the perfusion of the region and the 
uptake of the tracer by the cells. Once in the 
brain cells, the complex is metabolised to 
polar, less diffusable compounds, complex 
de-esterification being the crucial reaction 
leading to hydrophilic conversion. After 
background clearance, brain images may 
be obtained from 10 min to 6 h after injec-
tion of the adult dose of 370–1110 MBq, the 
optimum imaging time being 30–60 min af-
ter injection. The primary route of excretion 
is via the kidneys, with 73% of the injected 
dose being cleared through the bladder 
during the first 24 h (up to 50% is cleared 
within the first 2 h). Approximately 11% of 
the injected dose is eliminated via the GI 
tract over 48 h [1].
99mTc-HMPAO primary complex is uncharged, 
lipophilic and of sufficiently low molecular 
weight to cross the BBB readily. However, it 
converts, at a rate of approximately 12% per 
hour, to a less lipophilic secondary complex 
which does not cross the BBB. This would 
limit the useful shelf-life of the product to 
30 min but the addition of cobalt stabiliser, 
1-5 min after preparation of radiopharma-
ceutical, lengthens its shelf-life to 5 h. The 
adult dose is 350–500 MBq. The primary 
complex clears rapidly from the blood after 
intravenous injection. Uptake in the brain 
reaches a maximum of 3.5–7% of the in-
jected dose within 1 min after injection. Up 
to 15% of the cerebral activity washes out of 
the brain by 2 min post injection, after which 
there is slight loss of activity for the following 
24 h due to the physical decay of 99mTc. Ac-
tivity not associated with the brain is distrib-
uted widely throughout the body, especially 
in the muscle and soft tissue. Approximately 
30% of the injected dose is found in the GI 
tract immediately after injection, with about 
50% of this being excreted over 48 h. In addi-
tion, over a 48-h period, 40% of the injected 
dose is excreted via the kidneys and urine [1].
The different retention mechanisms of 99mTc-
ECD and 99mTc-HMPAO are the reasons for the 
different behaviour of the tracers in specific 
disorders; for example, in subacute stroke 
the distribution of 99mTc-ECD seems to reflect 
metabolic activity more closely, while 99mTc-
HMPAO is better correlated with cerebral 
perfusion (Fig. 1) [1]. The tracers are not inter-
changeable, and 99mTc-ECD and 99mTc-HMPAO 
14
SPECT do not provide absolute quantitative 
blood flow values but rather estimate rela-
tive regional flow differences based on the 
comparison of count density ratios between 
various regions of the brain. Normally, there 
is intense uptake of tracer in the grey matter 
of the cortex and basal ganglia, with signifi-
cantly lower uptake in the white matter.
Figure 1: Brain perfusion SPECT imaging with 99mTc-HMPAO in a patient with suspected brain 
death after CNS trauma. There is complete absence of brain perfusion (cerebrum, cerebellum, 
brain stem) 
Chapter 2     Tracers for Brain Imaging
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Common indications for 99mTc-ECD and 99mTc-
HMPAO according to the EANM guidelines 
for brain perfusion SPECT are:
• Evaluation of cerebrovascular disease:
• Acute stroke
• Chronic ischaemia (chronic 
cerebrovascular disease)
• Preoperative evaluation for potential 
ischaemia following carotid artery 
sacrifice
• Postsurgical lateralisation and localisation 
of epileptogenic foci
• Evaluation of suspected dementia (early 
detection and differential diagnosis of 
various forms of dementia)
• Evaluation of traumatic brain injury
• Evaluation of suspected inflammation
• Assessment of brain death
Prior to the investigation, patients should 
preferably avoid excessive stimulants (caf-
feine, cola, energy drinks), alcohol, smoking 
and any other drugs known to affect the CBF. 
(It is necessary to discuss drug withdrawal 
with the clinician caring for the patient.)
Metabolic tracers
The main metabolic substrates of the brain 
are oxygen and glucose. Both metabolic 
pathways are studied with specific tracers. 
Oxygen-15 is the tracer used in research to 
study the regional cerebral metabolic rate of 
oxygen (rCMRO2), while glucose metabolism 
is studied with analogues of  glucose. 2-(18F)
Fluoro-2-deoxy-D-glucose ([18F]FDG) today 
represents the workhorse of imaging in sev-
eral fields of PET nuclear medicine. [18F]FDG 
is a glucose analogue and is therefore taken 
up in cells via glucose transporters (glucose 
does not freely cross the BBB or cell mem-
brane); it is then phosphorylated by hexoki-
nase into FDG-6-phosphate, which cannot 
be metabolised (unlike glucose) and is con-
sequently trapped in the cell (Fig. 2) [1].
Figure 2: Mechanism of metabolic trapping of 
[18F]fluorodeoxyglucose in cells
Following intravenous administration of 
100–400 MBq, the pharmacokinetic profile 
of [18F]FDG in the vascular compartment is 
bi-exponential. It has a distribution half-life 
of 1 min, a large volume of distribution and 
an elimination half-life of approximately 
12 min without being metabolised. Elimina-
tion is mainly renal. Approximately 20% of 
the injected dose is excreted in urine dur-
ing the first 2 h. After administration, FDG 
is distributed mainly to the brain and heart. 
Approximately 7% of the injected dose is 
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accumulated in the brain within 80–100 min 
after injection. Approximately 3% of the 
injected activity is taken up by the myo-
cardium within 40 min, while ca. 0.3% and 
0.9%–2.4% is accumulated in the pancreas 
and lungs, respectively [1]. In the brain, glu-
cose metabolism provides approximately 
95% of the ATP required for brain function 
and is tightly connected to neuronal activ-
ity both in physiological conditions and in 
several diseases affecting the brain. Changes 
in neuronal activity induced by disease are 
reflected in an alteration in glucose metabo-
lism. Since the accumulation of [18F]FDG in 
brain tissue depends on facilitated transport 
of glucose and hexokinase-mediated phos-
phorylation, it is suitable for imaging of re-
gional cerebral glucose consumption and is 
currently the most accurate in vivo method 
for the investigation of regional human brain 
metabolism. Its clinical use can be regarded 
as established for a number of diagnostic 
questions in neurology, neurosurgery and 
psychiatry [4]. 
Depending on the clinical question and the 
type of equipment, [18F]FDG imaging may 
include static limited field tomographic im-
ages or dynamic tomographic images (used 
when absolute quantification of regional 
metabolic rates of glucose is needed), 2D or 
3D acquisition mode and attenuation cor-
rection (mandatory for [18F]FDG PET brain 
imaging).
Normally, there is high tracer uptake in the 
grey matter of the cortex and basal ganglia; 
uptake in the white matter is significantly 
lower. Common indications for [18F]FDG in 
PET brain imaging according to the EANM 
procedure guidelines for PET brain imaging 
using [18F]FDG [4] are:
• Dementing disorders: early diagnosis 
and differential diagnosis of dementing 
disorders, such as Alzheimer’s disease 
and frontotemporal dementia. The typical 
topographic patterns of hypometabolism 
may help to diagnose the main 
neurodegenerative diseases at the 
predementia stage.
• Neuro-oncology: differential diagnosis 
of cerebral space-occupying lesions, 
detection of viable tumour tissue 
(recurrence), non-invasive grading.
• Epilepsy (interictal injection): preoperative 
evaluation of partial epilepsy in adults and 
children to identify the functional deficit 
zone.
• Movement disorders: differentiation 
between Parkinson’s disease and atypical 
parkinsonian syndromes.
Tracers targeting the dopaminergic system 
(neurotransmission and receptors)
The synaptic cleft is the location where in-
teractions between cells take place. The 
neurotransmitter released by the presyn-
aptic neuron reaches the postsynaptic cell 
Chapter 2     Tracers for Brain Imaging
EA
NM
17
membrane, where receptors are present, 
and initiates the neurotransmission chain of 
events. The transmitter can also re-enter the 
presynaptic neuron via the reuptake chan-
nels, which actively participate in modu-
lating the intracleft concentration. All the 
constituents of the synaptic transmission 
chain, i.e. transmitter, receptors and reuptake 
channels, can be modulated by functional 
requests as a consequence of local physiol-
ogy or disease and under the effect of drugs. 
All three are possible targets of imaging with 
radiolabelled tracers. On account of the im-
portance of the brain functions connected 
with its integrity (its dysfunction leads, for 
example, to movement disorders and cogni-
tive decline), the dopaminergic system is the 
most extensively studied neurotransmitter 
system in brain nuclear medicine imaging. 
Figure 3: Dopaminergic radioligands for SPECT and PET 
Various SPECT and PET dopaminergic trac-
ers are currently available for routine clinical 
practice and research (Fig. 3). [18F]fluorodopa 
and cocaine derivatives labelled with  123I 
and  99mTc ([123I]β-CIT, [123I]FP-CIT and [99mTc]
TRODAT-1) are the most frequently used trac-
ers for the study of nigrostriatal dopaminer-
gic dysfunction in Parkinson’s disease (Fig. 4).
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Figure 4 A, B: Dopamine reuptake transporter (DAT) SPECT imaging ([123I]FP-CIT). (A) Normal 
uptake in the striatum (caudate nucleus, putamen). (B) Patient with Parkinson’s disease: asym-
metrically decreased uptake is seen in the striatum (more pronounced on the right side). There 
is bilaterally reduced uptake in the putamen posteriorly 
PET/SPECT can also be used non-invasively 
to indirectly monitor changes in neurotrans-
mitter concentration, providing that a PET 
radioligand specific and selective for the 
system of interest is available and the radio-
ligand binds to the same site as the endog-
enous ligand or neurotransmitter. The D2 re-
ceptor radioligands [11C]raclopride and [123I]
IBZM are, for example, particularly sensitive 
to changes in dopamine levels. Dopamine 
receptor ligands have been used for the 
identification of postsynaptic dopaminergic 
deficit in parkinsonian neurodegenerative 
disorders (D2  receptor ligands), for the as-
sessment of neuroreceptor/neurochemical 
changes and drug occupancy in psychiatric 
disorders (D1 and D2 receptor ligands) and for 
pharmacological studies on endogenous do-
pamine changes (D2 receptor ligands). 
6-[18F]Fluorolevodopa is a metabolic tracer 
that is taken up into dopaminergic nerve ter-
minals and converted into [18F]dopamine. The 
radiotracer can be used as a measure of do-
pamine synthesis and dopaminergic neuron 
density and, therefore, presynaptic dopami-
nergic function. In Parkinson’s disease, con-
ventional MRI is unable to identify any ana-
tomical abnormalities. With [18F]F-DOPA PET, 
the loss of dopaminergic neurons is clearly 
detected in the striata and has been shown to 
be useful in early differentiation of Parkinson’s 
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disease from other movement disorders. In 
addition, [18F]F-DOPA can be used to detect 
a subclinical parkinsonian-like pattern (i.e. 
degeneration of dopaminergic neurons) in as-
ymptomatic adult identical twins [1].
Brain neurotransmission SPECT using 
123I-labelled dopamine transporter ligands
The dopaminergic neurotransmitter system 
plays a major role in movement disorders, 
particularly in parkinsonism and dementia 
with Lewy bodies. The nigrostriatal dopami-
nergic pathway is best analysed at the striatal 
level, where the nigrostriatal neurons end 
and connect to the postsynaptic nerve ter-
minals using dopamine as a neurotransmit-
ter which binds to the postsynaptic D1 and 
D2 receptors. Both pre- and postsynaptic 
levels can be targeted by PET or SPECT trac-
ers. Presynaptic events can be summarised 
as follows. Dopamine is stored in vesicles 
before being released into the synaptic cleft. 
Vesicular monoamine transporter 2 (VMAT-2) 
transports cytosolic and newly synthesised 
dopamine into vesicles. The sodium-depen-
dent  dopamine  active transporter (DAT), 
which is located in the membrane of the pre-
synaptic nigrostriatal nerve terminals, is re-
sponsible for the reuptake of dopamine from 
the synaptic cleft. L-DOPA is taken up by the 
presynaptic neurons via amino acid trans-
porter and decarboxylated to dopamine by 
L-aromatic acid decarboxylase (Fig. 3) [5].
Various PET tracers have been used to study 
these presynaptic targets, such as 18F-DOPA 
for aromatic acid decarboxylase, 11C-DTBZ 
for VMAT-2 and 11C-PE21 for DAT. Various 
cocaine analogues that are labelled with 123I 
and are suitable for SPECT have been shown 
to bind with high affinity to DAT. Currently 
β-CIT (DOPAS-CAN®) and FP-CIT (ioflupane, 
DaTSCAN®) are commercially available and 
widely used for clinical evaluation of patients 
in Europe [5]. The administered dose of [123I]
ioflupane in adults is 150–250 MBq. [123I]Ioflu-
pane is cleared rapidly from the blood, with 
only 5% remaining at 5 min after intravenous 
injection. Uptake in the brain is rapid, with 
7% of the injected activity being present in 
the brain after 10 min, decreasing to 3% after 
5 h. The primary route of excretion is via the 
kidneys, with 60% of the injected dose being 
excreted in the urine at 48 h post injection; 
faecal excretion is calculated at approximate-
ly 14% [1]. Normally, there is intense uptake 
in the striatal structures (caudate nucleus 
and putamen).
According to the EANM Guidelines [5], com-
mon indications for brain neurotransmission 
SPECT using 123I-labelled dopamine trans-
porter ligands are:
• Detection of loss of functional dopami-
nergic neuron terminals in the striatum of 
patients with clinically uncertain parkinso-
nian syndrome; differentiation of essential 
tremor from Parkinson’s disease, multiple 
system atrophy and progressive supra-
nuclear palsy (on its own, it is unable to 
discriminate between Parkinson’s disease, 
multiple system atrophy and supranuclear 
palsy)
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• Differentiation of dementia with Lewy 
bodies from other dementias
• Early diagnosis of neurodegenerative par-
kinsonism; assessment of the presynaptic 
deficit in early Parkinson’s disease
• Assessment of disease severity (DAT bind-
ing is related to the clinical stage and 
severity of Parkinson’s disease)
• Differentiation between presynaptic par-
kinsonism and other forms of parkinson-
ism (neuroleptic-induced parkinsonism)
Prior to the investigation, patients should 
avoid taking any medications or drugs of 
abuse which could significantly influence 
the visual and quantitative analysis of DAT 
binding ligands. A withdrawal period of at 
least 5 times the drug’s biological half-life is 
suggested. Smoking may interfere with DAT 
availability [5].
Brain neurotransmission SPECT/PET using 
dopamine D2 receptor ligands
The dopaminergic neurotransmitter system 
plays a major role in movement disorders, 
particularly in parkinsonism. Using SPECT 
and PET, various functional aspects of dopa-
minergic neurotransmission can be visual-
ised in vivo.
Currently nuclear medicine investigations 
predominantly assess two aspects of the 
dopaminergic system: the binding of the 
presynaptic dopamine transporter and the 
status of the postsynaptic dopamine D2 re-
ceptor, since the majority of D2 receptors are 
located postsynaptically. According to their 
pharmacological response, dopamine recep-
tors are divided into D1-like receptors (D1, D5) 
and D2-like receptors (D2, D3 and D4). Assess-
ment of D1-like receptors has not gained any 
clinical significance, but a number of clinical 
investigations have focussed on the D2-like 
receptor system [6]. 
The most widely applied radiotracers for 
imaging D2-like receptors with SPECT are 
123I-labelled IBZM and epidepride, both of 
which are commercially available. For PET, 
[11C]raclopride, [18F]fallypride and [18F]des-
methoxyfallypride (DMFP) are the most com-
monly used radiopharmaceuticals in Europe 
[6]. These dopamine receptor antagonist 
derivatives are not selective radiopharma-
ceuticals for the D2 receptor, since they also 
bind the D3 receptor; however, the vast ma-
jority of D2-like receptors in the striatum are 
D2 receptors. Since the available radiotracers 
show considerable variation in their affinity 
and selectivity for the D2 receptors and their 
pharmacokinetic properties, there are differ-
ences between them with respect to specific 
binding ratios and the optimal time point 
for acquisition. As with DAT tracers, there is 
physiological uptake of tracer in the striatum.
According to the EANM Guidelines [6], com-
mon indications for brain neurotransmission 
SPECT/PET using dopamine D2 receptor li-
gands are:
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1. Differential diagnosis of parkinsonian 
syndromes (differentiation of Parkinson’s 
disease from other neurodegenerative 
parkinsonian syndromes characterised by 
loss of D2 receptors, i.e. multiple system 
atrophy and progressive supranuclear 
palsy)
2. Assessment of the extent of D2 receptor 
blockade during treatment with 
dopamine D2 antagonists (neuroleptics)
3. Huntington’s disease (D2 receptor imaging 
can confirm degeneration of postsynaptic 
D2 receptors)
4. Wilson’s disease (D2 receptor imaging 
findings are related to the severity of 
neurological symptoms and may show 
the degree of neuronal damage due to 
cytotoxic copper deposition in striatum)
5. Pituitary adenoma (D2 receptor imaging 
is helpful when assessing the dopamine 
receptor status/availability of pituitary 
adenoma, which may have implications 
for the medical treatment strategy)
Tracers targeting other neurotransmitter 
systems and receptors
Use of PET as a tool for neuroreceptor map-
ping can be very important for elucidation 
of basic mechanisms of disease and for in-
vestigation of correlations with clinical pa-
rameters. The antagonist radioligand [11C]
WAY100635 has been used extensively to 
study 5HT1A receptor (serotonin) dysfunction 
in human disease states (neurodegenerative 
disorders such as Alzheimer’s disease and 
neuropsychiatric disorders such as depres-
sion) [1]. The neuropharmacological data 
obtained from receptor-specific PET/SPECT 
studies can additionally help to increase 
knowledge of potential therapeutic targets 
for novel pharmaceutical agents by deter-
mining their dose-occupancy profile. This can 
be done using the radiolabelled drug under 
investigation or by monitoring its effects on 
the binding of an established radioligand [1].
Tracers for the cholinergic system can be used 
for the study of neurodegenerative disorders 
such as Alzheimer’s disease, Parkinson’s dis-
ease, Lewy body dementia and progressive 
supranuclear palsy. Tracers for the central ben-
zodiazepine (BZD) receptors ([11C]flumazenil, 
[123I]iomazenil) have been used in patients 
with epilepsy to identify the epileptogenic 
focus characterised by a focal decrease in 
BZD receptor density, for the study of neu-
ronal loss in Alzheimer’s disease and for the 
study of BZD receptor density in patients with 
schizophrenia or post-traumatic stress disor-
der (PTSD). Peripheral benzodiazepine bind-
ing sites (PBBS) are present at low levels in the 
normal brain. These sites are highly expressed 
in vivo by activated microglia, which are asso-
ciated with CNS inflammation in a wide range 
of pathologies. In combination with MRI, to 
aid with anatomical definition, PET imaging 
using the PBBS-selective ligand [11C]PK11195 
provides a generic indicator of active disease 
in the brain and, to date, has been used in 
clinical studies of stroke, multiple sclerosis, 
dementia, Parkinson’s disease, Huntington’s 
disease, epilepsy and schizophrenia [1].
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Tracers targeting amyloid
Amyloid plaques and neurofibrillary tangles 
are pathological markers found in the post 
mortem brains of patients with Alzheimer’s 
disease. It is thought that these plaques are 
present as long as 10 years before any clinical 
symptoms of disease appear [1]. PET imag-
ing of amyloid-β has emerged as a valuable 
biomarker to support the in vivo diagnosis 
of Alzheimer’s disease. Recently, several PET 
tracers have been developed that bind to 
amyloid plaques and hence can be used as 
amyloid imaging agents (e.g. [11C]BIP, [11C]
SB-13). [11C]BIP PET scans show a twofold in-
crease in retention of signal in subjects with 
Alzheimer’s disease compared with controls. 
This increase in signal suggests widespread 
amyloid deposition in cortical areas and 
striata in Alzheimer’s disease [1]. Further an-
alogues of the tracer labelled with 18F have 
been developed and are currently being 
introduced into clinical practice; examples 
include [18F]florbetapir (18F-AV-45), [18F]flute-
metamol and [18F]florbetaben [1].
Brain tumour imaging using labelled 
amino acid analogues
Increased amino acid transport in brain tu-
mour cells results from overexpression of 
the transporter systems and is related to al-
terations in the tumour vasculature and tu-
mour cell proliferation. In comparison with 
conventional anatomical imaging methods, 
radiolabelled amino acids offer significant 
improvements in the diagnostic evaluation 
of cerebral tumours. The contrast they dis-
play is far superior to that obtained with [18F]
FDG because of the low uptake of amino 
acids in normal brain tissue, and they may 
be more tumour specific as their uptake 
is less influenced by inflammation [7]. The 
most frequently used radiolabelled amino 
acid is (methyl-11C)-L-methionine ([11C]MET). 
In an effort to overcome the disadvantages 
of the short half-life and complex metabo-
lism of [11C]MET, and despite changes in 
amino acid structure, several fluoro- and 
iodo-amino acids have been developed. 
These agents include 3-(123I)iodo-α-methyl-L-
tyrosine ([123I]IMT), used for SPECT, and O-(2-
(18F)fluoroethyl)-L-tyrosine ([18F]FET), used 
for PET. They are both transported by the 
same specific amino acid transport system as 
[11C]MET but are not incorporated into pro-
teins. They display rapid accumulation into 
brain tumours that is independent of BBB 
disruption (Fig. 5). Several 18F-labelled amino 
acids are available; [18F]FET, due to its ease of 
synthesis, high in vivo stability and fast brain 
and tumour uptake, has been selected as the 
representative compound of this category.
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Figure 5 A, B: Brain PET/CT imaging with [18F]FET in a patient with suspected recurrence of 
glioblastoma. (A) PET image. An area of increased tracer uptake in the frontal lobe is seen on 
the right side. (B) CT image. 
Despite differences in blood clearance, up-
take kinetics and relation to protein syn-
thesis, [11C]MET, [123I]IMT and [18F]FET show 
similar results in the diagnostic evaluation 
of cerebral tumours [7]. Doses in adults are 
100–400 MBq (typically 185 MBq) for [123I]IMT, 
200–250 MBq for [11C]MET and 200–250 MBq 
for [18F]FET. 
According to the EANM Guidelines [7], com-
mon indications for brain tumour imaging 
using labelled amino acid analogues are:
1. Detection of viable tumour tissue 
(radiolabelled amino acid imaging is 
superior to [18F]FDG-PET in confirming 
low-grade recurrence).
2. Tumour delineation: Radiolabelled amino 
acid tracers are superior to CT and MRI for 
estimation of true tumour extension in 
low- as well as high-grade gliomas. Due to 
lower uptake in normal brain tissue, they 
are also superior to [18F]FDG for delinea-
tion of low-grade tumours, in which [18F]
FDG uptake is found to be decreased 
compared with normal cortex or basal 
ganglia. With [18F]FET, large brain vessels 
may be visualised due to high blood pool 
radioactivity.
3. Selection of the best biopsy site (labelled 
amino acid imaging is recommended to 
guide the stereotactic biopsy, which is 
the gold standard in the classification and 
grading of glioma).
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4. Non-invasive tumour grading (grading 
of cerebral gliomas using labelled amino 
acids is controversial: [18F]FDG PET 
appears better suited to differentiate 
between tumour grades).
5. Therapy planning (in conjunction with 
anatomical imaging, radiolabelled amino 
acid imaging may be used to better de-
fine the tumour volume to be resected or 
irradiated).
6. Tumour response (changes in uptake on 
labelled amino acid imaging may predict 
the response to locoregional chemo- and 
radiotherapy as early detection of residual 
tumour after surgery may be possible).
As the number of PET/SPECT centres grows, 
applications in clinical neurology will in-
crease for early and/or presymptomatic di-
agnosis of diseases. As more target-specific 
radiotracers and ligands are developed, their 
use in clinical research and drug develop-
ment will help determine optimal drug dos-
ing regimens and elucidate the downstream 
effect of drug actions.
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Table 1
Common PET/SPECT radiotracers/ligands and their intended targets in clinical neurology 
(adapted from Sampson’s Textbook of Radiopharmacy, 4th ed. [1]
Target PET/SPECT radiotracer/ligand
Cerebral blood flow [15O]water, 99mTc-HMPAO, 99mTc-ECD
Cerebral glucose metabolism [18F]fluorodeoxyglucose (FDG)
Dopamine synthesis [18F]fluorodopa (F-DOPA)
Dopamine D1 receptors [
11C]SCH23390
Dopamine D2/3 receptors
[11C]raclopride, [11C]FLB457, [123I]iodobenzamide, 
[123I]epidepride
Dopamine reuptake (transporter) sites [11C]RTI-32, (11C)CFT, [123I]ioflupane
Serotonin (5HT) 1A receptors [11C]WAY 1000635
Serotonin (5HT) 2A receptors [11C]MDL 100907, [18F]altanserin
Serotonin reuptake (transporter) sites [11C]DASB, [123I]β-CIT
Peripheral benzodiazepine sites [11C]PK11195, [123I]PK11195
Central benzodiazepine sites [11C]flumazenil
Amyloid [11C]PIB, [18F]flutemetamol, [123I]IMPY
Opioid receptors [11C]diprenorphine
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Introduction
Single-photon emission computed tomog-
raphy, or SPECT as it is commonly known, 
has been used for many years as an imaging 
modality in the detection of oncological ab-
normalities of the brain even though it is not 
the modality of choice for evaluation of brain 
lesions.  This chapter will discuss the evolu-
tion of SPECT and SPECT/CT imaging, the 
uses and advantages of SPECT and SPECT/CT 
in brain oncology, the radiopharmaceuticals 
that have been used for this indication, imag-
ing technique and data processing and, final-
ly, the future of SPECT imaging in oncology. 
The evolution of SPECT and SPECT/CT
SPECT imaging was introduced in the 1970s. 
It enables the creation of a 3D image from 
multiple gamma camera images taken by 
cameras continuously rotating around an 
area of interest. The 3D images obtained 
using SPECT offer improved sensitivity and 
resolution compared with 2D images and are 
easier to compare with MRI and CT images. 
SPECT also permits better tumour localisa-
tion as the 3D imaging component allows 
different views (sagittal, coronal and trans-
axial) to be displayed, thereby offering im-
proved visualisation of the abnormality. 
SPECT/CT cameras in which both the SPECT 
gamma camera system and the CT camera 
system have been integrated into one gan-
try have been available since the late 1990s. 
The SPECT/CT systems allow for the fusion 
of the nuclear medicine SPECT images with 
the CT images. This results in a better image 
showing both the physiological aspects of 
the disease and anatomical information. It 
also makes it much easier to pinpoint the tu-
mour location.
Uses and advantages of SPECT and 
SPECT/CT in brain oncology 
SPECT and SPECT/CT have been used widely 
in the assessment of brain tumours and have 
been shown to be most useful in the imaging 
of recurrent gliomas and intracranial lympho-
mas.  SPECT imaging allows assessment of 
tumour malignancy based on the functional 
imaging aspect, while SPECT/CT plays an im-
portant role in localisation of the tumour for 
the purpose of surgery.  After surgery and/or 
radiotherapy, SPECT and SPECT/CT are used 
to help monitor the disease by evaluating 
differences at the tumour site that can in-
dicate gliosis, radiation necrosis or tumour 
recurrence. SPECT permits the functional im-
aging of tumours of an indeterminate nature 
in order to evaluate their significance. It also 
helps to differentiate intracranial lymphomas 
from toxoplasmosis. 
Radiopharmaceuticals for brain imaging 
with SPECT and SPECT/CT
Several radiopharmaceuticals have been 
used for brain imaging in SPECT and 
SPECT/CT (Table 1).  All of these radiopharma-
ceuticals are discussed in detail in Chapter 2, 
but we shall also cover them briefly in this 
chapter. The most important quality that the 
radiopharmaceutical must have is the ability 
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to cross the blood-brain barrier and localise 
in normal brain tissue. This quality is needed 
to permit evaluation of abnormalities within 
the brain tissue. Two of the most commonly 
used radiopharmaceuticals are technetium-
99m (99mTc) bicisate (ethyl cysteinate dimer, 
ECD) and 99mTc-exametazime (hexamethyl-
propylene amine oxime, HMPAO).  
HMPAO is used in SPECT imaging in both un-
stabilised and stabilised preparations. 99mTc-
HMPAO and 99mTc-ECD can appear to show 
normal to decreased activity in abnormal 
brain tissue, but 99mTc-ECD has been known 
to show increased activity in tumours. Thal-
lium-201 chloride (201Tl) is also used in SPECT 
oncological imaging as it has high uptake 
in brain tumours and can assist in biopsy 
guidance. Figure 1 demonstrates 201Tl SPECT 
scans of different grades of glioma. 
Technetium-99m sestamibi has also been 
shown to have increased activity in tumours 
and has been used in SPECT oncological im-
aging. Figure 2 shows transaxial slices of a 
99mTc-sestamibi SPECT scan. 
The injected activities and uptake times for 
each of the above radiopharmaceuticals are 
displayed in Table 1.
Imaging technique and data processing
SPECT and SPECT/CT imaging should be 
performed bearing the following guidelines 
in mind:
Patient preparation:
• atients should avoid caffeine, alcohol and 
other drugs that can affect cerebral blood 
flow for 24 h prior to the study. 
• Patients should not smoke cigarettes on 
the day of the study.
• A thorough detailed history needs to be 
taken, focussing on past head trauma and 
previous radiological studies.
Pre-injection: 
• Ensure that the patient can comply with 
the scan procedures.
• Explain the scan procedure to the patient 
or to the designated healthy care proxy or 
caregiver.
• Have the patient relax in a dimly lit room 
where there are no external stimuli, 
including direct light, music, reading 
or speaking, for 20–30 min prior to the 
injection. Whether the eyes are kept 
opened or closed depends on the 
individual department’s policy.
• Obtain intravenous access with either an 
angiocath or a butterfly needle at least 10 
min prior to injection.
• Instruct the patient not to move, speak or 
read for at least 5 min after injection.
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• The patient should relax in the dimly 
lit room for 20–60 min or according to 
the departmental procedure during the 
uptake phase of the radiopharmaceutical 
(see Table 1).
Acquisition:
• After the uptake phase has been 
completed, the patient should void before 
being brought into the camera room.
• Position the patient on the imaging 
table in a supine position so that he or 
she is comfortable, with the arms down. 
Position the head so that it is in the 
middle of the field of view of the camera. 
The entire brain should be included in the 
field of view and a head holder or other 
light head restraint should be used to 
help reduce patient motion. 
• When imaging, use the smallest radius 
possible around the patient’s head to 
ensure diagnostic images are obtained.  
It is ideal to be able to set up a contour 
radius to enable the camera head to be as 
close as possible to the head at all times. 
If the camera does not allow for a contour 
radius to be set up, then it is best to use 
the smallest circulatory radius possible to 
ensure maximum image resolution. 
• Monitor the patient throughout the 
scan to ensure safety and to watch for 
motion. 
• A camera with multiple detectors or 
a dedicated brain imaging camera is 
preferred to a single-head system for 
SPECT. A SPECT/CT camera is also preferred 
as the scans can be fused for evaluation.
• The energy peak should be set at 140 keV 
and the energy window to 20%. 
• Low-energy high-resolution or ultra high-
resolution collimators should be used 
and the highest resolution collimators 
are preferred. Fan beam, parallel-hole 
collimators can be used if needed.
• The matrix should be 128×128 or greater. 
Acquisition pixel size should be 1/3–1/2 
the expected reconstructed resolution. 
It may be necessary to zoom in order to 
achieve the required pixel size. 
• The orbit should be 360° and as close as 
possible to the patient.
• A continuous acquisition is preferred 
over step and shoot with 20–40 s per 
projection.
• Segmenting the data will help reduce 
patient motion in the resulting images.
Data processing:
• All studies should be filtered in three 
dimensions (x, y and z), using low-pass 
filters (Butterworth) and at the highest 
pixel resolution.
• Be sure to reconstruct the entire brain 
from vertex to cerebellum using either 
the filtered back projection (FBP) or the 
iterative reconstruction method.  
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• Attenuation correction should be used 
on all data unless a specific protocol or 
case states otherwise. When a SPECT/CT 
is performed, the CT scan should be used 
for the attenuation correction. In the case 
of a stand-alone SPECT camera, Chang 
attenuation correction should be used. 
• Data should be reformatted for display in 
coronal, sagittal and transverse slices. 
• When SPECT/CT is performed, not 
only should the CT scan be used for 
attenuation correction (as mentioned 
above) but the resulting SPECT images 
can also be fused with CT for detailed 
images. 
Future of SPECT and SPECT/CT 
SPECT and SPECT/CT for imaging of brain 
tumours both entails challenges and of-
fers further potential rewards. PET scanners 
have rapidly gained popularity in the field 
of nuclear medicine as a means of obtain-
ing functional images of brain tumours. In 
most cases, SPECT tumour studies provide 
a similar amount of diagnostic information 
to that acquired with PET. This is useful as 
there are areas that do not have easy access 
to PET radiopharmaceuticals or PET cameras. 
As stated earlier, the main drawback of SPECT 
imaging of tumours is the lack of anatomical 
detail.  However, the advent of SPECT/CT 
has allowed for the co-registration or fusion 
of scans, resulting in images that show both 
anatomical and functional detail. Such im-
ages are very useful for tumour localisation 
and treatment planning.
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Table 1: Radiopharmaceuticals used for brain imaging in SPECT systems, with injected activities 
and uptake time
Radiopharmaceutical
Injected 
activity
Route Uptake time
99mTc-HMPAO
555–1110 MBq
(15–30 mCi)
Intravenous 
(through filter)
Recommended uptake time: 90 min
Minimum uptake time for interpretable 
images: 40 min
99mTc-ECD
555–1110 MBq
(15–30 mCi)
Intravenous
Recommended uptake time: 45 min
Minimum uptake time for interpretable 
images: 20 min
99mTc-Sestamibi
740 MBq
(20 mCi) Intravenous
Recommended uptake time: 
20–30 min
201Tl
111–148 MBq
(3–4 mCi)
Intravenous
Uptake time: 10–30 min
Delayed images can be acquired 
2–4 h post injection
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Figure 2: 99mTc-Sestamibi SPECT scan of a brain glioma demonstrating uptake in the tumour.
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Introduction
Molecular imaging techniques are used to 
generate maps of functional and biochemi-
cal activity in target tissues in vivo. Currently, 
positron emission tomography (PET) is one 
of the most successful techniques in the di-
agnostic work-up of brain tumours, its impor-
tance deriving from its ability to address vari-
ous metabolic features of gliomas that are rel-
evant to diagnosis, classification, characteri-
sation, preoperative evaluation, radiotherapy 
planning and post-therapeutic monitoring. 
Combined PET/CT imaging of brain tumours 
has similarly grown in importance, especially 
thanks to the increasingly widespread avail-
ability of radiopharmaceuticals. PET/CT not 
only contributes to differential diagnosis, but 
also offers the possibility of tailoring imag-
ing to different clinical indications. The two 
main metabolic features extensively studied 
so far are glucose metabolism by means of 
18F-FDG and amino acid transport (incor-
poration) using amino acid radiopharma-
ceuticals such as 11C-methionine (11C-MET), 
18F-fluoroethyltyrosine (18F-FET), 18F-labelled 
3'-deoxy-3'-fluorothymidine (18F-FLT) and 18F-
dihydroxyphenylalanine (18F-DOPA; fluoro-
dopa). In this chapter, in the spirit of continu-
ity with EANM and international guidelines 
on the topic [1–5], we shall cover the major 
clinical applications of these techniques, to-
gether with acquisition methods and patient 
preparation; some notes are also provided on 
quantitative imaging.
PET/CT acquisition techniques
PET/CT is defined as an integrated or multi-
modality technique that employs a combina-
tion of a PET and a CT system with a single, 
conjoined patient handling system [1]. It al-
lows sequential acquisition of corresponding 
PET and CT portions of the examination with 
the patient in the same position for both ex-
aminations and enables co-registration both 
data sets.
CT protocols
Attenuation correction is mandatory for 
PET/CT brain imaging. In older generation 
PET scanners, attenuation correction was 
achieved by transmission imaging acquired 
by the PET tomograph itself, using a 68Ge/68Ga 
source. Alternatively, some PET systems had 
transmission sources with 137Cs.
PET/CT systems have the ability to use the 
CT scan for attenuation correction [6]. The 
advantage of the CT scan is that the detec-
tion of X-rays from the CT scan is not affected 
by the emission photons; this allows the 
CT scan to be performed after the injection 
of the radiopharmaceutical, without affect-
ing the accuracy of the attenuation correc-
tion. A CT scan can be done for diagnostic 
purposes, using a regular tube current, or 
only for the purpose of attenuation cor-
rection, using a low tube current (typically 
10–30 mAs), i.e. a low-dose CT scan, which 
significantly reduces the radiation exposure. 
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The choice of type of CT scan depends on the 
purpose of the imaging and the clinical indi-
cations. If anatomical information is already 
available, a low-dose CT scan for the purpose 
of attenuation correction can be considered, 
whereas if recent anatomical information is 
not available, a diagnostic CT scan (with con-
tiguous slices) may be preferred. A diagnos-
tic CT (high mAs, contrast media injection) 
requires specific skills in radiology and spe-
cific radiologist guidelines must be followed. 
When CT is used for attenuation correction 
and localisation only (i.e. is not intended to 
be clinically diagnostic), the suggested work-
flow is:
• CT topogram
• Low-dose CT
• PET acquisition
When a contrast-enhanced diagnostic CT scan 
is also needed, it is advisable to perform it 
after PET acquisition, to avoid any possible 
impact of IV contrast on PET images and 
standardised uptake value calculation. 
CT acquisition parameters (Table 1) are 
strictly dependent on the equipment avail-
able and national regulations, the latter be-
ing particularly relevant to patient X-ray ex-
posure. The ALARA principle always applies 
and must be followed to avoid unnecessary 
exposure.
PET protocols
High-quality PET brain images can be ob-
tained only if strict procedures are adhered 
to, including respect to patient preparation, 
administration of adequate radiopharma-
ceutical activity, patient positioning and use 
of standardised acquisition protocols [8].
Patient preparation may vary for different 
radiopharmaceuticals and different indica-
tions (Table 2). It is commonly accepted 
that for 18F-FDG PET the patient should fast 
for at least 4 h to allow optimal cerebral 
uptake that is not influenced by increased 
serum glucose levels. Blood glucose levels 
should be checked prior to 18F-FDG admin-
istration. When hyperglycaemia is present 
(>160 mg/dl), 18F-FDG uptake is reduced in 
the whole brain and stochastic noise is in-
creased. However, in brain tumours, hyper-
glycaemia does not need to be corrected 
and can even enhance detectability [1]. 
Before the scanning procedure is started, the 
patient should void the bladder to ensure 
maximum comfort during the study. The pa-
tient should be informed about the total ac-
quisition time and advised to void again after 
the scanning session to minimise radiation 
exposure. The patient should be positioned 
comfortably in a quiet, dimly lit room for 
several minutes before 18F-FDG administra-
tion and during the uptake phase of 18F-FDG 
(at least 20 min) and should be instructed 
not to speak, read or be otherwise active. It 
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is desirable to have the cannula for intrave-
nous administration in place 10 min before 
18F-FDG administration. If a dynamic image 
is requested, the above procedures are to be 
followed with the patient positioned directly 
on the tomograph bed instead of in a differ-
ent room. 
Post-processing routines allow correction for 
minor obliquities of head orientation, so it is 
more important to reduce the probability of 
motion during acquisition than to achieve 
perfect head alignment. The patient must be 
informed of the necessity to avoid voluntary 
movements of the head and must be asked 
for her/his active cooperation. If cooperation 
is poor, sedation may be required. The pa-
tient’s head should be only lightly restrained, 
avoiding use of a fixed container that can 
create claustrophobia. If movement artefacts 
can be expected, segmentation of data ac-
quisition into multiple sequential acquisitions 
may permit the exclusion of segments of pro-
jection data affected by patient motion. 
The administered dose and scan param-
eters are strictly dependent on national 
regulations and the scanner used. EANM 
guidelines for 18F-FDG [1] suggest, for 
adults, 300–600 MBq (typically 370 MBq) 
in 2-D mode and 125–250 MBq (typically 
150 MBq) in 3-D mode. 
In preparation for a radiolabelled amino 
acid PET scan, patients are advised to take 
a low-protein meal 4 h before the injection, 
although this requirement is controversial. 
The patient may be requested to avoid tak-
ing specific drugs during preceding clinical 
evaluations [10].
Imaging may be performed as a dynamic ac-
quisition or a static acquisition 20 min after 
injection of 330–400 MBq of 11C-methionine 
or 18F-FET. As with 18F-FDG, radiopharmaceu-
tical administration consists in intravenous 
injection of a bolus followed by flushing with 
physiological saline solution. After the ad-
ministration, an interval of 10 min must be 
allowed before scanning.
Table 3 shows examples of how PET/CT scan 
is performed with two tomographs accred-
ited by the EARL project [11–13]. As noted 
above, we suggest that protocols should be 
adapted according to the scanner employed, 
following company suggestions and guide-
lines, both national and international.
18F-DOPA is an amino acid radiopharmaceu-
tical that accumulates in brain tumours via a 
transporter-mediated mechanism similar to 
that responsible for uptake of methionine. 
Many imaging protocols have been tested, 
for instance with scanning starting at an 
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earlier time point after injection (e.g. 20 min) 
or at a late time point, as is recommended 
for striatal imaging (e.g. 60–70 min) [14]. The 
European Association of Nuclear Medicine 
guidelines on paraganglioma imaging rec-
ommend a dose of 4 MBq/kg and imaging 
at 30–60 min after injection. In the evalua-
tion of brain tumours the best time interval 
for acquisition is between 10 and 30 min 
after injection because tumour uptake is 
near maximum and because imaging at this 
juncture is sufficiently early to avoid peak 
uptake in the striatum. All these parameters 
refer to adults; we recommend the EANM 
paediatric dosage card as a useful tool for 
determination of the activity to be adminis-
tered in children.
Quantitative PET/CT
PET/CT scans offer the possibility of acquir-
ing quantitative information on radiophar-
maceutical biodistribution inside a living 
organism, but robust standardisation is re-
quired to ensure reproducibility and to al-
low the use of imaging biomarkers in multi-
centre trials in which different scanners are 
employed. Efforts aimed at harmonisation of 
acquisition, evaluation and quantification of 
PET/CT studies have been concluded or are 
ongoing worldwide.
In Europe, the research branch of EANM, 
EARL, set up the 18F-FDG PET/CT accredita-
tion programme, which is also endorsed by 
the EORTC imaging group. It was launched 
in July 2010 with the objective of providing 
a minimum standard of PET/CT scanner per-
formance. The programme requires imaging 
sites to perform strict continuing quality con-
trol, making them highly eligible as partici-
pants in multicentre studies. Participation in 
the EARL programme is also useful as a qual-
ity self-test for departments, to ensure that 
routine patient examinations are of a high 
quality [11–13].
For tumour imaging, semiquantitative esti-
mates of glucose metabolism such as the 
standardised uptake value (SUV) are typically 
used. SUVs may vary significantly if acquisi-
tion procedures are not standardised, and 
correct, reproducible standardisation re-
quires efforts at every step of the schedule. 
For 18F-FDG exam quantitation, a static image 
is sufficient, usually acquired at 30 or 60 min 
after injection (after 18F-FDG has reached a 
plateau concentration in the lesion). In ad-
dition, the exact total activity of 18F-FDG 
administered and the patient’s weight and 
height for measurement of body surface area 
are required. A calibration factor is also need-
ed. These semiquantitative estimates can be 
corrected for blood glucose concentration. 
When using methionine, the first quantifica-
tion method routinely used is the tumour-to-
normal background ratio (T/N ratio), which 
compares uptake in the tumour to that in the 
contralateral frontal lobe or the correspond-
ing contralateral hemisphere. Generally, a 
threshold greater than 1.5–1.9 is used for the 
diagnosis of brain tumour, but large prospec-
tive studies are needed to set a fixed T/N cut-
off ratio. SUVs should also be used (maximum 
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or mean) but their true diagnostic value is 
still a matter of debate. MET accumulation 
in brain tumours reaches a plateau at 5–10 
min after the radiopharmaceutical injection. 
As for 18F-FDG scans, the SUV is influenced 
by many factors, some being technical, such 
as acquisition starting time, and others more 
clinical, such as the plasma concentrations of 
N-acetylaspartate, which may affect the up-
take of MET in a competitive fashion. 
Quality criteria and artefacts
Compliance with the above procedures may 
be expected to ensure an appropriate, sym-
metrical and readily interpretable represen-
tation of the reconstructed dataset. Internal 
landmarks can be used for reorientation to 
achieve a standardised image display. Reori-
entation procedures based on the intercom-
missural line are commonly used. The display 
of additional coronal and sagittal images is 
mandatory. Three-dimensional display of 
the dataset can be helpful for more accu-
rate topographic orientation in some clinical 
questions and to appreciate overall patterns 
of disease. The images should be critically ex-
amined by technologists after the scan to en-
sure that quality criteria are matched. Tech-
nologists also have to discuss with reporting 
physicians particular cases that may require 
additional scanning or reconstructions. Dur-
ing interpretation for the presence of move-
ment or attenuation artefacts, it is desirable 
to have a normal database available, prefer-
ably obtained on the same type of tomo-
graph, using the same acquisition position-
ing and parameters and the same type of 
reconstruction and attenuation correction as 
are used in routine scans. Matching spatial 
resolution is the most important parameter 
for optimal database use. This allows assess-
ment of normal variability of regional 18F-FDG 
uptake and improves diagnostic accuracy. 
Data interpretation should take into consid-
eration global changes, such as relative corti-
cal hypometabolism and regional decreases 
or increases in 18F-FDG uptake. Increased up-
take can be observed in active epileptogenic 
foci, tumours and inflammation. Known mor-
phological changes such as atrophy should 
be considered in the interpretation. 
The following list identifies some possible 
sources of misinterpretation that must be 
taken into consideration when deciding 
whether a scan matches quality criteria:
• Artefacts (Figs. 1,2)
 - Patient movement
 - Scanner related
 - Induced by inappropriate processing
 - Insufficient attenuation correction
 - Soft tissue or skull uptake following 
surgery in the area of the skull or brain
• Unintended cerebral activation (i.e. visual 
or motor activation)
• Psychotropic drugs or corticosteroid use
• Sedation
• Recent radiotherapy or chemotherapy
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Figure 1: Movement artefact: MIP (top left), PET (top right), CT (bottom left) and fused PET/CT 
(bottom right) images
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Figure 2: Metallic artefact: MIP (top left), PET (top right), CT (bottom left) and fused PET/CT 
(bottom right) images 
Brain imaging with 18F-FDG
The Warburg effect, i.e. the increase of an-
aerobic glycolysis even in aerobic conditions, 
explains the glucose avidity of tumour cells 
and constitutes the basis for the 18F-FDG up-
take (Fig. 3). Despite the high physiological 
background uptake of 18F-FDG in normal brain, 
which limits the possibility of discriminating 
neoplastic lesions, 18F-FDG PET/CT applications 
are reported in the literature for the purposes 
of tumour diagnosis, metabolic grading and 
prognosis, volume estimation and follow-up.
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Figure 3: 18F-FDG-positive brain lesion on axial CT (left) and fused PET/CT (right) images
Delbeke et al. described a sensitivity of 94% 
and a specificity of 77% for 18F-FDG PET in 
the detection of high-grade gliomas [16]. 
Some authors suggest that delayed imag-
ing at 3 up to 7 h post injection could help 
in the analysis of normal grey matter uptake 
and oncological uptake [17].
18F-FDG uptake has been used to assess the 
prognosis in patients with high-grade (grade 
3 or 4) astrocytomas, the uptake being high-
er in patients with a poorer prognosis and 
lower in those with a superior mean survival 
[18]. Similar results regarding the associa-
tion of tumour 18F-FDG uptake with patient 
survival were also reported by Alavi et al.: a 
positive PET scan with hypermetabolic brain 
lesions correlated with a poor prognosis as 
the rate of glycolysis increased in line with 
the degree of malignancy in primary cerebral 
tumours [19]. Another interesting potential 
application that has been investigated is the 
use of 18F-FDG PET/CT to differentiate among 
common enhancing brain tumours such as 
lymphomas, high-grade gliomas and metas-
tases [20]. 
18F-FDG PET/CT imaging is also used to 
provide an early assessment of the efficacy 
of chemotherapy based on its value in pre-
dicting tumour metabolic response to te-
mozolomide, which allows oncologists to 
adopt a more tailored approach [21]. Some 
authors have studied the potential of 18F-FDG 
to improve accuracy in stereotactic biopsy. 
The literature available so far on the use of 
18F-FDG PET/CT in primary tumours remains 
somewhat heterogeneous; nevertheless, 
thanks also to its widespread diffusion and 
standardisation, this technique is still attrac-
tive and promising as a complementary pro-
cedure that assists in completion of tumour 
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characterisation as the basis for improving or 
changing patient management [22].
Brain imaging beyond 18F-FDG
In order to overcome the limitations of the 
use of 18F-FDG in brain imaging, which are 
due to its physiological uptake in the grey 
matter, other radiopharmaceuticals have 
been developed. In particular, radiola-
belled amino acids (11C-methionine, 18F-FET, 
18F-DOPA) are currently the most commonly 
used PET radiopharmaceuticals for imaging 
of brain tumours. Another radiopharmaceu-
tical introduced for imaging of cellular pro-
liferation is choline, a precursor in the phos-
pholipid synthesis required for the produc-
tion of the cell membrane. Choline is usually 
labelled with 11C or 18F. Somatostatin recep-
tor expression on the tumour surface, on the 
other hand, may be investigated by means of 
somatostatin receptor PET/CT thanks to the 
development of somatostatin analogues.
In this chapter, however, we prefer a more 
technical approach to a purely clinical one, 
and we have therefore decided to group ra-
diopharmaceuticals according to the radio-
nuclide used (Table 4) instead of the tumour 
features analysed. Therefore the following 
sections will focus on 18F- radiopharmaceuti-
cals other than 18F-FDG, 11C-radiopharmaceu-
ticals and 68Ga-radiopharmaceuticals.
With regard to the metabolic pathways and 
tumour features, the main families of avail-
able radiopharmaceuticals are summarised 
in Table 5.
Other 18F-labelled radiopharmaceuticals
L-Dihydroxyphenylalanine (L-DOPA) is not an 
amino acid, but it is regarded as an amino 
acid analogue, being the product of the es-
sential amino acid L-tyrosine. It was first in-
troduced as a marker of the dopaminergic 
system and is widely used to investigate the 
in vivo transport to the basal ganglia for the 
diagnosis and follow-up of patients affected 
by Parkinson’s disease. Within oncology, it 
is known as a radiopharmaceutical for the 
noradrenaline system, which may be used to 
investigate neuroendocrine tumours such as 
phaeochromocytoma and neuroblastoma.
18F-DOPA PET/CT has also been proposed for 
the study of primary brain tumours because 
of the high uptake in tumours (Fig. 4) as com-
pared with the very low uptake in normal brain 
tissue (the basal ganglia represent the only ex-
ception). A sensitivity of 85% and a specificity 
of 89% have been reported for 18F-DOPA PET 
in the detection of primary brain tumours, and 
the method was identified as having further 
prognostic potential as a predictor of tumour 
grade and proliferation [24].
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Figure 4: 18F-DOPA PET/CT showing increased uptake in a left temporo-mesial astrocytoma
While a standard acquisition protocol is usu-
ally employed when imaging with 18F-DOPA, 
in a study by Schiepers et al that focussed on 
the kinetics of 18F-DOPA in brain tumours, dy-
namic PET images were acquired over a peri-
od of 75 min starting soon after injection. The 
results suggested that 18F-DOPA was trans-
ported but not trapped in tumours and that 
the uptake curve could be related to tumour 
grade. High-grade tumours showed an early 
peak of activity followed by a sharp decline 
whereas low-grade tumours showed a more 
smoothed curve with a gradual decline [25].
Magnetic resonance imaging (MRI) still rep-
resents the mainstay in primary brain tumour 
imaging; however, in an interesting study in-
volving comparative evaluation of 18F-DOPA 
PET and MRI in a population of 91 patients 
with histologically proven gliomas, concor-
dance between MRI and PET was observed 
in 90% of cases [26].
The use of 18F-DOPA for detection of recur-
rence of primary neoplastic disease in the 
brain is still a largely unexplored area.
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18F-Fluoroethyltyrosine (FET) is an artificial 
amino acid taken up into upregulated tu-
mor cells via enhanced expression of type L 
amino acid carriers and increased carrier-me-
diated transport, but not incorporated into 
proteins (in contrast to natural amino acids 
such as methionine). In a systematic review 
and meta-analysis by Dunet et al., 18F-FET 
showed an excellent performance in the ini-
tial evaluation of newly diagnosed brain pri-
mary tumours, with a sensitivity of 82% and 
an average specificity of 76%. 18F-FET yielded 
high-contrast images for both high- and low-
grade brain tumour, with low physiological 
uptake in surrounding normal brain [27].
18F-Fluorothymidine (FLT) is a marker of DNA 
synthesis in brain tumours; its uptake by 
brain tumours is possible in areas with a dis-
rupted blood-brain barrier. Its sensitivity for 
low-grade gliomas has been shown to be 
lower than that of methionine PET.
11C-radiopharmaceuticals
Methionine is an amino acid that is usually 
labelled with 11C for brain tumour imaging. 
Owing to the many further evaluations be-
yond the early feasibility studies, it is the most 
commonly used radiopharmaceutical for this 
purpose in different countries. Analogously 
to 18F-FET, its increased uptake appears to be 
a consequence of the upregulation of L-type 
amino acid transporter 1 (LAT1), reflecting 
cell proliferation.
11C-methionine PET/CT is indicated both at 
diagnosis, when it can contribute in assess-
ing the degree of malignancy and the prog-
nosis, in guiding biopsy and in evaluating 
tumour extent during radiation therapy (RT) 
planning, and after treatment, for evaluation 
of persistence of disease, response to therapy 
or relapse and for differentiation of recur-
rence from necrosis (Figs. 5–7). 
A
B
Figure 5: Methionine PET/CT [sagittal (A) and 
coronal (B) views] showing multiple foci of 
recurrent glioblastoma
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Figure 6 A–C: 18F-FDG PET/CT and 11C-methionine. An occipital brain lesion seen on CT images (A) 
shows faint 18F-FDG uptake (B) and intense 11C-methionine uptake
B CA
Figure 7 A–C: MRI (A), 18F-DOPA (B) and 11C-methionine (C) imaging of a low-grade astrocytoma 
11C-methionine PET offers high-contrast im-
aging of the brain, reportedly superior to the 
contrast achieved with 18F-FDG PET. It allows 
the detection of both high- and low-grade 
gliomas, but it is especially useful with regard 
to the former, for which it has a sensitivity be-
tween 76% and 95% [28]. Other intracranial 
tumours such as benign and malignant me-
ningiomas, pineal adenomas, and haeman-
gioblastomas also show intense methionine 
uptake, although false-positive results may 
be seen in benign conditions, such as de-
myelination, leukoencephalitis and abscess. 
Imaging can be performed as a dynamic or 
static acquisition 10 min after injection of 
370 MBq of 11C-methionine.
A multimodality approach including con-
trast-enhanced MRI, 11C-methionine PET and 
18F-FDG-PET is suggested for tumour grading 
and prognostication: a higher methionine 
uptake is related to a poor outcome, albeit 
better in low-grade and non-contrast-en-
hancing gliomas, whereas higher 18F-FDG 
uptake is a better predictor of poorer out-
come in high-grade and contrast-enhancing 
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gliomas. 11C-methionine PET has also been 
reported to detect progression with a sensi-
tivity of 90% and a specificity of 92%, whereas 
MRI alone showed a lower specificity (50%) 
for progression [29].
The increased phosphorylcholine synthesis 
in tumours constitutes the substrate for the 
clinical application of the choline-based ra-
diopharmaceuticals in the imaging of brain 
cancer. The concentration of choline in nor-
mal cerebral cortex is low, whereas moder-
ate uptake is seen in the choroid plexus and 
cavernous sinus. Extracerebral tissues such 
as extraocular eye, masticatory muscles and 
bone marrow show a moderately higher ra-
diopharmaceutical activity; parotid glands 
demonstrate intense uptake.
Towards the end of 1990s, 11C-choline was in-
troduced as a novel radiopharmaceutical to 
evaluate brain and prostate cancer [30] and 
in 2001 brain tumour images were acquired 
with 18F-choline in a patient with recurrent 
anaplastic astrocytoma [31].
Ohtani et al. compared 11C-choline PET, MRI 
and 18F-FDG PET in a series of patients with 
suspected brain tumours. They observed 
a correlation between 11C-choline and the 
histological tumour grade, with higher cho-
line uptake in high-grade gliomas, and sug-
gested that the combination of 11C-choline 
PET and MRI could improve the detection of 
high-grade gliomas [32] (cf. Fig. 8).
A B C
Figure 8: Oligodendroglioma. 11C-Choline PET (A), PET/CT (B) and post-processing fusion with 
brain MRI (C). The yellow arrow highlights the temporal lesion. Normal uptake is present in 
the choroid plexus 
In a comparative analysis of 11C-choline, 
11C-methionine and 18F-FDG PET, 11C-methio-
nine imaging was shown to be useful for the 
evaluation of grade, type and proliferative 
activity of astrocytic tumours, while choline 
appeared more useful in evaluating oligo-
dendroglial tumours. Both were superior to 
18F-FDG PET in terms of tumour localisation 
in all types of glioma [33].
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Glioblastomas and meningiomas are de-
scribed to show moderately intense choline 
uptake, whereas uptake in grade II and III 
gliomas is generally faint.
Choline PET appears a promising imaging 
technique for radiation therapy planning, of-
fering precise delineation of the biological 
target volume, and it is also able to discrimi-
nate between radiation necrosis and tumour 
recurrence with higher accuracy than MRI or 
18F-FDG PET.
A B
Figure 9 A, B: 68Ga-DOTANOC imaging of a frontal meningioma
68Ga-radiopharmaceuticals
Somatostatin is a neuropeptide produced 
by various neuronal, endocrine and immune 
cells. Imaging of somatostatin receptor (SSR) 
expression on tumour cells is widely applied 
and standardised. There are several peptides 
with a different range of affinity for soma-
tostatin receptor subtypes; at present the 
most frequently used radiopharmaceuticals 
are 68Ga-DOTATOC, 68Ga-DOTANOC (Fig. 9) 
and 68Ga-DOTATATE. These radiopharmaceu-
ticals are routinely employed for the imag-
ing of neuroendocrine tumours, in particular 
those arising from the gastroenteropancreat-
ic tract; however, some intracranial tumours 
can show increased expression of SSR and 
therefore can be evaluated for this feature as 
well. Contradictory data have been reported 
on the positivity of 68Ga-DOTA-peptide PET 
in series of glial tumours: Reubi et al. [34] 
concluded that SSRs are expressed predomi-
nantly by low-grade gliomas, with 82% of 
low-grade gliomas (WHO grades 1 and 2) 
showing SSR expression compared with only 
2% of high-grade gliomas (WHO grades 3 
and 4). Others reported SSR expression 
mainly in high-grade gliomas, relating this 
observation to the loss of differentiation [35].
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Meningiomas are the most common non-
glial brain tumour arising from the arach-
noid membrane and overexpress SSR, par-
ticularly the SSR subtype 2; this explains the 
utility of 68Ga-DOTA-peptide imaging for 
meningioma [36].
In this scenario the role of SSR PET is to better 
define lesions that are indeterminate at MRI 
or CT but also to improve the contouring in 
RT planning and contribute in predicting the 
response to radiopeptide therapy. Other pos-
sible applications of SSR PET with respect to 
brain tumours are represented by pituitary 
adenoma, haemangioblastoma, medullo-
blastoma and neuroendocrine metastases to 
the brain from other sites [37].
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Tables
Table 1: Recommended preparation, contrast medium injection and CT acquisition parameters 
for brain imaging (adapted from [7])
Patient preparation Diet (3 h)
Patient position Supine/head first
Contrast medium injection Contrast medium 300–350 mg l/ml
First injection 60 ml, 1 ml/s
Delay 3 min
Second injection 50 ml, 1.5 ml/s
Acquisition Starting at the end of second injection
CT acquisition parameters Volume of investigation Vertex to C1 
Collimation N x 0.75 mm
Slice thickness 3–5 mm
Slice increments Continuous
Pitch 1
Rotation time 0.75–1 s
mAs 250
X-ray tube voltage 120
Resolution matrix 512 x 512
FOV 240 mm
Reconstruction filter Soft tissue
EA
NM
51
References Chapter 4     
Table 2: Patient preparation when using radiopharmaceuticals other than 18F-FDG (adapted 
from [9])
11C-Flumanezil No seizure during 1 day before scan  
(no standard/common practice)
11C-Methionine Low-protein diet 4 h before scan (no standard/common practice)
18F-Fluorothymidine No fasting required
18F-DOPA No dopaminergic or dopaminomimetic drugs 12 h before scan
18F-Fluoroethyltyrosine Low-protein diet 4 h before scan (no standard/common practice)
Table 3: Practical examples of different parameters used for brain imaging with two different 
EARL-accredited PET/CT scanners: scanner A is from 2006, with no time-of-flight technology and 
6-slice CT; scanner B is from 2012, with time-of-flight technology and 64-slice CT (adapted from [14])
Scanner A Scanner B
CT protocol CT protocol
Topogram 50 mA 
110 kV 
256 mm
Topogram 10 mA 
120 kV 
250 mm
Dose modulation 
parameters
80 mA 
130 kV
Dose modulation 
parameters
280 mA, maximum 
value 
140 kV
Slice 3 mm Slice 3.75 mm
Collimation 6 x 2 mm Collimation 64 x 3.75 mm
Rotation time 1 s Rotation time 1 s
Pitch 1.0 Pitch 0.984:1
Reconstruction for 
attenuation correction
H10s very smooth + 
3 mm, FOV 300 mm
Reconstruction for 
attenuation correction
AC wide view 
3.75 mm, FOV 500 mm
Reconstruction for 
imaging
H31s medium smooth 
+ 3 mm, FOV 250 mm
Reconstruction for 
imaging
Standard wide view 
0.625 mm, FOV 500 mm
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Scanner A Scanner B
PET protocol PET protocol
Scan duration bed 10 Scan duration bed 10 min
Matrix 256 Matrix 256
Zoom 2 DFov 30 cm
Reconstruction Iterations 2, subsets 8 Reconstruction VUE Point FX, iterations 
3, cut-off 4 mm, 
subsets 18, sharp IRON
Filter Gaussian Filter No filter axis Z
FWHM 4 mm FWHM /
Abbreviations: AC, attenuation correction; DFOV, display field of view; FOV, field of view;  
FWHM, full-width at half-maximum; IRON, General Electric proprietary name;  
VUE Point FX, General Electric proprietary name
Table 4: PET radionuclides in brain tumour imaging (modified from [23])
Radionuclide Half- 
life  
(min)
Mean ß+ 
energy  
(MeV)
Maximum ß+ 
energy  
(MeV)
Example of radiopharmaceutical
18F 109 0.25 0.63
18F-Fluorodeoxyglucose (FDG) 
18F-Dihydroxyphenylalanine (F-DOPA) 
18F-Fluoroethyltyrosine (FET) 
18F-Fluorothymidine (FLT) 
(18F-Choline)
11C 20.4 0.39 0.96 11C-Choline 
11C-Methionine
68Ga 68.1 0.84 1.90 68Ga-DOTA-peptide
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 Table 5: PET radiopharmaceutical families in brain tumour imaging
Metabolic pathways/tumour features Radiopharmaceutical
Amino acids: protein synthesis 
11C-Methionine
18F-Fluoroethyltyrosine (FET)
Amino acid analogues 18F-Dihydroxyphenylalanine (F-DOPA)
Nucleosides: DNA replication/cell proliferation 18F-Fluorothymidine (FLT)
Phospholipids: cell membrane synthesis
11C-Choline
(18F-Choline)
Somatostatin receptor expression 68Ga-DOTA-peptides
54
Chapter 5
Imaging in neurological and vascular brain diseases (SPECT and SPECT/CT) 
Filipa Lucena, Eva Sousa and Tânia F. Vaz
Introduction
Since the first in vivo studies of cerebral func-
tion with radionuclides by Ingvar and Lassen 
[1], nuclear medicine (NM) brain applications 
have evolved dramatically, with marked im-
provements in both methods and tracers. 
Consequently it is now possible to assess not 
only cerebral blood flow and energy metab-
olism but also neurotransmission [2]. Planar 
functional imaging was soon substituted by 
single-photon emission computed tomogra-
phy (SPECT) and positron emission tomog-
raphy (PET); it now has limited application in 
brain imaging, being reserved for the assess-
ment of brain death [3, 4]
In recent years, owing to their wide availability 
and superior spatial resolution, structural tech-
niques such as computed tomography (CT) 
and magnetic resonance imaging (MRI) have 
replaced NM functional imaging techniques 
in the assessment of patients with neurologi-
cal disorders. However, SPECT and PET can 
make valuable contributions in an expanding 
number of clinical situations, complementing 
structural imaging [5, 6]. In fact, multimodal 
approaches now have an established clinical 
role in neuroimaging applications, whereby 
the structural images permit anatomical lo-
calisation of the radiopharmaceutical distribu-
tion and also allow for some corrections (e.g. 
attenuation correction) [6].
Commonly accepted clinical indications for 
SPECT brain imaging include presurgical 
lateralisation and localisation of epilepto-
genic foci and the evaluation of suspected 
dementia, movement disorders, traumatic 
brain injury, cerebrovascular diseases (acute 
stroke, chronic ischaemia, preoperative eval-
uation and assessment of brain death), brain 
tumours and brain infections [7–10].
The available radiopharmaceuticals include 
brain perfusion tracers and neurotransmis-
sion binding agents. There are currently no 
SPECT tracers for the specific study of brain 
metabolism [11] (cf. Chapter 2).
Brain perfusion scintigraphy
Brain perfusion scintigraphy allows the as-
sessment of regional cerebral blood flow 
(rCBF), using radiopharmaceuticals that dis-
tribute proportionally to the regional tissue 
blood flow after intravenous injection and 
remain trapped for a sufficient length of time 
to allow acquisition of SPECT images. These 
specific perfusion compounds are small, neu-
tral, lipophilic and able to cross the blood-
brain barrier by passive diffusion [12]. The 
most widely used radiopharmaceuticals for 
brain perfusion SPECT are 99mTc-hexameth-
ylpropylene amine oxime (99mTc-HMPAO) 
and 99mTc-ethyl cysteinate dimer (99mTc-ECD). 
Non-specific perfusion radiopharmaceuti-
cals, such as 99mTc-diethylenetriamine penta-
acetic acid (99mTc-DTPA), can also be used for 
the evaluation of brain death, providing in-
formation on intracranial vascular flow.
Patient considerations
General information regarding patient prep-
aration can be found in Table 1, including 
specific considerations for each step of the 
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procedure. From a general point of view, 
patient preparation includes the withdrawal 
of any factor known to disturb rCBF, as it will 
affect the normal pattern of radiopharma-
ceutical distribution in brain. The length of 
time for which restrictions are imposed var-
ies depending on the duration of the distur-
bance produced in the rCBF. The restrictions 
may include dietary constraints, withholding 
of medication and control of environmental 
variables, such as exposure to visual, auditory 
and somatosensory stimuli. Special attention 
should be paid to potential disturbances in 
the minutes prior to injection of the radio-
pharmaceutical and during the uptake phase. 
The preparation procedure requires correct 
evaluation of the patient’s ability to cooper-
ate and good communication skills on the 
part of the NM technologists so that all the 
information and recommendations can be 
effectively conveyed [7, 13]. In uncoopera-
tive patients, sedative medication (e.g. short-
acting benzodiazepine) can be considered as 
long as administration is after the radiophar-
maceutical uptake phase, thereby avoiding 
sedation-induced blood flow changes [7, 8].
Technical considerations regarding image 
acquisition and processing
When positioning the patient for image ac-
quisition, NM technologists should observe 
various guidelines in order to avoid factors 
that may interfere with the obtained data 
and the clinical interpretation of results 
(cf. Table 1). 
Correct head positioning should be achieved 
using a head holder provided by the gamma 
camera manufacturer [13]: the centre of the 
head of the patient should be aligned with 
the centre of rotation, preventing displace-
ment of the head to the periphery of the field 
of view; the canthomeatal line (i.e. the line 
extending from the ear to the eye) should be 
oriented as vertically as possible; and there 
should be no rotation or lateral tilt of the 
head. Commercially available brain SPECT 
processing applications allow reorientation 
of the data after acquisition; however, these 
data manipulations may introduce errors, in-
cluding image blurring, highlighting the fact 
that head positioning is an important step in 
the procedure [13, 14]
Immobilisation devices should be used to 
provide slight restraint and, when comple-
mented by a comfortable position for the 
patient, reduce the probability of movement 
during SPECT acquisition [13].
Different acquisition protocols (cf. Table 1) 
can be used according to the clinical indica-
tions. Currently, planar imaging is used only 
for brain death studies, in early and delayed 
phases, either alone or in combination with 
SPECT, with brain-specific or non-specific 
agents. On the other hand, SPECT imaging 
is acquired in most clinical situations, after 
intravenous injection of 370–1110 MBq (in 
adults) of 99mTc-brain-specific radiopharma-
ceuticals and with a variable time delay be-
tween the injection and the acquisition in ac-
cordance with the radiopharmaceutical and 
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the clinical indication [7, 8, 15, 16]. Regardless 
of these variations, images should be com-
pleted within 4 h after injection owing to the 
radioactive decay [7].
Concerning SPECT acquisition parameters, 
the radius of rotation should be as short as 
possible, preferably less than 15 cm [7, 13, 17]. 
In this context, head holders deliver an addi-
tional advantage in eliminating the distance 
imposed by the shoulders and gamma cam-
era bed and allowing closer positioning of the 
detectors around the patient’s head. A typical 
SPECT acquisition is best acquired over a 360° 
rotation, along 120 projections with sufficient 
time per image to obtain a total number of 
counts exceeding 5 million (without scatter 
correction) [7, 13, 17]. Multidetector or dedi-
cated brain SPECT cameras will contribute 
to a decrease in total scan time and yield 
high-quality images. Also, detector sensitivity 
should be taken into account so that the time 
per projection can be controlled in order to 
obtain suitable statistical data [7, 13, 17].
Occasionally, brain perfusion scintigraphy 
can be performed under the effect of certain 
interventions with the goal of performing 
comparisons with a baseline procedure. In 
these cases, acquisition and processing are 
identical to those for the general procedure: 
· Vasodilatory challenge with acetazolamide 
(DiamoxTM) or an equivalent is indicated in the 
evaluation of several brain vascular disorders 
as it leads to an increase in rCBF in normal ce-
rebral vessels via dilatation. The 2-day protocol 
is simpler and preferable. The challenge por-
tion is performed first and if this yields normal 
results, omission of the baseline study may be 
considered. For further information regard-
ing this intervention, the relevant guidelines 
should be consulted [7, 8].
· Epileptic focus localisation: It is well estab-
lished that during an epileptic seizure an 
increase in cortical blood flow occurs in the 
area of the focal discharge [11]. Patients with 
focal epilepsy refractory to therapy may ben-
efit from surgical ablation of the seizure focus 
[4]by Drs. Fred A Mettler and Milton J Guiber-
teau, provides the practical and comprehen-
sive guidance you need to master key nuclear 
imaging techniques. From physics, instru-
mentation, quality control, and legal require-
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nuclear medicine. This excellent resource in 
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full text online at www.expertconsult.com, 
high-quality images, and unknown case sets 
for self assessment.Get comprehensive cover-
age of key techniques such as PET/CT, cardi-
ac-gated SPECT, and tumor-specific radionu-
clides, as well as Cerebrovascular System, Car-
diovascular System, Conventional Neoplasm 
Imaging and Radioimmunotherapy, and 
Positron Emission Tomography Imaging. Ref-
erence practical clinical guidance at a glance 
from important \”Pearls and Pitfalls\” in each 
chapter and. helpful appendices including 
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Injection Techniques, Pediatric Dosages, Non-
radioactive Pharmaceuticals, and many more 
Assess your understanding with a section of 
Unknown Case Sets-expanded in this edition. 
Find information quickly and easily with a full-
color format. Access the fully searchable text 
online at www.expertconsult.com. Apply the 
latest best practices thanks to extensive up-
dates of clinical guidelines that reflect recent 
changes in the practice of nuclear medicine, 
including the use of sodium fluoride (F-18 FDG 
for infections and Na F-18 for skeletal imaging, 
and brain perfusion scintigraphy contributes 
in localisation of the epileptogenic focus dur-
ing the ictal state [11]. For this purpose a 2-day 
protocol that documents perfusion in the ictal 
and interictal states can be performed. The 
main challenge when using this procedure 
concerns the radiopharmaceutical injection. 
Individual doses must be readily available at 
the patient’s bedside, allowing for rapid injec-
tion by a trained NM technologist at the onset 
of the seizure. In this way, the distribution of 
the radiopharmaceutical will reflect the rCBF 
at the time of ictus and delayed SPECT images 
will show the location of increased blood flow. 
Interictal SPECT studies add useful informa-
tion to the ictal study [7, 8].
General information on technical consider-
ations regarding imaging acquisition and 
processing is presented in Table 1.
Table 1: General information and procedures for brain perfusion SPECT and SPECT/CT [3, 7, 8, 18, 19]
PATIENT PREPARATION
Before arrival • Avoid, if possible, caffeine, alcohol, smoking, and any drugs known to affect rCBF.
At NM 
department
• Evaluate the patient for ability to cooperate  
(e.g. lie still for approximately 30–60 min).
• Place an intravenous cannula 10–15 min prior to radiopharmaceutical injection.
• Position the patient comfortably in a quiet room, with no interaction with other 
patients.
• Instruct the patient to keep the eyes and the ears open and also to not speak, read 
or move from at least 5 min before until 5 min after injection.
• If sedative medication is considered, it should be administered at least 5 min after 
radiopharmaceutical injection, and a few minutes before data acquisition.
• If vasodilation is considered, contraindications must be evaluated and the dosage 
of acetazolamide, prepared. The radiopharmaceutical is injected about 15–20 min 
after injection of acetazolamide because it is at this time that the vasodilatory 
effect is most pronounced.
• Patients should void prior to acquisition for maximum comfort during the study.
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PATIENT PREPARATION
Continuous supervision of patients during the procedures is necessary,  
especially for those with epilepsy and dementing disorders.
In the case of brain death scintigraphy no preparation is needed.
RADIOPHARMACEUTICAL
Administered 
activity
Adults: 
• 259–925 MBq for 99mTc-HMPAO (typical activity: 740 MBq) [7, 15]
• 370–1110 MBq for 99mTc-ECD (typical activity: 1110 MBq) [8, 16] 
Children (according to the EANM paediatric dosage card table Version 1.2.2014): 
• 99mTc-HMPAO: “baseline activity” = 51.8 MBq
• 99mTc-ECD: “baseline activity” = 32 MBq
• Administered activity = “baseline activity” × multiple 
• Minimum recommended: 110 MBq
DATA ACQUISITION
Time delay, 
injection - 
imaging
• 99mTc-HMPAO: best image quality at 90 min; after 30 min the image will be 
interpretable
• 99mTc-ECD: best image quality at 30–60 min
• Acquisition completed within 4 h after injection
Patient 
positioning
• Supine position with head on head holder and lightly restrained by immobilisation 
device
• Maximum possible vertical orientation of canthomeatal line
• No rotation or lateral tilt of the patient’s head
• Head of the patient centred in the gamma camera centre of rotation
Gamma 
camera
• Multiple detector (triple or dual head) or dedicated brain SPECT
• LEHR or LEUHR parallel-hole collimators. Fan-beam collimators might be preferred
Photopeak • 15–20% energy window centred around 140 keV
Dynamica • 1–3 s per frame for at least 60 s. Matrix 64×64 pixels. Anterior projection 
Statica 
• 500–1000 kcts. Matrix ≥128×128 pixels. Anterior, lateral and (if possible) posterior 
projections
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DATA ACQUISITION
SPECT
• Radius <15 cm, Matrix ≥128×128 pixels, <3° angulations in a 360° rotation; 
hardware zoom may be necessary; mode acquisition step and shoot (frequently) or 
continuous (reduce scan times); 120 projections, 20–30 s per projection, >5 million 
total counts (without scatter correction)
Zoom
• Selected to give an acquisition pixel size 1/3 to 1/2 of the expected resolution  
(e.g. 1.5 zoom)
CT scan (SPECT/
CT systems) 
[20–23] 
• CT for attenuation correction: 120–140 kV, 2.5 mA, rotational speed of 1 s, slice 
thicknesses of 3–5 mm, increment of 2.5 mm
DATA PROCESSING
Review of 
projection 
data
• Review of projection data in cine mode and sinograms is helpful for an initial 
determination of scan quality, patient motion and artefacts.
• Motion correction algorithms, if available, may be used before reconstruction for 
minor movements, but rescanning is necessary if there is substantial head motion.
Colour scale/
table
• Continuous colour scales. (For example, a common colour scale used is 
represented here:  . The brain regions with high 
perfusion are orange to white, and regions with lower perfusion are blue to black.)
• After use of a standard colour scale, only adjustments for background subtraction 
or contrast are recommended.
SPECT
Reconstruc-
tion
• Reconstruct the whole brain, including cerebellum.
• Filtered back-projection (FBP) or iterative reconstruction (e.g. OSEM) (may improve 
detection accuracy).
• Highest pixel resolution (one-pixel slice thickness).
• Filter and reconstruction parameters (cut-off, order, iterations and subsets) 
will depend on the injected activity, camera sensitivity and resolution, type of 
acquisition, clinical application and diagnostic reporting sensitivity.
Attenuation 
correction
• Chang’s method (homogeneous correction matrix, μ=0.12–0.14 cm−1) using the 
shape contouring of the head.
• Non-uniform attenuation correction method (e.g. CT scan) is recommended.
Display
• Images are reformatted into slices in 3 orthogonal planes (axial, coronal 
and sagittal). Correct reorientation is important for visual interpretation and 
semiquantification.
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DATA PROCESSING
Semiquantifi-
cation
• Regions of interest (ROIs) can be used to determine tracer uptake ratios in different 
cerebral regions, allowing estimation of the relative rCBF distribution within the 
brain. Corresponding structures in contralateral hemisphere or another reference 
region (e.g. cerebellum, hemisphere, total brain) can be compared and asymmetry 
indices may be used to enhance differences in rCBF.
• Spatial normalisation, comparison to normal databases and voxel-based analysis 
can also be performed.
• Image subtraction can be useful in the assessment of patients with epilepsy.
a Acquired only in cases of brain death scintigraphy with 99mTc-DTPA
Normal and pathological brain patterns
Although the brain presents a high vascular 
demand (about 15–20% of the cardiac out-
put), its limited ability to store energy means 
that a tightly regulated blood flow is required 
in order to provide the necessary amount of 
glucose and oxygen [5, 17, 24, 25]. Synaptic 
activity at the neuronal cell bodies represents 
the primary utilisation of blood, explaining 
the increased grey matter to white matter 
blood flow ratio of approximately 4:1 (80 ml/
min/100 g and 20 ml/min/100 g, respectively) 
[5, 11, 25]. This factor impacts on the distribu-
tion of the radiopharmaceutical in brain struc-
tures and the effect is visible on the acquired 
images. Cortical and subcortical grey matter 
structures are clearly distinguishable from 
white matter, presenting symmetrical uptake 
in both hemispheres [13]. Even though both 
99mTc-labelled radiopharmaceuticals (99mTc-
HMPAO and 99mTc-ECD) express the same spe-
cific brain pattern, slight differences may be 
observed (e.g. with regard to regional uptake 
in the thalamus and the cerebellum and non-
specific scalp and facial tissue background ac-
tivity) that seem to be related to the trapping 
mechanism [11, 13, 17] (Fig. 1). 
Figure 1: Normal brain perfusion SPECT with 
99mTc-HMPAO (transverse plane), showing 
cortical and subcortical grey matter uptake. 
In several pathologies, this normal pattern 
can be altered and the characterisation of 
distinct pathological patterns may help in 
the differential diagnosis. For example, cer-
tain subtypes of dementia, such as Alzheim-
er’s disease (AD), frontotemporal dementia 
(FTD) and dementia with Lewy bodies (DLB) 
present different patterns of regional hypo-
perfusion on brain perfusion scintigraphy. 
Classically, hypoperfused regions involve the 
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parieto-occipital cortex in AD, the bilateral 
frontal cortex in FTD and both frontal regions 
and the posterior association cortex in DLB 
[26].
In patients with intractable partial epilepsy 
who are candidates for epilepsy surgery, 
brain perfusion scintigraphy has an impor-
tant role in localising the ictal onset zone and 
seizure propagation pathways, both of which 
present as a focus or regions of hyperperfu-
sion on ictal phase imaging. Regions of func-
tional deficit associated with the ictal onset 
zone may also be identified on interictal 
phase imaging. In this context, image sub-
traction may be a valuable tool in the assess-
ment and interpretation of the results [27].
Brain perfusion scintigraphy is also helpful 
in vascular brain diseases owing to its value 
in predicting the malignant course of brain 
swelling with large hemispheric infarctions 
and in evaluating cerebral perfusion in non-
acute cerebrovascular disease [18, 28].
Flow imaging of rCBF with suitable radio-
pharmaceuticals has been used for early 
detection of stroke. Depending on the stage 
of stroke, i.e. early or late (cf. Fig. 2), the scinti-
graphic findings can be used to select those 
patients who may benefit from thrombolytic 
therapy. Although CT and MRI are more of-
ten employed, SPECT is sometimes advanta-
geous owing to its ability to detect ischaemic 
events earlier and with greater sensitivity and 
to predict accurately the infarct size (includ-
ing the penumbra area, i.e. the area that ben-
efits from early reperfusion interventions and 
is at the highest risk for expansion of irrevers-
ible injury) [6, 18, 29].
Later stages
“Misery 
perfusion”
“Luxury 
perfusion” 
rCBF is reduced
Tissue oxygen metabolism 
 is maintained
Ischaemia progresses
Damage to blood vessels
Stroke
Early stages
(i.e. few hours)
Figure 2: Early and later stages of stroke and flow/metabolism characterisation
Brain perfusion scintigraphy has also been 
shown to be effective in the study of transient 
ischaemic attacks. In these cases, imaging 
is performed under pharmacological stress 
using a cerebrovascular dilator such as ac-
etazolamide. Since abnormal vessels do not 
display a dilatory response to acetazolamide, 
SPECT images show a significant reduction in 
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radiotracer uptake in the cerebral regions fed 
by the affected blood vessels (analogous to 
observations when performing myocardial 
perfusion imaging with dipyridamole) [6]. 
In cases of chronic ischaemia, brain perfu-
sion scintigraphy can assess the functional 
reserve capacity before and after the ad-
ministration of acetazolamide in order to 
demonstrate impaired vascular reserve and 
maximum vasodilation in a territory referable 
to the presenting symptoms [7, 19]. 
Semiquantification based on regions of in-
terest (ROIs) provide an estimate of relative 
differences in rCBF based on comparison of 
radiopharmaceutical uptake ratios between 
affected and reference regions (e.g. right/left 
asymmetries) [7, 19].
Brain neurotransmission SPECT
There are several neural pathways that can 
be evaluated by brain SPECT imaging. In this 
chapter we focus on the assessment of dopa-
minergic system neurotransmission.
Parkinson’s disease (PD) is a neurodegen-
erative disorder in which there is progres-
sive loss of dopamine neurons in the nigros-
triatal system, leading to widespread motor 
symptoms (e.g. bradykinesia, rigidity, tremor 
and impaired balance) and cognitive impair-
ments [30, 31]including Parkinson’s disease, 
multiple system atrophy and progressive su-
pranuclear palsy. The results of post-mortem 
studies point to dysfunction of the dopami-
nergic neurotransmitter system in patients 
with parkinsonism. Nowadays, by using sin-
gle-photon emission tomography (SPET.
Studies with radiopharmaceuticals that bind 
to transporters or receptors of neurotrans-
mitters are usually very accurate and offer a 
good approach for quantification of the do-
paminergic neurons lost. These techniques 
of functional molecular imaging are very 
useful for evaluation of disease progression 
and response to therapeutic interventions 
and for assessment and monitoring of the 
neural mechanisms underlying parkinson-
isms. Additionally, other major clinical ap-
plications are the differential diagnosis 
between PD and other neurodegenerative 
parkinsonian syndromes, between parkin-
sonian syndromes and essential tremors 
(ET) and between DLB and other dementias 
[9, 10, 30, 32]performing, interpreting and 
reporting the results of clinical dopamine 
D2 receptor SPECT or PET studies, and to 
achieve a high quality standard of dopamine 
D2 receptor imaging, which will increase 
the impact of this technique in neurological 
practice.The present document is an update 
of the first guidelines for SPECT using D2 re-
ceptor ligands labelled with (123. In Europe, 
the most widely used radiopharmaceuticals 
for SPECT in this context are iodine-123 
N-(3-fluoropropyl)-2β-carbomethoxy-3β-
(4-iodophenyl)nortropane ([123I]FP-CIT) and 
iodine-123 2β-carboxymethoxy-3β-(4-iodo-
phenyl)tropane ([123I]β-CIT) for imaging of 
the DAT (presynaptic) and [123I]iodobenza-
mide (123I-IBZM) and [123I]epidepride for imag-
ing mainly of the D2 receptor (postsynaptic). 
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The study of transporter and receptor bind-
ing allows assessment of (a) the presynaptic 
nigrostriatal neurons through evaluation of 
the dopamine transporter (DAT) and (b) the 
postsynaptic dopaminergic function through 
evaluation of the dopamine receptors D2 and 
D1 [9, 10, 30]including Parkinson’s disease, 
multiple system atrophy and progressive su-
pranuclear palsy. The results of post-mortem 
studies point to dysfunction of the dopami-
nergic neurotransmitter system in patients 
with parkinsonism. Nowadays, by using sin-
gle-photon emission tomography (SPET. 
Patient considerations
General information regarding patient prep-
aration can be found in Table 2, including 
specific considerations for each step of the 
procedure.
Table 2: General information and procedures for brain SPECT with DAT ligands ([123I]β-CIT and 
[123I]FP-CIT) and dopamine D2 receptor ligands ([
123I]IBZM and [123I]epidepride) [9, 10]
PATIENT PREPARATION
[123I]β-CIT and [123I]FP-CIT [123I]IBZM and [123I]epidepride
Before arrival Avoid smoking, and any drug that 
causes binding potential deficit, such 
as: cocaine, amphetamines, central 
nervous system stimulants, modafinil, 
antidepressants, adrenergic agonists, 
anticholinergic drugs, opioids, 
anaesthetics.
Withdrawal of drugs known to affect D2 
receptor binding, such as: dopamine 
agonists, neuroleptics, other drugs (e.g. 
metoclopramide, cinnarizine, flunarizine, 
amphetamine, methylphenidate).
At NM 
department
• Evaluate the patient for ability to cooperate  
(e.g. lie still for approximately 30–60 min).
• For exams with 123I-ligands it is necessary to block the thyroid gland with an 
adequate regimen (e.g. at least 200 mg of sodium perchlorate given at least 5 min 
prior to injection) to prevent accumulation of free radioactive iodine in the thyroid.
• Patients should void prior to acquisition for maximum comfort during the study.
RADIOPHARMACEUTICAL
Administered 
activity
• Adults: 150–250 MBq (typical activity, 185 MBq) [9, 10] 
• Children: No data available and no clinical indications established
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DATA ACQUISITION
Time delay, 
injection – 
imaging
• [123I]FP-CIT: 3–6 h after injection
• [123I]β-CIT: 18–24 h after injection
• [123I]IBZM: 1.5–3 h (best image quality at 2 h)
• [123I]Epidepride: 2–3 h
Positioning • Similar to brain perfusion SPECT
The preparation procedure requires correct 
evaluation of the patient’s ability to cooper-
ate and good communication skills on the 
part of the NM technologist so that all the in-
formation and recommendations can be ef-
fectively conveyed. Sedation can be consid-
ered in uncooperative patients and should 
be given at the earliest 1 h prior to the SPECT 
acquisition [9, 10].
For exams with 123I-ligands it is necessary to 
block the thyroid gland with an adequate 
regimen (cf. Table 2).
Patient preparation includes the withdrawal 
of any drugs that affect the binding to DAT 
or D2 receptors: a withdrawal period at least 
five times the drug’s biological half-life is rec-
ommended. Antiparkinsonian drugs do not 
markedly affect DAT binding and therefore do 
not need to be withdrawn prior to DAT SPECT, 
but it is possible that L-DOPA drugs down-
regulate DAT expression and caution is ad-
vised in intra-individual follow-up studies. The 
binding of the radioligand to the D2 receptors 
can be compromised by many antiparkinso-
nian drugs (in particular dopamine agonists), 
neuroleptics and other drugs [9, 10]. 
Technical considerations regarding imaging 
acquisition, processing and quality control
When positioning the patient for imaging 
acquisition, NM technologists should take 
into account various factors that may inter-
fere with the data obtained and the clinical 
interpretation of the results. Correct head po-
sitioning is essential, as previously described 
for brain perfusion SPECT, and immobilisa-
tion devices are also recommended [9, 10].
Different acquisition protocols (cf. Table 2) 
are used for image acquisition with DAT 
([123I]β-CIT and [123I]FP-CIT) and D2 receptor 
ligands ([123I]IBZM and [123I]epidepride). All 
of these radiopharmaceuticals are admin-
istered by intravenous injection of 150–250 
MBq (typically 185 MBq). For DAT tracers, the 
interval between the injection and image 
acquisition is 8–24 h for [123I]β-CIT and 2–6 
h for [123I]FP-CIT. Regarding the D2 receptor 
tracers, the images should be acquired 1.5–3 
h (preferably 2 h) after administration of [123I]
IBZM and 2–3 h after administration of [123I]
epidepride [9, 10]. 
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Regardless of the variations, it is recom-
mended that a fixed interval is used between 
radiopharmaceutical administration and im-
age acquisition to ensure that data are com-
parable between subjects and intra-individu-
al follow-up studies [9, 10].
General information on imaging acquisition 
and processing is presented in Table 3. 
Table 3. General data acquisition and processing information for brain SPECT and SPECT/CT 
with dopamine transporter ligands ([123I]β-CIT and [123I]FP-CIT) and the dopamine D2 receptor 
ligand ([123I]IBZM and [123I]epidepride) [9, 10, 33, 34]
[123I]β-CIT and [123I]FP-CIT [123I]IBZM and [123I]epidepride 
D
AT
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Gamma 
camera
• Multiple detector (triple or dual head) or dedicated brain SPECT
• LEHR or LEUHR parallel-hole collimators. Fan-beam collimators may be preferred
Rotation
• Smallest possible rotational radius (typical 11–15 cm)  
with appropriate patient safeguard 
• Angle increments of 3° (360° rotation) with circular orbit
Matrix • ≥128×128 pixels
Photopeak • 15–20% energy window centred around 159 keV
Zoom
• Selected to give an acquisition pixel size 1/3 to 1/2 of the expected resolution 
(e.g. 1.5 zoom)
Acquisition • Step and shoot (frequently) or continuous mode (reduces scan times)
Total counts
• >1.5 million (FP-CIT);  
>1 million (β-CIT)
• >3 million
Total scan 
time
• Triple-head camera: 30 min (e.g. 120 
projections, 40 each head;  
45 s/projection)
• Dual-head camera: 30–45 min  
(e.g. 120 projections, 60 each head; 
30–40 s/projection)
• The number of s/projection depends 
on the sensitivity of the system
• Dual-head camera: 40–50 min  
(e.g. 120 projections, 60 each head; 
40–50 s/projection)
• Triple-head camera: for the same scan 
time, higher count statistics
CT scan 
(SPECT/CT 
systems) 
[20–23] 
• CT for attenuation correction: 120–140 kV, 2.5 mA, rotational speed of 1 s,  
slice thicknesses of 3–5 mm, increment of 2.5 mm
• Anatomical location of radiopharmaceutical accumulation:  
20–40 mA (other parameters are the same)
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[123I]β-CIT and [123I]FP-CIT [123I]IBZM and [123I]epidepride 
D
AT
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Review of 
projection 
data
• Review of projection data in cine mode and sinograms is helpful for an initial 
determination of scan quality, patient motion and artefacts.
• Motion correction algorithms, if available, may be used before reconstruction for 
minor movements, but rescanning is necessary if there is substantial head motion.
Colour scale/
table
• Continuous colour scales, preferably the “cold” colour scales.
• After use of a standard colour scale, only adjustments for background 
subtraction or contrast are recommended. 
Re-
construction
• Filtered back-projection (FBP), or preferably, iterative reconstruction (e.g. OSEM).
• For FBP, a low-pass Butterworth filter is recommended, with a cut-off of 0.4–0.5 
and a power factor of 8–10. Filtering includes either 2D prefiltering of the 
projection data or 3D postfiltering of the reconstructed data.
• For OSEM, the reconstruction parameters can be: 2, 4 or 6 iterations, 10 subsets.
• The reconstructed pixel size should be 3.5–4.5 mm with one-pixel slice thickness.
Attenuation 
correction
• Chang’s method (homogeneous correction matrix, μ=0.1 cm-1) using shape 
contouring (if available) of the head.
• CT scan (measured correction matrix).
Display
• Images are reformatted into slices in 3 orthogonal planes (axial, coronal and sagittal). 
Correct reorientation is important for visual interpretation and semiquantification.
Semiquanti-
fication
• Select transverse slices (highest striatal binding slices, at least 3 consecutive 
slices, or the entire striatal volume) for ROI definition.
• ROIs should be drawn in the striatum and the striatal subregions (caudate, 
putamen), to assess specific dopamine transporter (CIT)/receptor ([123I]IBZM) 
binding. The reference regions (background) without (or with low) density can 
be the occipital cortex or cerebellum.
• Semiquantification techniques: classic manual ROIs (most widely used), manual 
volumes of interest (VOIs), more advanced automated systems using VOIs and 
voxel-based mathematical systems.
The influence of SPECT acquisition param-
eters, such as radius of rotation, rotation, 
number of projections and use of dedicated 
cameras, has already been described and 
those considerations also apply to DAT and 
D2 receptor ligand scintigraphy. After the 
data acquisition, planar projection images 
and the sinogram/linogram should be im-
mediately inspected by the NM technologist 
in order to identify any patient motion that 
might require repetition of the acquisition. 
Minor patient movement can be easily cor-
rected using motion correction algorithms 
provided by commercial workstations. In 
these exams a certain degree of movement 
is to be tolerated given the patients’ clini-
cal conditions; nevertheless, the correction 
provided by algorithms may not be accurate 
and therefore should be used wisely.
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In general, after processing and image re-
formatting into three orthogonal planes, vi-
sual assessment of the images is performed 
and segmentation procedures are used to 
obtain semiquantitative information. Sev-
eral segmentation methods may be applied 
(e.g. ROI) manually, semi-automatically or full 
automatically. When segmentation is per-
formed manually, the use of non-continuous 
colour tables may overestimate findings 
due to abrupt colour changes. Semiquanti-
fication is intended to allow assessment of 
the ratio between specific binding (in the 
striatum and striatal subregions) and non-
specific binding regions (e.g. occipital cor-
tex, cerebellum). The reference ROI is drawn 
in regions with absent (or low) binding po-
tential (low density of DAT and D2 ligands). 
The segmentation method is similar for DAT 
and D2 receptor ligands. It is helpful if the 
ROI size (which should be at least twice the 
full-width at half-maximum) and shape are 
standardised (e.g. by use of an atlas or tem-
plates). When feasible, ROI definition may be 
based on individual morphology as revealed 
by image fusion with MRI, which is particu-
larly important when low specific binding is 
expected (e.g. in the case of a severe loss or 
blockage of the DAT) [9, 10, 35]. 
It is useful to compare the patient-specific 
binding values (cf. Eq.1) [33] with data from 
normal subjects (preferably age-matched) 
obtained with the same technique.
Specific binding values= 
(mean counts of striatal ROI – mean counts of non-specific ROI
(mean counts of non-specific ROI)
(Eq.1)
These values can be obtained from a central 
database or can be established for each de-
partment. It is only possible to use control 
values from a central database if phantom 
studies are performed and are demonstrat-
ed to allow comparable calculations for the 
different imaging set-ups used. Sometimes 
intra-individual comparisons are useful in 
patient follow-up (i.e. baseline vs follow-up 
for therapy control or assessment of disease 
progression), and standardised evaluations 
using approaches based on stereotactic nor-
malisation are especially useful for more reli-
able verification of subtle changes [9, 10, 35]. 
Normal and pathological brain patterns
Functional imaging provides information on 
regional abnormalities in dopaminergic sys-
tem function (pre- and postsynaptically). The 
highest density of dopamine neurons oc-
curs in the nigrostriatal dopamine pathway, 
which is related to the increased radiophar-
maceutical uptake by these structures in DAT 
and D2 receptor imaging.
In the transverse plane of the normal brain im-
age, the striatum is clearly visible and symmet-
rical (right and left striatum). It is composed of 
the caudate and the putamen, the head of the 
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caudate having the shape of a small sphere 
and the putamen, that of a crescent (Fig. 3). 
The image appearance is similar with both 
types of ligand in healthy controls [30, 35].
Figure 3: [123I]FP-CIT scintigraphy (transverse 
plane) reconstructed by FBP, showing the 
symmetrical striatum in a healthy control. 
When imaging with DAT ligands, binding 
decreases with the evolution of PD, parkin-
sonian syndromes (e.g. multiple system atro-
phy and progressive supranuclear palsy) and 
DLB. Initially, reduced uptake is observed in 
the putamen, while in later stages caudate 
uptake is also affected. In patients with PD, 
the uptake of DAT ligands is related to the 
clinical stage and disease severity and has an 
important role in early diagnosis and assess-
ment [30, 35].
In dementias other than DLB and ET, the 
SPECT image with DAT ligands is normal 
[9, 10, 30, 32]performing, interpreting and 
reporting the results of clinical dopamine 
D2 receptor SPECT or PET studies, and to 
achieve a high quality standard of dopamine 
D2 receptor imaging, which will increase 
the impact of this technique in neurological 
practice.The present document is an update 
of the first guidelines for SPECT using D2 re-
ceptor ligands labelled with (123, allowing 
the differential diagnosis between parkin-
sonian syndromes and ET and also DLB and 
other dementias.
In the case of D2 receptor imaging, there is a 
difference in binding between PD and other 
parkinsonian syndromes, which allows dif-
ferential diagnosis that is not possible on the 
basis of DAT imaging [30]including Parkin-
son’s disease, multiple system atrophy and 
progressive supranuclear palsy. The results of 
post-mortem studies point to dysfunction of 
the dopaminergic neurotransmitter system 
in patients with parkinsonism. Nowadays, 
by using single-photon emission tomogra-
phy (SPET. In the early stages of PD there is 
a short-lived increase in D2 receptor binding 
(postsynaptic) in response to depletion of 
synaptic dopamine levels. Disease progres-
sion and increasing degeneration of nigros-
triatal dopamine neurons leads to a slight 
decrease in binding in late stages; by com-
parison, in other parkinsonian syndromes a 
decrease is observed throughout the course 
[30]including Parkinson’s disease, multiple 
system atrophy and progressive supranucle-
ar palsy. The results of post-mortem studies 
point to dysfunction of the dopaminergic 
neurotransmitter system in patients with 
parkinsonism. Nowadays, by using single-
photon emission tomography (SPET). 
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 As the presynaptic dopaminergic neurons 
are affected in PD and in atypical parkinson-
ism, it is useful to perform joint evaluation of 
pre- and postsynaptic function, by assessing, 
with specific radiopharmaceuticals, DAT and 
D2 receptors [36].
Challenges and opportunities in SPECT 
and SPECT/CT imaging for neurological 
and vascular brain diseases
In recent years neuroimaging has evolved 
rapidly, with major contributions from func-
tional and structural imaging techniques. The 
greatest challenges at present include the 
optimisation of instrumentation and com-
putation and also the development of new, 
more accurate radiopharmaceuticals. 
Improvements in image quality and quanti-
fication methods will enhance spatial reso-
lution and sensitivity, optimise the integra-
tion of different modalities and support the 
development of new algorithms for recon-
struction and processing of data [37]. In this 
context the use of databases of normalised 
values representative of normal or pathologi-
cal populations also has an important role, 
providing anatomical information or localisa-
tion and allowing more accurate quantifica-
tion procedures [38]. Attenuation correction 
(AC) for brain SPECT imaging is also a sub-
ject that will need further research. For brain 
perfusion images, AC should be performed 
with CT (from SPECT/CT) rather than Chang’s 
method given that application of the lat-
ter approach often causes overestimation 
of frontal perfusion and underestimation of 
posterior perfusion, i.e. non-uniform attenua-
tion correction is required to accurately esti-
mate rCBF [20, 39]. On the other hand, when 
performing DAT and D2 receptor imaging no 
significant differences in visual interpretation 
or semiquantification are observed depend-
ing on whether CT or Chang’s method is used 
for AC; Chang’s method is to be preferred in 
this context in order to avoid the additional 
radiation exposure from CT [21].
Crucial to the growth of NM techniques is the 
continued development of molecular probes 
that can bind to the target biological recep-
tor with high selectivity. In the field of brain 
imaging, the development of new tracers 
with more specific and better characteristics 
is contributing greatly to improvements in 
SPECT imaging, and numerous relevant re-
search initiatives are being conducted [40]. 
It is certain that new challenges and oppor-
tunities will arise from closer collaboration 
between those working on fundamental/
applied research and on the clinical appli-
cations of brain SPECT; the outcome will be 
enhanced non-invasive in vivo visualisation 
of biological processes at the molecular and 
cellular levels, to the benefit of patients.
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Chapter 6 
Imaging in Neurological and Vascular Brain Diseases (PET/CT) 
Ian Law, Valentina Garibotto and Marco Pagani
PET/CT cameras and brain imaging 
Since the introduction of the first systems 
in 2001, the field of clinical PET/CT has ex-
perienced impressive growth in terms of 
system design and functionality, supportive 
software solutions and the availability and 
range of clinically approved PET tracers. De-
velopments were initially directed towards 
the creation of solutions for implementation 
primarily in systemic oncology, rather than 
in brain studies. Over the intervening years, 
however, clinical brain PET imaging has ben-
efitted tremendously through the use of 
available equipment and organisation. The 
number of clinical brain PET scans at a clinical 
site might not initially be sufficient to justify 
the acquisition of a PET/CT scanner, but as a 
supplementary element in a production line 
dominated by oncology, brain PET studies 
can play a very significant role.
There are no technical or practical limitations, 
as such, to the potential uses of PET/CT scan-
ners for clinical brain PET scanning. Unen-
hanced CT of the head is performed initially 
and may be either of a clinical quality for di-
agnostic reading or a low-dose CT scan for 
the purpose of attenuation correction. The 
CT scanning has a duration of <1 min, so the 
number of CT slices, 4–128, is of no practical 
consequence in clinical routine. The number 
of CT slices does not significantly impact the 
clinical CT quality. All PET/CT systems have 
an axial field of view of 15–21 cm and will, 
thus, be able to acquire a full 3D brain vol-
ume in one bed position (see “Fact Box” next 
page”).
PET/CT clinical indications in neurological 
and vascular diseases
Dementias 
Dementia is a syndrome characterised by de-
terioration in multiple cognitive functions, as-
sociated with functional impairment and with 
a chronic course, due to a brain dysfunction. 
Neurodegenerative dementias are increas-
ingly prevalent, given their strong association 
with aging of the population, and are one of 
the most relevant causes of disability and de-
pendency among elderly people [1]. Alzheim-
er’s disease (AD) is the most common form, ac-
counting for up to 70% of cases; among other 
types, the most frequent are vascular dementia, 
dementia with Lewy bodies (DLB) and fronto-
temporal lobar degeneration (FTLD). The neu-
rodegenerative process of dementia presum-
ably lasts over decades, with a long preclinical 
phase without symptoms and a “prodromal” 
phase, identified by the term “mild cognitive 
impairment” (MCI), during which symptoms 
are mild, with a cognitive performance below 
average but without functional impairment 
[2]. The differential diagnosis among the vari-
ous forms is a critical and complex process, 
particularly in these early phases. An early di-
agnosis is important for disease management 
and proper treatment and also represents a re-
lief for patients and caregivers [3]. The different 
forms of dementia affect specific brain areas 
and neurotransmission systems and have dif-
ferent neuropathological features, identified 
by PET imaging, such as regional neuronal 
dysfunction or abnormal protein depositions; 
PET imaging is thus considered a “biomarker” 
of disease in the current recommendations on 
diagnostic guidelines [4]. 
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FACT BOX
Tips and tricks for the technologist:
Optimising scanner use
A 10-min 18F-FDG PET brain scan can be performed 40 min p.i. Whole-body 18F-FDG PET/CT 
is performed 60 min p.i. Thus, brain PET/CT scanning need not occupy a time slot for 
whole-body PET/CT if it is performed as the first scan in the morning. The two patients for 
brain and whole-body PET scanning are injected at the same time point with 18F-FDG when 
it becomes available, and the brain scanning will be finished before the whole-body PET 
scanning needs to commence.
Head movements
The most important duty of the technologist in order to accomplish a successful and diag-
nostic PET brain scan is to ensure secure head fixation during the scanning period, and to 
identify any head movements that nevertheless occur. Patients with neurological diseases 
may have difficulties in understanding and retaining instructions, have seizures during 
scanning, be agitated or suffer age-related degeneration in the spine. All of these factors 
may contribute to head movements during scanning. It is important (a) to identify these “at 
risk” patients prior to scanning through direct contact with patients, caregivers and refer-
ring clinicians and inspection of patient history and (b) to take appropriate measures. Such 
measures might be:
• Secure head fixation in a sturdy head holder, and placement of a leg rest under the 
knees to prevent downward patient movement.
• Placement of marks on the skin using a marking pen.
• Performance of a list mode acquisition or a range of short dynamic scans, e.g. 5 × 2 min. 
If head movements occur during the scan, a reconstruction of the first 5 min may be of 
sufficient clinical quality.
• Control for significant movement (>5–10 mm) at the end of scanning. If such 
movement has occurred, repeat CT for attenuation correction alone or in combination 
with a new brain 18F-FDG scanning sequence depending on circumstances.
If head movements occur, the CT attenuation and PET emission scans will no longer be aligned 
and significant artefacts may be present. If these artefacts were to pass unnoticed, an errone-
ous diagnosis would be made (e.g. Fig. 1). For more details, see the EANM guidelines [7].
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Figure 1 A–C: Examples of typical 18F-FDG PET images in healthy young subjects who moved 
their heads after low-dose CT (CT-AC), causing misalignment and quantitative reduction in 
regional activity. To the right are statistical surface projections (Scenium, Siemens) comparing 
the subjects with a database of age-matched controls. The observed changes could have led to 
misdiagnosis in a clinical setting if their cause had gone unnoticed, underlining the importance of 
head fixation. (A) Coronal images showing the consequence of movement (1.0 cm) in the scanner 
in the axial direction, with false reductions in uptake in the frontal areas bilaterally (red arrows). 
(B) Sagittal images showing the consequence of rotation of the head anteriorly (1.2 cm), with 
false reductions in uptake in the mesial frontal areas bilaterally (red arrows). (C) Transverse images 
showing the consequence of rotation of the head to the left (1.0 cm), with false reductions in 
uptake in the left cortical hemisphere and false increases in uptake in the right cortical hemisphere 
(red arrows)
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Figure 2: Example of a typical 18F-FDG PET image in Alzheimer’s disease (AD): the posterior 
cingulate cortex, precuneus and lateral parietal cortex have a significantly reduced metabolism 
(upper row) compared with a normal reference population (lower row: the green overlay indicates 
areas with significant hypometabolism, as analysed by BRASS™, Hermes Medical Solutions)
PET imaging of brain glucose metabolism, 
using 18F-fluorodeoxyglucose (18F-FDG) as 
the tracer, is a validated and routinely used 
method to show regional abnormalities, 
some of which are typical for the different de-
mentia syndromes [5–7]. AD is characterised 
by hypometabolism involving the temporo-
parietal association cortices, in particular the 
precuneus and posterior cingulate cortex (an 
example is provided in Fig. 2). Patients with 
DLB have a pattern similar to AD patients, the 
hypometabolism often extending to the oc-
cipital cortex and possibly sparing the pos-
terior cingulate region. FTLD includes various 
syndromes, such as the behavioural variant 
of frontotemporal dementia (bvFTD), char-
acterised by hypometabolism in frontal re-
gions, and corticobasal degeneration (CBD), 
which typically shows asymmetrical cortical 
(frontoparietal) and subcortical hypometab-
olism contralateral to the affected hemibody 
(Fig. 3). The visual identification of these spe-
cific patterns can be supported by various 
automated methods, usually based on the 
normalisation of individual images to a refer-
ence space and then on the semi-quantifica-
tion of abnormalities relative to the distribu-
tion observed in a group of healthy subjects 
[8, 9]. An example is provided in Fig. 2.
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Figure 3: Example of the hypometabolism observed in cases of corticobasal degeneration 
(CBD) involving the frontoparietal cortex and the basal ganglia of the left hemisphere (arrows) 
During the last decade, specific tracers able 
to visualise amyloid plaques in vivo have 
been tested and validated in humans. The 
first was the 11C-Pittsburgh compound B (11C-
PIB), which was able to bind fibrillary amyloid 
with a good correlation with post-mortem 
measures [10–12]. More recently, 18F-labelled 
compounds, patented by industrial com-
panies, have been approved by regulatory 
agencies both in Europe and in the United 
States for use in patients with prodromal or 
atypical dementia. These tracers have been 
validated in phase II and phase III trials for 
their ability to discriminate healthy controls 
and patients with AD and to identify amyloid 
deposits in vivo, as compared with results at 
autopsy [13, 14]. Different strategies for visual 
reading of the images have been proposed 
for the different tracers, based on the use 
of quantitative indices such as the ratio of 
the mean standardised uptake value (SUV) 
across cortical regions to the SUV measured 
in a reference region, typically the cerebel-
lum. In general, a positive image shows sig-
nificant cortical uptake of the tracer, while 
a negative image shows variable uptake in 
white matter and no relevant cortical signal 
(examples are provided in Fig. 4). 
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Figure 4: Examples of typical positive (upper row) and negative (lower row) amyloid PET images, 
obtained using an 18F-labelled tracer [in this case florbetapir (AV-45)] 
Amyloid imaging is considered an early 
marker of the AD pathological process, reach-
ing the threshold of positivity about 17 years 
before the clinical onset of overt dementia 
[15]. Appropriate criteria for the clinical use 
of amyloid PET imaging have been published 
recently [16]. In particular, this examination is 
advised for patients with persistent or progres-
sive cognitive impairment that has an atypical 
or unclear clinical presentation or early onset 
(before 65 years of age). In subjects with MCI, 
amyloid imaging has a high positive predictive 
value for progression to AD [12]. A consistent 
finding across different amyloid PET imaging 
studies is that around 30% of cognitively nor-
mal elderly subjects have a positive scan, in 
agreement with the proportion of cognitively 
normal elderly subjects with an autopsy diag-
nosis of AD [17, 18]. These individuals might 
be at higher risk for subsequent development 
of dementia, but this is still a debated topic, 
currently under investigation. First, the expres-
sion of clinical disease is due to not only the 
amount of “pathology” in the brain but also 
the capacity of the brain to cope with dam-
age, called the “reserve capacity”. The concept 
of cognitive reserve is based on the observa-
tion that individuals with a high educational 
level and intelligence preserve a normal 
functional level for longer than less educated 
people, despite neurodegeneration [19]. Vari-
ous PET studies have shown that cognitive 
reserve modulates the interaction between 
some measures of pathology and clinical se-
verity [20–22]. Second, amyloid deposits are 
possibly the first event in the pathological cas-
cade of AD, but by themselves do not account 
for cognitive decline: other factors, such as the 
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aggregation of hyperphosphorylated tau pro-
tein, play a central role in the onset and pro-
gression of neurodegeneration [2]. New PET 
tracers aimed at imaging tau aggregates are 
currently under development and preliminary 
results suggest that they may provide crucial 
information about the interplay of amyloid 
deposits and the earliest clinical signs [23].
Finally, a large panel of other PET tracers rele-
vant to the investigation of dementias exists, 
e.g. tracers able to visualise different neuro-
transmission systems, such as the cholinergic 
or dopaminergic system, or to measure the 
occurrence of neuroinflammation, which is 
presumably a factor contributing to the pro-
gression of the neurodegenerative process 
[24]. These tracers, which are of utmost inter-
est for a better understanding of the patho-
logical processes of dementia, are still limited 
to dedicated research centres and are being 
evaluated in clinical trials. 
Epilepsy 
Epilepsy is one of the most common chronic 
neurological conditions, affecting 0.7% (0.5–
1%) of the population. It has very significant 
social and professional consequences and is 
associated with increased mortality. Around 
30–40% of patients with epilepsy suffer from 
focal seizures that are refractory to anti-epi-
leptic drug treatment [25]. In these patients, 
surgical resection of the epileptic focus is the 
only treatment that can possibly cure the con-
dition, and its success depends strongly on 
accurate presurgical localisation of the focal 
abnormality. 18F-FDG PET is one of the imag-
ing modalities of choice for this purpose. The 
intravenous administration of the tracer has 
to be performed during EEG monitoring of 
the epileptic activity, which is a major deter-
minant of the imaging findings. Indeed, while 
an “ictal” injection, during a seizure, will show 
the increased perfusion and metabolism in 
the epileptic focus, an “interictal” injection will 
depict the dysfunctional cortex (often includ-
ing the epileptic focus and some regions of 
seizure propagation) as a hypometabolic area 
compared with the surrounding cortex [26]. 
Interictal imaging is preferable, given that truly 
ictal images require coordination of radiotrac-
er availability and seizure onset and duration, 
which is difficult to assure. Interictal 18F-FDG 
PET has a sensitivity above 80% for identifica-
tion of the epileptic focus in temporal lobe epi-
lepsy [27–30]. The contribution of 18F-FDG PET 
imaging is particularly relevant when no lesion 
is identified on magnetic resonance imaging 
(MRI) or in the case of multiple abnormalities as 
it limits the need for invasive recording [26, 31]. 
Indeed, it has been reported that MRI-negative 
temporal lobe epilepsy patients with clear 
unilateral anterior temporal hypometabolism 
show the same positive outcome as patients 
with a morphologically visible lesion [32]. An 
example of a “non-lesional” patient with a posi-
tive PET is shown in Fig. 5. PET can also be deci-
sive in situations of multifocal lesions or multi-
focal epileptic activity. In tuberous sclerosis, an 
autosomal dominant disorder characterised 
by multiple cortical malformations (tubers), 
the most hypometabolic tuber is concordant 
with invasive localisation of the epileptic focus 
in a majority of patients [33]. 
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Figure 5: Example of a patient with no visible lesion on MRI (upper row) but with clear 
hypometabolism in the left temporal pole on 18F-FDG PET (indicated by arrows, lower row), 
concordant with the clinical and EEG findings 
Other PET tracers have shown promising 
results in specific applications: for example, 
11C-flumazenil, a GABA antagonist, could be 
useful to localise pathological brain tissue in 
temporal lobe epilepsy, with increased up-
take on the pathological side [34]. 11C-AMT 
(α-[¹¹C]-methyl-L-tryptophan) displays posi-
tive uptake in the most epileptogenic tuber 
in tuberous sclerosis in about 70% of cases 
[33]. These tracers are used in specific re-
search settings and are not currently applied 
in clinical practice. 
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neuro-
degenerative disease that has an incidence 
of 2–3/100,000 new cases per year [35] and is 
characterised by progressive muscle paralysis 
associated with degeneration of motor neu-
rons in primary motor cortex, brainstem and 
spinal cord [36]. ALS-mimicking conditions 
include pure upper motor neuron disease 
(primary lateral sclerosis, PLS), pure lower 
motor neuron disease (progressive muscu-
lar atrophy) and FTLD, the latter sharing with 
ALS similar cognitive symptomatology. 
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PET represents a valuable tool in the diagnos-
tic work-up and for the differentiation of ALS 
from mimicking diseases. Various radiotrac-
ers (11C-flumazenil [37], 11C- (R)PK11195 [38], 
18F-DPA-714 [39], 11C-(L)-deprenyl-D2 [40]) 
have been used to assess changes in regions 
affected by ALS, including those for the eval-
uation of activity in the white matter [38–40], 
which plays a significant role in the progres-
sion of the disease. However, most of the PET 
studies in ALS have been performed using 
18F-FDG, focussing on patients and normal 
controls as a comparison group and looking 
for ALS-related metabolic patterns. Patients 
with ALS usually demonstrate diffusely de-
creased 18F-FDG uptake in primary and sup-
plementary motor and premotor cortices as 
well as clusters of relative hypermetabolism 
in the mesiotemporal regions, occipital cor-
tex, cerebellum, corticospinal tracts and up-
per brain stem (Fig. 6), reflecting a complex 
neuropathophysiology involving degenera-
tion of grey matter and areas of reactive mi-
croglial activation. The presence of astrocy-
tosis and activated microglia in corticospinal 
tract, midbrain and pons has also been sup-
ported by findings from 1H-magnetic reso-
nance spectroscopy (increased myo-inositol 
[41]) and other PET investigations (increased 
uptake in peripheral benzodiazepine recep-
tors [38, 39] and astrocytes [40]). 
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Figure 6: Comparison of 18F-FDG PET findings 
in ALS patients and controls using statistical 
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parametric mapping. Statistically significant 
differences (p<0.05 false discovery rate 
corrected) are highlighted on an MRI T1 
template. (A) sagittal view; (B) coronal view; 
(C) transverse view. Clusters of significant 
hypermetabolism are seen in the midbrain, 
cerebellum, medial temporal lobes and 
corticospinal tracts
Recently the potential of 18F-FDG as an im-
portant biomarker for the diagnosis of ALS 
has been confirmed by two investigations in 
which extremely large patient cohorts were 
recruited [42, 43]. Both studies analysed the 
diagnostic ability of PET in ALS and found 
that it showed a sensitivity of about 95% in 
separating patients from controls [42, 43] 
and of 71% in separating ALS from PLS [43]. 
Pagani et al. [42] reported in 195 ALS patients 
a mixed 18F-FDG hypermetabolic–hypometa-
bolic pattern, with marked hypometabolism 
in the frontal, premotor and occipital cortices 
and relative hypermetabolism in white mat-
ter, midbrain and the medial temporal cortex. 
PET findings have also been compared in pa-
tients with sporadic ALS without mutations 
of ALS-related genes, patients with ALS and 
comorbid FTD and patients with ALS carry-
ing the C9orf72 mutation [44]. More wide-
spread cortical and subcortical involvement, 
especially in the frontotemporal cortex, was 
associated with a more severe clinical course 
in those with the C9orf72 mutation.
In addition, PET has a promising role in dis-
criminating ALS from ALS-mimicking pathol-
ogies, thereby contributing to recruitment 
of suitable subjects for clinical trials and al-
lowing early interventions when appropriate 
[45]. Longitudinal examinations, identifying 
significant changes over time, and novel 
PET/MRI technology, providing a simultane-
ous assessment of structural and functional 
lesions, will in the future play a pivotal role in 
better understanding the pathophysiology 
of this complex and fatal disease.
Stroke
Background 
Stroke is the third leading cause of death 
globally and the second most frequent cause 
of death in the developed world after coro-
nary artery disease [46]. It is also a major cause 
of chronic disability, particularly among the 
elderly population. The annual stroke rate is 
in the range of 1.4–4 per 1000. Approximate-
ly 30% of cases are attributed to cerebral 
haemorrhage and 70% to cerebral ischaemia. 
Stroke may arise as a result of a combination 
of different factors. Ischaemic strokes can 
be produced through thrombotic, embolic 
and haemodynamic mechanisms. Clinically 
infarcts are commonly considered as athero-
thrombotic (local thrombosis in relation to 
atheroma of the vascular wall), cardioembolic 
(embolism of cardiac origin, e.g. atrial fibrilla-
tion, recent myocardial infarction, aortic valve 
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disease) or lacunar (occlusion of one of the 
small penetrating end-arteries at the base 
of the brain, often resulting from microath-
eroma formation). A lesion between 3 and 15 
mm in diameter is commonly regarded as a 
lacune. Occasionally, an ischaemic infarction 
may turn into a haemorrhage. The clinical 
symptoms are of sudden onset and depend 
on the location and size of the lesion. Infarcts, 
particularly the lacunar ones, may be clinical-
ly silent or transient. If the symptoms last <24 
h, the term transient ischaemic attack (TIA) 
is used. While TIAs generally do not cause 
permanent brain damage, they are a seri-
ous warning sign and should not be ignored. 
There are many risk factors for stroke: age, 
gender, ethnicity, heredity, hypertension, 
cigarette smoking, hyperlipidaemia, diabetes 
mellitus, obesity, fibrinogen and clotting fac-
tors, oral contraceptives, erythrocytosis and 
haematocrit level, prior cerebrovascular and 
other diseases, physical inactivity, diet and 
alcohol consumption, illicit drug use and ge-
netic predisposition [47]. 
Nuclear imaging has been used extensively 
in the study of neurovascular diseases over 
the past five decades and has yielded impor-
tant knowledge on the pathophysiology of 
acute stroke. In clinical practice, however, the 
primary methods of choice in the diagnostic 
work-up of acute stroke and neurovascular 
diseases are CT and MRI scanning. At the mo-
ment non-enhanced CT of the brain remains 
the mainstay of imaging in the setting of an 
acute stroke (Fig. 7) since it is fast, inexpensive 
and readily available. Its main limitation is the 
low sensitivity in the acute setting, where MRI 
has an advantage. PET/CT is not indicated in 
acute stroke. However, diagnostic CT of the 
brain is easily available in all PET/CT systems 
and can provide important additional infor-
mation relevant to the interpretation of any 
functional defects found, e.g. in dementia. 
Knowledge of the various presentations of 
neurovascular disease becomes important in 
the differential diagnosis of vascular demen-
tia (VaD), AD and mixed dementia (AD with 
concomitant stroke or small vessel disease). 
Chapter 6     Imaging in Neurological and Vascular Brain Diseases (PET/CT) 
EA
NM
83
T2 MRI
R L
RCBF Baseline RCBF Acetazolamide CT 2 mth post PET
Figure 7: Patient with diabetes mellitus, hypertension and multiple previous TIAs. CT angiography 
showed occlusions of the right internal carotid and right vertebral arteries. There are typical 
watershed infarctions in the centrum semiovale on T2-weighted MRI (red arrows). PET measurements 
of rCBF at baseline using 15O-water show discrete hypoperfusion in the right hemisphere, which is 
particularly pronounced above the infarcts (white arrow). During acetazolamide stimulation, the 
perfusion was increased by 60% in the left hemisphere, but decreased by 9% in the right middle 
cerebral artery territory, consistent with cerebrovascular steal (green arrow, same scale as baseline). 
The patient refused reconstructive vascular surgery and sustained an ischaemic stroke during an 
infection-induced hypotensive episode in the same risk areas as had been defined on PET 2 months 
earlier (hypointense lesions, orange arrows), demonstrating the clinical validity of the method
Furthermore, quantitative measurements of 
the regional cerebral blood flow (rCBF) us-
ing positron emission tomography (PET) still 
occupy a specialised clinical niche within 
nuclear imaging for evaluation of the hae-
modynamic response in patients with cere-
brovascular occlusive disease prior to revas-
cularising surgery.
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Dementia and stroke 
Many of the risk factors mentioned in the 
preceding section are shared between de-
mentia and stroke. About 30% of dementia 
patients will show signs of cerebrovascular 
disease that may be synergistic with AD in 
producing the clinical syndrome of demen-
tia. Mixed dementia is the second most com-
mon form of dementia after AD (10–20%), 
while VaD alone accounts for 10% of cases. 
VaD increases in prevalence with age [48]. It 
may arise from multiple cortical infarctions, 
strategic strokes and subcortical white mat-
ter lesions [49]. The neuropsychological char-
acteristics of VaD may be different from those 
seen in AD. Disturbances in frontal-executive 
functions (Fig. 8), rather than memory, are of-
ten the more dominant feature and memory 
impairment may be absent in some patients 
with significant cognitive deficits.
Vascular disease will often give rise to a re-
gional decrease in activity encompassing 
the infarcted area and neighbouring areas 
to varying degrees (Fig. 8). Cases of vascular 
disease may also be metabolically silent. It is 
important to be familiar with the concept of 
diaschisis, the idea that damage to one part 
of the nervous system can have effects at a 
distance due to loss of input [50]. Thus, it was 
demonstrated as long ago as 1964, using 
the Lassen-Ingvar krypton-85 method [51], 
that stroke patients had a strikingly low rCBF 
measurement also in the structurally intact 
healthy hemisphere [52]. The most common 
forms are crossed cerebro-cerebellar diaschisis 
[53], where damage to one hemisphere leads 
to depression of the contralateral cerebel-
lar hemisphere; thalamo-cortical diaschisis, 
where damage/stroke in the thalamus leads 
to depression of the ipsilateral hemisphere 
[54]; and cross cerebello-cerebral diaschisis, 
where damage to one cerebellar hemi-
sphere leads to depression of the contralat-
eral cerebral hemisphere [55]. Furthermore, 
decreased activity in cortical areas may be 
evident if the infarct is located subcortically, 
involving and undercutting white matter 
tracts (Fig. 8). Thus, for each individual area of 
decreased metabolic activity in patients eval-
uated for dementia using 18F-FDG PET/CT, it 
is necessary to determine whether the re-
duction in activity can be explained by local 
or distant neuronal damage/vascular lesion. 
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Figure 8 A–C: Examples of typical 18F-FDG PET images in patients referred for PET/CT or PET/MRI for 
evaluation of dementia. To the right are statistical surface projections (Scenium, Siemens) comparing 
the subjects with a database of age-matched controls. (A) PET fusion with simultaneously acquired 
T1-weighted MRI: transverse images. The red arrows indicate circumscribed lacunar infarcts with 
decreased activity uptake involving the left head of the caudate and the anterior thalamus; 
these lesions are undercutting projections to the structurally intact left frontal lobe, giving rise 
to a moderate reduction in activity (green arrows). FTD could have been considered, but this 
is vascular dementia. There is also an infarct in the pons (not shown). (B) CT and PET transverse 
images. CT shows extensive subcortical hypointense signals (leukoaraiosis) indicative of subcortical 
ischaemia (red arrows) that cannot alone explain the pattern of cortical metabolic reduction 
(green arrow), suggesting a mixed vascular and neurodegenerative origin. (C) CT and PET/CT 
transverse images show a subcortical infarct in the right temporal region (red arrow), leading 
to a larger metabolic defect in the temporoparietal cortex (green arrow) through disruption of 
subcortical–cortical circuits. The PET image alone could be misread as demonstrating signs of 
neurodegeneration in the absence of supportive correlation with CT
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Chronic cerebrovascular disease
Atherosclerotic internal carotid artery occlu-
sion causes approximately 10% of TIAs and 
15–25% of ischaemic strokes in the carotid 
territory. The 2-year risk of ipsilateral ischaemic 
stroke while a patient is receiving medical 
therapy is 10–15% [56]. This risk, however, de-
pends on the capacity of the brain tissue to 
compensate, e.g. by increasing the regional 
oxygen extraction fraction (rOEF). Increased 
rOEF indicates that the last defence before 
stroke has been mobilised. In symptomatic 
patients with increased rOEF, the 2-year risk of 
ipsilateral ischaemic stroke is 30–40%, while it 
is only 5% in symptomatic patients with nor-
mal rOEF [57]. In the event of symptomatic 
occlusions of the carotid arteries to the brain, 
a revascularising surgical procedure may be 
considered: the so-called extracranial–intra-
cranial bypass operation (EC-IC). In the most 
common version of the EC-IC bypass opera-
tion, a branch of the external carotid artery, 
usually the superficial temporal artery, is 
anastomosed to a branch of the internal ca-
rotid artery on the occluded side, usually the 
meningeal artery. The procedure is not with-
out risk, and there is a 10–15% likelihood of 
perioperative stroke [58, 59]. Thus, the overall 
risk is the same as in medically treated symp-
tomatic patients over 2 years. Consequently, 
only the subgroup of high-risk patients should 
be considered for the operation. Supportive 
symptoms and findings that may predict hae-
modynamic failure and high risk of stroke and 
death are usually manifested as repeated TIAs 
or stroke, with typical subcortical “watershed” 
infarcts on T2-weighted MRI (Fig. 7), ortho-
static limb shaking, impaired vasoreactivity to 
acetazolamide challenge and increased rOEF 
on PET scanning [60]. 
In the event of carotid occlusion, the affected 
hemisphere receives its blood supply from 
communicating arteries of the circle of Willis 
and collaterals between the extracranial and 
intracranial arteries. If these are not sufficiently 
developed, there will be a pressure drop in the 
most distant arterioles of the arterial tree at the 
border zones between vascular territories (wa-
tershed areas). This will initially be compensat-
ed haemodynamically by vasodilation, which 
will stabilise rCBF and can be measured as an 
increase in regional cerebral blood volume 
(Fig. 9). Metabolic compensation will follow 
via an increase in oxygen extraction from the 
capillary blood, the rOEF rising from 30–40% 
to 70–80%. In patients with exhausted perfu-
sion reserve, rCBF will behave in a pressure-
passive manner. The arterioles are maximally 
dilated, and rCBF will change with the perfu-
sion pressure. If the patient experiences a lon-
ger lasting pressure drop (e.g. due to systemic 
infection, cardiovascular disease, dehydration 
or blood pressure-lowering drugs) and the 
compensatory mechanisms are insufficient, 
an ischaemic infarction will develop (Fig. 7) 
[61, 62]. Acetazolamide (Diamox) is a carbo-
anhydrase inhibitor and a potent vasodilator 
of the cerebral vessels that increases rCBF by 
20–60%. Only arterioles that are not already 
dilated will respond to acetazolamide, while 
the haemodynamic response in affected re-
gions will be either reduced, unaffected or 
negative. The last-mentioned phenomenon 
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is called “cerebrovascular steal” or the “reverse 
Robin Hood effect”. The increased rCBF in the 
unaffected hemisphere decreases perfusion 
pressure and rCBF in the affected hemisphere 
(Fig. 9). EC-IC bypass surgery can reverse these 
changes [63] and may increase the cognitive 
performance [64], but the clinical benefit in 
terms of stroke risk and survival is still con-
troversial. In a recent randomised clinical trial, 
195 patients were randomised to either opti-
mal medical treatment or surgery based on 
PET measurements of increased rOEF in the 
symptomatic hemisphere (the COSS study). 
The study endpoint was 2-year stroke recur-
rence, the rate of which was found to be 21% 
in the surgical group and 23% in the medically 
treated group. The latter was far below the 
expected rate of 40% from prospective ob-
servational investigations, and the study failed 
to demonstrate a significant difference in the 
two treatments [58]. 
Figure 9: A schematic representation of the vascular response to carotid occlusion and vasodilation 
using acetazolamide. The two internal carotid arteries are represented as two arrows connected 
by the circle of Willis, which subsequently supplies feeding arteries to the two hemispheres. The 
bars in the hemispheres represent the vasodilatory state of the arterioles in brain tissue. In the 
healthy brain (top row), acetazolamide dilates the arterioles and increases rCBF symmetrically in 
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the two hemispheres by 20–60%. In carotid artery occlusion (lower row) – represented by the black 
box in the left carotid – the ipsilateral hemisphere is fed through a more or less patent collateral 
blood supply in the circle of Willis; these arterioles are dilated because of the ensuing decrease 
in perfusion pressure, which stabilises rCBF. When the arterioles in the unaffected contralateral 
hemisphere are dilated, the perfusion pressure will decrease even further ipsilaterally. Depending 
on the residual vasodilatory capacity, the rCBF will be increased, unaffected or decreased. The last-
mentioned phenomenon is known as the cerebrovascular steal phenomenon
The measurement of vasoreactivity in re-
sponse to acetazolamide requires quanti-
tative assessment of the rCBF using either 
15O-water PET or the stable xenon-CT SPECT 
method [65]. Both methods are available 
only in specialised units. 15O-water has a half-
life of only 2 min and an on-site cyclotron is 
required for on-line continuous production 
of the tracer. Furthermore, quantification of 
rCBF measured in mL blood flow per 100 g 
tissue per minute necessitates arterial cannu-
lation and continuous blood sampling with 
radioactivity measurements for kinetic mod-
elling with calculation of parametric images. 
In the acetazolamide challenge, rCBF is mea-
sured at rest and approximately 20 min after 
injection of 500–1500 mg acetazolamide i.v. 
The baseline rCBF image is subtracted from 
the acetazolamide-stimulated rCBF image, 
and all images are fused to T2-weighted/
FLAIR MRI. The baseline rCBF image allows 
estimation of the extent of infarction and 
hypoperfusion around the areas of signal 
change on MRI. Regions of interest are drawn 
on the three major intracerebral artery terri-
tories in both hemispheres for quantification 
of rCBF and reactivity. However, as compro-
mised haemodynamic reactivity is often in 
the watershed areas, the subtraction image 
is the most efficient way of directly revealing 
the location of increased and decreased rCBF. 
Acetazolamide challenge is also used in com-
bination with transcranial Doppler flow mea-
surements. To date there have been virtually 
no reports of adverse effects of acetazolamide 
challenge [66]. One case report did, however, 
cite a stroke episode 24 h after injection, 
which could have been related to the mildly 
diuretic effect of acetazolamide [67].
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PET/CT in Radiotherapy Planning of Brain Tumours 
Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu 
Introduction
Brain tumours can be classified, according to 
their origin, into primary (those originating 
from the central nervous system) or secondary 
(those originating from other tissues and 
metastasising to the central nervous system). 
Primary brain tumours include low-grade 
and high-grade malignant lesions according 
to the World Health Organisation, the most 
frequent being meningioma (30%) and 
glioblastoma multiforme (20%).
For patients with high-grade brain tumours, 
the ideal treatment is surgery (complete re-
section of the tumour, if possible preserving 
neurological function) followed by adjuvant 
chemotherapy and radiotherapy. The utility 
of radiation therapy has been demonstrated. 
Technological advances are increasingly im-
proving the efficacy of the treatment (mea-
sured by survival) based on increased treat-
ment precision (reducing the radiation dose 
to healthy tissue and the associated toxicity) 
without any reduction in the radiation dose 
to the treatment volume.
Radiotherapy planning requires multidisci-
plinary collaboration and a sequential pro-
cess that begins with a tumour board deciding 
to irradiate a tumour and ends with the ap-
plication of a treatment plan signed by a 
board-certified radiation oncologist [1, 2]. A 
key aspect is the appropriate selection and 
delineation of the target volumes and organs 
at risk, which is typically done by a radiation 
oncologist on contrast-enhanced CT and/
or MRI. The images used need to be the 
best available in terms of diagnostic efficacy 
(sensitivity, specificity, positive and negative 
predictive values) and must have high spa-
tial resolution. CT and MRI comply with these 
requirements [2]. However, a high contrast 
resolution (i.e. the ability to differentiate 
pathological from normal tissues) is also 
essential. This is where PET enters the picture.
Why add PET/CT to radiotherapy planning 
of brain tumours?
PET/CT in radiotherapy planning
CT and MRI have a high spatial resolution 
and display the anatomy and morphologi-
cal changes in great detail. Their main draw-
back is their low contrast resolution, as a 
consequence of which it is not possible to 
differentiate between viable tumour tissue 
and surgery-, radiotherapy- or chemotherapy 
-related changes (pseudo-progression, 
pseudo-regression) [3]. In contrast, PET has 
a high contrast resolution, and by supply-
ing functional information on the biological 
and molecular characteristics of the tumour 
it helps in differentiating viable tumour from 
treatment-related changes, thereby improving 
treatment planning for high-precision radio-
therapy. Many studies have analysed the role 
of different PET tracers for gross tumour vol-
ume (GTV) delineation.
PET tracers
18F-Fluorodeoxyglucose (18F-FDG) is the 
main PET tracer used in oncology as it pro-
vides useful information in many tumours. 
However, it has been shown to be of limited 
value in the radiotherapy planning of brain 
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tumours [3, 4]. The main issue with 18F-FDG 
is the low contrast between viable tumour 
and normal brain tissue. 18F-FDG uptake is 
increased in anaplastic areas [3].
Radiolabelled amino acids (AA) such as 11C-
methionine (MET), 18F-fluoroethyl-tyrosine 
(FET) and 18F-fluoro-L-dopa (FDOPA) are the 
main PET tracers used for the characterisa-
tion, therapy planning and follow-up of brain 
tumours, and all three of the aforementioned 
tracers share similar characteristics regarding 
uptake intensity and distribution in brain tu-
mours. Normal cerebral tissue has a relatively 
low uptake of AA PET tracers as compared 
to tumour cells, which incorporate them at 
a high rate; furthermore, uptake of AA PET 
tracers is not dependent on disturbances of 
the blood-brain barrier. 
Tumour target volumes defined using AA 
PET differ from those outlined with MRI using 
standard sequences such as T1-weighted 
after gadolinium contrast enhancement (T1-
Gd), both in size and in geometrical extension 
[5]. In fact, the tumour target volume as 
defined on T1-Gd MRI seems insufficient to 
include the real biological tumour extension 
of high-grade brain tumours. 
PET/CT technical requisites
In order to maximise the potential benefits 
of incorporating the metabolic information 
provided by PET, it is crucial to be aware of 
all the factors that must be taken into ac-
count to guarantee that the images acquired 
comply with the requirements for treatment 
planning and treatment delivery [6, 7]. These 
factors are:
1. Initial patient positioning. Accurate posi-
tioning that ensures consistency and daily 
reproducibility of treatment is essential when 
delivering high doses to a tumour, as an im-
portant limitation is the tolerance level of the 
surrounding normal tissue [7]. To ensure the 
comfort of the patient during all treatment 
sessions, the initial evaluation must include 
the physical status and limitations as well as 
the psychological impact (claustrophobia). In 
order to achieve accurate alignment, an im-
mobilisation device is used in conjunction 
with reference ink or tattoo marks [7]. Posi-
tioning includes: (a) removing all clothing 
from the upper body to promote comfort 
and ensure daily reproducibility; (b) removing 
dentures or implants and instructing the 
patient not to chew anything during the 
treatment; (c) supporting the head to prevent 
or limit involuntary movements.
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1A
1B
Figure 1 A, B: Table top with a neck support
2. Table top. The table top must be flat, nar-
row and rigid and should allow registration 
or indexing of immobilisation devices [7]. 
Figure 1 presents a table top with a neck 
support.
2 A
2 B
Figure 2 A, B: Positioning of a patient with the 
laser light system
3. Laser lights. Lateral and sagittal lasers must 
be used to ensure accurate alignment and 
positioning. The laser light system installed 
in the PET/CT unit must be in accordance 
with the one installed in the radiotherapy 
unit. Quality controls of the laser lights of 
the PET/CT system must be done routinely 
to maintain consistency with the treatment 
unit [7]. Figure 2 shows positioning of a pa-
tient with the laser light system.
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3 A
3 B
3 C
3 D
Figure 3A–D: Immobilisation systems that 
must be individualised include thermoplastic 
masks. The mask is initially rigid (A) but can 
become pliable when placed in warm water 
(B). This permits the mask to be moulded to 
the head and shoulders of the patient (C). It 
can be attached to the treatment table once 
the material has cooled (D)
4. Immobilisation. The use of immobilisation 
devices is essential to deliver high doses of 
radiation to the treatment volume while 
ensuring the protection of critical organs 
(e.g. crystalline lens, optic chiasm, pituitary 
gland). Immobilisation systems must be in-
dividualised for each patient and should be 
anchored to fastening systems which in turn 
must be fixed to the treatment table. For 
brain tumours, immobilisation systems in-
clude: (a) neck supports (standard, frames or 
vacuum bags) (Fig. 1) and (b) thermoplastic 
masks which are initially rigid (Fig. 3 A) but 
become pliable when placed in warm wa-
ter (Fig. 3 B), allowing moulding of the mask 
to the head and shoulders of the patient 
(Fig. 3 C) and attachment to the treatment 
table once the material has cooled (Fig. 3 D).
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When does radiotherapy planning with 
PET/CT have an added value? 
AA PET/CT is of specific value for delineation 
of the GTV in high-grade gliomas, especially 
those that are non-contrast enhancing 
on T1-Gd MRI, and low-grade tumours 
that are ill defined on MRI. Additionally, 
as already mentioned, it is of great value 
in differentiating between treatment-
related changes (pseudo-progression and 
pseudo-remission or pseudo-response) and 
residual/recurrent tumour [3, 8]. PET/CT with 
radiolabelled AA or DOTATOC can be used 
for GTV delineation in meningiomas and 
glomus tumours. Further research is needed 
regarding the role of PET with other tracers, 
such as 18F-fluorothymidine (FLT) to evaluate 
proliferation, 18F-fluoromisonidazole (FMISO) 
to assess hypoxia and 18F-galacto-arginine-
glycine-aspartic acid (RGD) to analyse 
angiogenesis and peptide expression [3,8]. 
How should it be done? Procedure, 
technical aspects and quality control
PET/CT procedure 
18F-FDG PET/CT must be performed in 
accordance with the EANM guidelines [9, 10]. 
When radiolabelled AA analogues are used 
instead of 18F-FDG, the guidelines dedicated 
to these must be followed [11]. If the 
PET/CT data are used for radiation planning, 
the examination should be performed in the 
position which will be used for radiotherapy, 
employing the same dedicated positioning 
devices as are used in the radiotherapy 
department [9]. The CT part of PET/CT must 
have special characteristics as it will be used 
for radiotherapy planning, and an additional 
CT will not be performed.
Technical approach to patient positioning 
for PET/CT for radiotherapy planning
Multidisciplinary collaboration between the 
nuclear medicine and radiation oncology 
units is essential. The patient must be posi-
tioned using the technical instruments men-
tioned above in the section “PET/CT techni-
cal requisites”.
Quality control of image fusion of PET/CT 
and planning CT for tumour delineation
Quality control of image fusion must be done 
routinely, ensuring the patient has been po-
sitioned adequately in accordance with the 
protocols.
PACS/RIS and software issues
DICOM must be transferred from the PET/CT 
to the radiotherapy unit.
Who should participate? Multidisciplinary 
collaboration 
The nuclear medicine and radiation oncology 
units must collaborate closely when planning 
the radiotherapy and delineating the 
volumes to treat. The relevant protocols must 
be strictly followed to achieve the maximum 
accuracy, consistency and reproducibility. 
The PET/CT study should be reported in 
accordance with established guidelines 
[9−11]. Volume delineation is done taking 
into account both MRI and PET. The GTV 
based on PET is added to the GTV based on 
MRI and they are fused with the CT (Fig. 4).
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B
Figure 4 A–D: Radiotherapy planning of a high-grade glioma using MRI and 11C-MET PET/CT: 
T1-weighted MRI (A), non-contrast-enhanced CT (B), T2-weighted MRI (C) and 11C-MET PET (D). 
T2-weighted MRI shows an extensive area of enhancement (volumes 1 and 2) that could be due 
to active tumour and/or oedema. T1-weighted MRI shows a small area of enhancement (volume 
2) and an area that does not enhance (volume 1). CT shows an area of changes (volumes 1 
and 2). If only MRI or CT were available, the treatment volume would have included both areas 
(volumes 1 and 2). However, 11C-MET PET evidenced high uptake (tumour) in volume 1 but 
no uptake at all (non-tumour) in volume 2. Because of this information, the treatment volume 
included only volume 1, sparing unnecessary toxicity in volume 2 
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What must be taken into account? 
Radiation protection issues: focus on 
radiotherapy workers 
When radiotherapy planning is done on 
PET/CT, radiation protection for radiotherapy 
workers must take into account their close 
contact with patients who have been 
injected with PET tracers.
Patient scheduling 
Patients referred for radiation treatment 
planning must be scheduled at the end of 
the morning or afternoon, after the standard 
PET/CT studies, in order to cause the least 
possible delay to the daily routine. These 
studies entail further complexity and time 
and therefore must be scheduled last.
Conclusion
Accurate position reproducibility to ensure 
daily reproducibility of treatment is essen-
tial when delivering high doses to a tumour. 
Multidisciplinary collaboration also plays a 
key role in patient positioning.
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Current clinical applications of PET/MRI in 
neurology 
Magnetic resonance imaging (MRI) is pivotal 
in the work-up of the majority of neurologi-
cal and psychiatric diseases since it provides 
morphological and functional information 
about the brain. Positron emission tomog-
raphy (PET), on the other hand, is able to 
detect and quantify a variety of pathophysio-
logical processes with very high sensitivity. In 
patients with symptoms of cognitive impair-
ment or movement disorders, for example, 
high-resolution and multi-contrast brain MRI 
is essential to rule out non-neurodegenera-
tive causes such as tumours, haemorrhages, 
ischaemic lesions or inflammatory diseases. 
Further, it is used to detect specific atrophy 
patterns, white and grey matter degenera-
tion and the implications of some metabolic 
changes [1]. However, structural changes 
that are specific to neurodegenerative dis-
eases are usually preceded by months to 
years of characteristic molecular and func-
tional alterations that can be detected with 
multi-tracer PET exclusively [2]: 
1. Characteristic impairments of brain 
glucose metabolism can be detected by 
[18F] fluorodeoxyglucose (FDG) PET and 
allow the early diagnosis of dementia dis-
orders while MR findings are still absent or 
unspecific (Fig. 1A).
A
T2 FLAIR Fusion [18F]FDG PET 
(Glucose metabolism)
Figure 1 A–C: Multi-tracer brain PET/MRI in neurodegenerative diseases. 
(A) A 61-year-old man with progressive aphasia and cognitive impairment; T2-weighted fluid 
attenuation recovery (FLAIR) MRI (left) shows enlarged ventricles, mainly left cortical atrophy and 
white matter lesions. Simultaneous [18F]FDG PET revealed severe left cortical hypometabolism 
(arrows, middle), indicating a form of frontotemporal dementia as underlying disease. 
2. Amyloid PET can accurately detect brain 
amyloid load in Alzheimer’s dementia (AD), 
in which the presence of amyloid deposits 
ultimately leads to cognitive decline (Fig. 1B).
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B
T2 FLAIR Fusion
[18F]Florbetaben PET 
(β-Amyloid)
Figure 1 A–C: Multi-tracer brain PET/MRI in neurodegenerative diseases. 
(B) A 44-year-old woman with cognitive impairment and a family history of Alzheimer’s dementia 
(father). Brain MRI (left) was unremarkable but the presence of intense β-amyloid depositions in the 
whole brain grey matter on [18F]florbetaben PET (arrows) confirmed the clinical suspicion of AD. 
3. [18F]DOPA PET can specifically visualise 
dopaminergic neurotransmission in the 
basal ganglia and is used in clinical routine 
in specialised centres to diagnose parkinso-
nian syndromes [3] (Fig. 1C). 
C
T2 TSE Fusion [18F]DOPA PET 
(Dopamine metabolism)
Figure 1 A–C: Multi-tracer brain PET/MRI in neurodegenerative diseases. 
(C) A 76-year-old woman with unspecific movement disturbance of the legs. T2-weighted turbo 
spin echo (TSE) MRI was unremarkable; moreover [18F]DOPA PET revealed age-appropriate 
dopamine synthesis in the basal ganglia (arrows). Thus, PET/MRI allowed the exclusion of 
neurodegenerative Parkinson’s disease as the underlying disorder
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Recently, an integrated amyloid PET/MRI ex-
amination algorithm has been proposed to 
deliver a maximum of imaging parameters, 
necessary for the diagnosis of a wide range 
of dementia disorders [1]. Conventional MRI 
is also essential in the clinical management 
of brain tumours. With a variety of contrasts 
it provides information about the type of 
tumour and its size, extension and grading. 
Moreover, (a) enhancement of areas after ap-
plication of a contrast agent (e.g. Gadovist) 
allows an estimation of blood-brain barrier 
breakdown, which is typical of high-grade 
malignant brain tumours, (b) dynamic sus-
ceptibility contrast perfusion measurements 
improve differentiation between recurrent 
tumour and radiation-induced necrosis and 
(c) MR spectroscopy provides information 
about malignant proliferation and promising 
targets for eventual tumour biopsy. 
In various clinical situations, however, MRI is 
insufficiently specific and does not deliver 
the desired information. Here, simultaneous 
amino acid PET is helpful, since it reflects 
the vastly increased amino acid transport 
into brain tumour tissue. PET is able to dis-
tinguish between unspecific changes after 
tumour (radiation) therapy and tumour re-
lapse. Amino acid PET is also helpful in the 
primary evaluation of unspecific MR findings 
to decide whether surgery or biopsy of cra-
nial masses is necessary (Fig. 2A). In addi-
tion, amino acid PET delivers reliable tumour 
volumes for radiation or surgery planning in 
situations in which the tumour itself cannot 
be distinguished from unspecific surround-
ing MRI signal abnormalities (e.g. due to oe-
dema) (Fig. 2B). Lastly, somatostatin receptor 
PET can highly selectively visualise tumour 
tissue arising from the meninges (Fig. 2C). Si-
multaneous PET/MRI also plays a role in basic 
research into brain function and pathological 
mechanisms in neurological diseases such as 
stroke, dementia and addiction. The combi-
nation of functional MRI, contrast-enhanced 
MRI and multi-tracer PET allows the simul-
taneous assessment of rapidly fluctuating 
brain signals like brain perfusion, transmitter 
release or the occupancy of specific recep-
tors in the brain. Related examination pro-
tocols exhibit a high degree of complexity 
and are usually restricted to special research 
facilities (for more information, see Werner et 
al. [2]). 
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A
T2 FLAIR T1 + CE Fusion [11C]Methionine PET
(Aminoacid transport)
Figure 2 A–C: Multi-tracer brain PET/MRI in neuro-oncology. 
(A) A 60-year-old woman with unspecific T2 fluid attenuation recovery (FLAIR) signal alteration, 
without contrast enhancement (CE) on the T1 contrast image (arrow). Moreover, amino acid transport 
assessed by [11C]methionine PET was unremarkable (right). A highly malignant glioma could be 
excluded and, due to the lack of symptoms, follow-up imaging was chosen over biopsy. 
B
T2 FLAIR T1 + CE Fusion [11C]Methionine PET
(Aminoacid transport)
Figure 2 A–C: Multi-tracer brain PET/MRI in neuro-oncology. 
(B) In this glioma patient the extension of signal alterations on the T2 FLAIR and T1 CE images 
(red lines) differed substantially. [11C]Methionine PET identified highly active tumour areas with 
increased amino acid transport (right). 
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C
T2 FLAIR T1 + CE Fusion [68Ga]DOTATOC PET
(Somatostatin Receptors)
Figure 2 A–C: Multi-tracer brain PET/MRI in neuro-oncology. 
(C) Somatostatin receptor imaging with the highly selective PET radioligand [68Ga]DOTATOC 
traced tumour tissue in this 74-year-old woman with a meningeal brain tumour (arrows). On 
MRI the contrast between tumour and healthy tissue was lower 
Advantages and limitations
Even before the introduction of hybrid PET/
MRI, the combination of sequentially ac-
quired brain MRI and PET information of-
ten proved superior to the single-modality 
approach in the diagnosis and work-up of 
neurological diseases. Although favourable, 
this imaging approach has not been ap-
plied consistently in clinical routine, mainly 
due to organisational issues and reimburse-
ment questions. It may be hypothesised 
that hybrid brain PET/MRI, simply by ensur-
ing consistent availability of both modali-
ties and their joint interpretation by trained 
physicians, may improve diagnostics in this 
field [2]. Compared with sequential MRI and 
PET(/CT) a hybrid examination has other ob-
vious advantages, such as improved patient 
comfort (through the scheduling of fewer 
examinations), reduced overall examination 
time and reduced radiation exposure. It has 
to be mentioned, however, that in order to 
obtain quantitative PET data the correction 
of the photon attenuation by head tissue is 
necessary and that, unlike in PET and PET/CT, 
this attenuation information is not gathered 
by CT or dedicated transmission scans but 
indirectly by MRI. An associated drawback is 
the fact that the attenuation correction (AC) 
algorithms currently implemented in PET/
MRI systems do not consider cortical bone, 
which leads to significant underestimation of 
the AC-PET signal. New AC approaches ad-
dressing this important issue have been de-
veloped but have not yet been implemented 
in the commercially available systems (May 
2015). Moreover, running a hybrid PET/MRI 
requires technologists who are specifically 
trained in both modalities. Nuclear medi-
cine technologists are trained in handling 
ionising radiation and are acquainted with 
time-critical scheduling of examinations 
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with short-lived radiotracers. In contrast, 
MRI technologists are trained in MR safety 
and skilfully operate the MR scanner to pro-
vide high-quality diagnostic images and mi-
nimise artefacts in a large variety of different 
sequences and protocols. For combined PET/
MRI, a basic understanding of the underlying 
physics of both modalities is required in the 
first instance in order to be able to adapt ac-
quisition parameters during a patient scan. 
To run a hybrid PET/MRI with a small staff, 
dual-trained technologists are desirable but 
such technologists are extremely rare. A joint 
statement of the Society of Nuclear Medicine 
and Molecular Imaging Technologist Section 
and the Section for Magnetic Resonance 
Technologists has underlined the need for 
advanced-level educational programmes for 
PET/MRI technologists [4]. 
Technical background and workflow 
aspects
Positioning and preparation
All patients receive intravenous access and 
are repeatedly asked about contraindications 
(e.g. ferromagnetic metal implants, pace-
makers). Due to the strong magnetic field, 
patients need to remove all metal objects 
and dentures before entering the examina-
tion room. The patient is then placed on the 
patient bed as comfortably as possible. This 
is achieved by use of positioning aids such 
as knee rolls and foam wedges to stabilise 
the head. The patient’s shoulder should be 
in contact with the head and neck coil. If the 
head is too big for the coil, the support pad 
can be removed to create some space. For 
hearing protection, earplugs or earphones 
should be chosen over headphones since 
they cause less attenuation of the PET signal. 
The upper part of the head and neck coil is 
closed and the patient is instructed regard-
ing the emergency bell. It is possible to at-
tach a mirror to the coil which shows the 
window to the control room in order to avoid 
the otherwise oppressive feeling when look-
ing at the ceiling of the gantry. Due to the 
relatively low room temperature at a PET/MRI 
facility, use of a blanket to cover the patient 
is recommended. Finally, the head centring 
is done via laser positioning, which should 
only be activated once the patient’s eyes are 
closed. With a strongly reclined head the pa-
tient is moved into the gantry until the laser 
cross is a little below the nose and the cen-
tre position is then confirmed by pressing a 
button. Thereafter, the single MR sequences 
need to be defined and the PET scan is 
planned; care has to be taken that the entire 
brain is within the field of view. While the PET 
acquisition times differ depending on the 
specific tracer, the following reconstruction 
parameters have generally been found to be 
optimal for brain imaging on a Siemens mMR 
PET/MRI system: 8 iterations, 21 subsets, Y 
offset = -41, zoom = 2.8, 3.0-mm Gaussian 
filter (University Hospital Leipzig, Germany). 
Once set-up has been completed, the PET/
MRI workflow itself is straightforward. The 
start of the PET acquisition is accompanied 
by automatic acquisition of the MR se-
quences for AC. During the PET acquisition, 
MRI can be handled flexibly; all subsequent 
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MR sequences are adapted and planned by 
means of a three-axis localiser prior to the 
actual MR scan. Additional individual MR se-
quences can be planned and acquired as de-
sired during the remaining PET scan time or 
beyond. Usually, the overall duration of a si-
multaneous PET/MRI study is determined by 
the MR examination time. Due to the distri-
bution dynamics and the relatively long half-
lives of the radiotracers, they are generally 
injected prior to the PET/MRI session. The in-
jection of MR contrast medium, on the other 
hand, is tightly coupled to individual MR se-
quences within the hybrid imaging protocol 
and is performed while the patient is lying in 
the scanner; however, even with simultane-
ous injection (e.g. [15O]H2O and gadobutrol 
in research applications in the scanner), no 
interactions have been reported [2]. 
Dual time-point amyloid PET/MRI
By collecting early dynamic (e.g. 1–8 min 
p.i.) data in an amyloid PET scan, informa-
tion on perfusion as a surrogate of glucose 
metabolism and on brain amyloid load can 
be derived with only one radiotracer. When 
this approach is combined with simultane-
ous MRI, the most important brain imaging 
information for the assessment of neurode-
generative disorders can be gathered dur-
ing one imaging session [1]. Despite use of 
a non-magnetic tungsten syringe shield, 
the space in the gantry is limited and intra-
venous access via a vein on the back of the 
hand is helpful in facilitating the manda-
tory tracer application within the system. 
Two MR localisers are acquired first, then a 
workflow break needs to be implemented in 
the protocol immediately before the actual 
diagnostic MRI and PET scan begins. Upon 
tracer injection within the scanner room by 
the technologist, the actual scan is started by 
a second person sitting at the console; it is 
necessary to write down the application time 
for post hoc calibration of the injected activ-
ity. If the tracer is applied during the actual 
scan, the tracer activity can only be entered 
into the system afterwards, which makes 
a retrospective reconstruction mandatory. 
At the end of the 10-min PET scan, during 
which MR sequences can be acquired, the 
patient is allowed a break and leaves the 
examination room so that another patient 
can be examined. After about 60–70 min the 
second part of the examination starts, again 
with two localisers. Now the application type 
and time can be entered and during the sub-
sequent 20-min PET scan, acquired from 90 
to 110 min, the remaining MR sequences can 
be acquired (see Fig. 3 for details).
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Figure 3: [18F]Florbetaben (amyloid) PET/MRI workflow. Upon injection of the radiotracer, the early 
10-min PET scan is started, which is accompanied by the acquisition of the DIXON sequence for 
attenuation correction (AC) and two more diagnostic MR sequences. After a break of ~70 min, the 
patient re-enters the scanner and during the late 20-min PET scan more diagnostic MR sequences 
can be acquired. Note: the DIXON VIBE sequence needs to be acquired again for AC of the second 
PET scan. Sequence: image plane/slice thickness (mm)/no. of slices/TR and TE (ms)/FOV (mm)/
matrix; 3D Dixon Vibe (DIXON): coronal/3.12/128/3.6 and 1.23/500×300/256; T2 fluid attenuation 
inversion recovery (FLAIR): axial/3/46/9000 and 93/230/320; T2 turbo spin echo (TSE): axial and 
coronal/3/50/6000 and 100/230/384; T1 FLASH: axial/3/50/395 and 2.97/230/320; susceptibility 
weighted imaging (SWI): axial/1/112/25 and 20/230/256; T1 magnetisation prepared rapid gradient 
echo (MPRAGE): sagittal/1/176/1900 and 2.53/250/256; echoplaner imaging (EPI): sagittal/1/176/1900 
and 2.53/250/256. Note: PET reconstruction parameters are provided in the main text 
Possible artefacts
As stated above, the PET signal needs to be 
corrected for the attenuation of photons 
on their passage through the tissue of the 
head. Current PET/MRI AC sequences clas-
sify three tissue classes: fat, water and air. As 
already noted, bone tissue is currently not 
considered, which leads to a ~10–15% un-
derestimation of the PET signal in the vicin-
ity of cortical bone [5]. Since the attenuation 
values in PET/MRI cannot be measured but 
rather must be predicted from the MR signal 
by advanced computer algorithms, prob-
lems may arise if there are any deviations 
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with irregular facial bone or skull lesions (e.g. 
due to prior neurosurgery). Hence, a ventricle 
shunt system may lead to misclassification of 
the surrounding brain tissue classes (Fig. 4A), 
but even without any visible cause the un-
derlying algorithms sometimes fail to assign 
the orrect attenuation values to the head tis-
sue classes (Fig. 4B).
Figure 4 A, B: Attenuation correction (AC)-related artefacts. (A) In this patient the MR signal is 
heavily distorted in the vicinity of the ventricular brain shunt [arrow in T1 with gadolinium (Gad)]. 
As a consequence, the system fails to derive a correct μ-map from the Dixon VIBE sequence 
for AC (μ-map) and this area is misclassified as air but not as part of the head. Hence, there is 
no corrected PET information in the affected voxels available [asterisk in PET(AC)] and the non-
corrected PET data need to be evaluated instead [PET(NAC)]. (B) The system wrongly assigned the 
attenuation values of fat and water (failed μ-map) whereas the correct assignment can be seen 
below (correct μ-map). Incorrect assignment of photon attenuation values results in an overall 
overestimation of the PET signal after reconstruction [failed PET(AC)]. The PET reconstructed 
from the correct Dixon-based μ-map delivers a substantially lower PET signal [correct PET(AC)]
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Chapter 9
Brain Death
Marko Grmek
Introduction
Brain death (BD) may be defined as the com-
plete and irreversible loss of all brain and 
brain stem functions [1, 2]. A person with 
BD is considered legally dead [3]. In certain 
cases, for example when treatment with 
mechanical ventilation is performed, some 
somatic functions such as circulation can be 
active despite BD.
In most European countries, when and how 
a person can be pronounced brain dead is 
precisely defined [4]. One would expect the 
procedures for determination of BD to be 
similar across Europe; in fact, however, they 
differ considerably. In approximately 50% of 
European countries, the diagnostic proce-
dure requires two or three clinical tests, with 
a specified minimum time interval between 
them, usually 6–24 h [4]. In other countries, 
an ancillary or confirmatory test is also re-
quired. The apnoea test is usually the final 
step in the determination of BD. Within the 
United States, the procedures for determin-
ing BD also differ considerably [5]. 
Ancillary tests 
Legislation and/or the guidelines usually de-
fine precisely when a certain ancillary test 
may be used in the diagnostic process for 
determining BD. The following are the most 
frequently used ancillary tests [6, 7]: cere-
bral angiography, electroencephalography 
(EEG), transcranial Doppler ultrasonography 
and cerebral scintigraphy. Selection of the 
test depends on the state or condition that 
has resulted or could result in BD and on 
the availability of the test. Ancillary tests can 
shorten the procedure for determining BD 
in some cases because these tests can im-
mediately follow the clinical examination; 
this is especially relevant in persons who are 
potential organ donors. An ancillary test can 
also be used in persons who are suspected of 
being brain dead but cannot be completely 
clinically examined, for example those with 
severe head injuries [7]. When the results of 
both the clinical examination and the ancil-
lary test match the BD diagnostic criteria, 
an apnoea test can be performed. Ancillary 
studies for determination of BD can also be 
performed in children [8].
Ancillary test results alone without a clinical 
examination do not suffice for a diagnosis of 
BD.
Brain death scintigraphy
Two types of scintigraphic examination can 
be used in the procedure for determining 
BD [2, 9, 10]. In the past, scintigraphy of the 
head (the brain) with hydrophilic agents 
was employed. Such radiopharmaceuticals 
[99mTc-pertechnetate, 99mTc-glucoheptonate 
and 99mTc-diethylene triamine penta-acetic 
acid (DTPA)] do not cross the blood–brain 
barrier (BBB). When using hydrophilic radio-
pharmaceuticals, only blood flow images 
of the head should be acquired. Since such 
images are sometimes difficult to interpret, 
this type of examination is now used only 
rarely when determining BD. Instead, the 
main diagnostic procedure for this purpose 
is brain perfusion scintigraphy with lipophilic 
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radiopharmaceuticals that do cross the BBB, 
e.g. 99mTc-hexamethylpropylene amine oxime 
(99mTc-HMPAO) and 99mTc-bicisate (99mTc-ECD).
Brain perfusion scintigraphy
Brain perfusion scintigraphy enables both 
presentation of the blood flow and perfu-
sion of the brain [2], making interpretation 
of examination results considerably easier. In 
line with the SNM Practice Guideline for Brain 
Death Scintigraphy, brain perfusion scintigra-
phy is primarily used as an ancillary test in de-
termining BD when the presence of certain 
clinical conditions is likely to render clinical 
assessment less reliable [11]. Such conditions 
include severe hypothermia, coma caused 
by barbiturates, electrolyte or acid–base 
imbalance, endocrine disturbances, drug 
intoxication, poisoning and neuromuscular 
blockade. BD scintigraphy may also be help-
ful in persons who are being considered as 
possible organ donors. 
The performance of brain perfusion scintig-
raphy to diagnose BD differs somewhat from 
its use in patients with neurological condi-
tions [12]: 
1. The examination must not further com-
promise the medical condition of the pa-
tient. For this reason, brain perfusion scintig-
raphy for determination of BD is usually not 
performed in persons with circulatory insta-
bility or when transport or movement could 
further compromise the person’s medical 
condition. 
2. It must be ensured that the radiopharma-
ceutical, 99mTc-HMPAO or 99mTc-ECD, is of the 
appropriate quality. Radiochemical purity 
should be determined on each vial prior to 
injection using the methods outlined in the 
package inserts. Radiochemical purity should 
be >90% for ECD and >80% for HMPAO. The 
recommended radiopharmaceutical activ-
ity is 370–1110 MBq. It is necessary to make 
sure that the correct radiopharmaceutical is 
applied.
3. The radiopharmaceutical is administered 
intravenously with the bolus technique. Such 
a technique allows acquisition of good blood 
flow images.
4. The acquisition takes place in two stages. 
First, a blood flow study of the head and neck 
is performed. Data acquisition begins simul-
taneously with the administration of the 
radiopharmaceutical. Usually, a one-minute 
series of 1- or 2-s images is acquired. Perfu-
sion images are obtained during the second 
stage, acquisition commencing 20 min after 
administration of the radiopharmaceutical. 
SPECT acquisition is most frequently used; 
only occasionally is planar scintigraphy in 
multiple projections performed. In both cas-
es, the entire brain and the brain stem must 
be visualised. 
5. Interpretation of the results of blood flow 
studies requires an experienced specialist 
who can recognise the presence or lack of 
activity in the brain. Interpretation of perfu-
sion images is less complicated. If activity in 
the brain and the brain stem does not appear 
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on the perfusion images, the examination re-
sult is compatible with BD.
Brain perfusion scintigraphy for 
determination of brain death – our 
experience
New legislation regarding the use of brain 
perfusion scintigraphy as an ancillary test in 
the process of determining BD was adopted 
in Slovenia in 2001. Prior to that, BD scintig-
raphy was used only rarely for this purpose. 
Since 2001, brain perfusion scintigraphy has 
been performed on 30–40 persons a year in 
whom the findings of clinical examination 
were compatible with BD. Between 2001 
and 2008, a total of 259 examinations in 253 
persons (174 men and 79 women) were per-
formed [13]. Patients were on average 41±19 
years old; 38 (15%) were younger than 20. 
Complete discontinuation of brain perfusion 
was established in 233 (90%) persons; in the 
remaining 26 (10%), BD was not confirmed 
because activity was present in a small or 
large part of the brain. Brain perfusion scin-
tigraphy was repeated after 1–8 days in six 
of these patients. Upon re-examination, no 
activity was visible in the brain in any of the 
patients.
In the Ljubljana University Medical Centre, 
Department for Nuclear Medicine, brain per-
fusion scintigraphy in the diagnostic process 
for determining BD is performed as follows: 
A request for BD scintigraphy: The nuclear 
medicine physician who receives a request 
for BD scintigraphy asks the radiopharmacy 
unit to prepare a radiopharmaceutical. The 
patient’s ward is asked to prepare the patient 
for transport to the Department for Nuclear 
Medicine within one hour. The schedule of 
work on the gamma camera is rearranged if 
necessary.
Preparation of the radiopharmaceutical: The 
radiopharmacist needs about one hour to 
synthesise stabilised 99mTc-HMPAO and per-
form quality control. A radiochemical purity 
of at least 80% is required.
Transportation and positioning of the patient 
to the gamma camera: When the radiophar-
maceutical has been prepared, the physician 
asks the patient’s ward to bring over the pa-
tient. The transportation usually takes around 
10 min. The patient is carefully moved from 
the bed to the gamma camera table and his 
or her head is fastened.
Radiopharmaceutical administration: Most 
patients already have an intravenous line 
inserted. We check whether the intravenous 
line is unobstructed, apply the stabilised 
99mTc-HMPAO, activity 600 MBq (proportion-
ately less in children), and flush the system 
with saline solution.
Image acquisition: A blood flow study is 
usually not performed. SPECT acquisition is 
initiated 15 min after the radiopharmaceutical 
administration and must encompass the 
entire brain, including the brain stem. The 
acquisition is usually performed on a double-
head gamma camera with the following 
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acquisition parameters: time per view, 20 s; 
no. of views, 2×32; matrix size, 128×128; 
zoom, 1.23; orbit, non-circular.
Reconstruction: The quality of the raw images 
is examined. If the images meet quality stan-
dards, a reconstruction is made. Iterative re-
construction is performed, with 12 iterations 
and 4 subsets. At the same time, the exam-
inee is moved from the gamma camera to his 
or her bed. 
Interpretation and reporting: Assessment of 
the scintigrams that have been obtained is 
straightforward (Fig. 1). Absence of activity in 
the brain and the brain stem is concordant 
with a diagnosis of BD. 
The duration of the procedure is approxi-
mately 2 h. 
Summary 
Brain death scintigraphy is one of the ancil-
lary tests that can be used in the process of 
determining BD. The most frequently used 
scintigraphic method is brain perfusion scin-
tigraphy with 99mTc-HMPAO. The procedure 
for and the interpretation of this examination 
are relatively uncomplicated. 
A
114
B
Figure 1A, B: Brain perfusion scintigraphy in determining BD. In the first investigation (A), activity 
is present in the brain and the criterion for BD is not fulfilled. The investigation was repeated on 
the same patient after 7 days (B). Absence of activity in the brain and brain stem confirms the 
cessation of brain circulation – the result is compatible with BD
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Chapter 10
Health Care in Patients with Neurological Disorders
Claudiu Peștean 
Introduction
All medical activities are focussed on pa-
tients. Even in the contexts of medical re-
search, the medical industry and medical 
care, every effort made by those involved is 
ultimately intended to benefit patients. Nurs-
ing aims to meet patients’ needs but also to 
promote their state of health, to prevent ill-
ness, to restore health and to help the patient 
to deal with illness or even death. 
From a nursing point of view, health pro-
motion consists in all those actions that in-
fluence the lifestyle of the patient in order 
to enhance quality of life. It entails not only 
measures that help in avoiding illness, but 
also steps to encourage the patient to be 
aware of his or her health status and to teach 
behaviours that can contribute in maintain-
ing or improving health. The provision of 
pertinent information and appropriate use of 
referrals are important elements in this pro-
cess [1].
Prevention of illness means to reduce risks 
and to maintain optimal functioning of the 
individual. In addition, early detection of ill-
ness is essential. For these purposes, educa-
tional programmes are needed, as well as 
health assessments at different levels and in 
different areas of interest [1].
By definition, in the ill patient these aims 
have not been accomplished, so the first pri-
ority is to assist in restoration of health. The 
specific activities employed to achieve this 
end represent the core of nursing practice; 
they start with those actions designed to 
assist in early detection of disease and end 
with patient education during the recovery 
process, which is very important in helping 
the patient to maintain his or her recovered 
health [1].
Nursing care
Nursing care consists in the nursing process. 
The nursing process should be constructed 
on the basis of a very strong relation with 
the patient and with the family or caregivers, 
and patients should be partners in the de-
sign and implementation of the process [1]. 
Nursing care involves a holistic approach to 
patients and their problems, as is underlined 
by most papers on nursing theory [2]. It is 
considered simultaneously to be both an art 
and a science [1]. In order to provide effective 
nursing care, it is necessary to have special 
skills such as determination, empathy, critical 
thinking abilities, and comprehensive medi-
cal knowledge. 
At the same time, the nursing process is a 
systematic and accurate method for provi-
sion of suitable medical care. Theoretical 
knowledge and practical skills are deployed 
with the aim of developing a strategy that 
will be most effective in helping the patient 
to recover health and also in teaching the pa-
tient how to maintain this state in collabora-
tion with those close to him or her and taking 
into account all the environmental factors 
that influence the patient’s life. The nursing 
process starts as all systematic methods start, 
with accurate documentation and a research 
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step, the so-called nursing assessment. Once 
the assessment has been completed, the 
practitioner will establish the nursing diag-
nosis, identifying the actual but also the po-
tential health problems. With these problems 
as input data, the nursing plan is established 
and applied, with inclusion of all nursing 
interventions to be imposed. Based on this, 
one can conclude that nursing care is an in-
dividualised process adjusted according to 
each patient’s needs. In the final part of the 
process – evaluation – the effectiveness of 
the implemented plan is assessed in order to 
determine the achievement of goals. Bear-
ing in mind these steps, the nursing process 
can be characterised as a systematic process, 
comprising an ordered sequence of activi-
ties. It is also a dynamic process because of 
the extensive interaction and the overlap be-
tween the nursing steps. 
The nursing process is interpersonal in na-
ture, being based, as already mentioned, 
on the complex relation between the prac-
titioner and the patient and being patient 
focussed and not task centered [1]. While the 
process is focussed on the patient, it is out-
come oriented because its aim is to achieve 
the goals identified as benefitting the pa-
tient; this is very important because knowing 
the outcomes that may be expected, nursing 
actions can be prioritised and nursing care 
successfully provided. 
The nursing process should be universally 
applicable and able to respond to a wide 
variety of individuals/patients and situations. 
The typical standardisation of the nursing 
process involves four main steps: assess-
ing, diagnosing, outcome identification and 
planning, and evaluating (Fig. 1).
Assessing
During the assessment, data are collected re-
lating to the patient’s health status, ability to 
manage his or her healthcare and the need 
for nursing care. In this phase a pertinent and 
comprehensive database is created which 
provides the starting point for the nursing 
plan (Fig. 1). Assessment is not limited to the 
initial part of the nursing care process; rather 
it should be ongoing because the health sta-
tus of the patient may change quickly, new 
information may be obtained and some in-
formation may no longer be relevant owing 
to changes that occur during the attainment 
of cure. The person who assesses the health 
status of patients will collect the data dur-
ing a comprehensive interview designed to 
gather information on the patient, the fam-
ily, and the environment, thereby providing 
a holistic perspective. The information is then 
prioritised according to the patient’s imme-
diate needs or how the interviewer antici-
pates the situation developing. Furthermore, 
the assessment is not restricted only to the 
interview. It is also based on data collected 
using an observational method, i.e. the per-
son who assesses the patient will analyse the 
patient’s condition, and on the results of evi-
dence-based techniques such as the nursing 
examination and measurements of specific 
medical parameters. 
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The recorded data are critically evaluated 
to detect all possible forms of bias, possible 
abnormal findings, possible inconsistencies, 
and missing information. The data will be 
structured upon significance-based criteria. 
Usually during the initial assessment the fo-
cus is on a specific problem. It is also possible 
to encounter physiological or psychological 
emergencies (as often occurs in neurology) 
and in these circumstances the assessment 
will concentrate on life-threatening prob-
lems. When the nursing process continues 
over a longer period, the initial assessment 
may be followed by further assessment activ-
ities designed to evaluate the patient’s status 
and compare it with the initial one. This is not 
so relevant in diagnostic nuclear medicine 
for neurological disorders, but it could be ap-
plied as a phase in the nursing process im-
plemented by the nursing team who assess 
the patient in the neurology department and 
send the patient for specific nuclear medi-
cine procedures. The collected data may be 
subjective, taken from the patient’s perspec-
tive, or objective, i.e. measurable and observ-
able. Both types of data should be collected 
because they complement one another [1].
Diagnosing
Upon completion of data collection, all the 
information is analysed and synthesised. A list 
of suspected problems, potential problems 
and risk factors is created and resources and 
strengths are identified as the basis for health 
promotion and health recovery actions [1] 
(Fig. 1). This second step of the nursing pro-
cess is termed nursing diagnosis. It is good 
to use a body systems approach to organise 
assessment data in order to better detect 
nursing problems [1]. The nursing diagnosis 
comprises all the identified problems that the 
nurse can treat independently. These prob-
lems may change from day to day in accor-
dance with the patient’s response to illness 
and the provided health care. Usually the 
written nursing diagnosis has two elements: 
the patient’s problem and its cause, i.e. the 
etiology; in addition, a third element can be 
included, namely the characteristics of the 
problem [1]. The nursing diagnosis should be 
critically evaluated and validated. When ap-
propriate, the nursing diagnosis may also be 
validated by the patient. This is one more ex-
ample of how the patient is a partner in the 
nursing process, not merely a client.
Outcome identification and planning
After the health problems have been identi-
fied and prioritised, the nursing actions can 
be planned (Fig. 1). In this stage the out-
comes will be established and the appro-
priate nursing interventions will be planned 
according to nursing theory and evidence-
based nursing guidelines. The nursing plan 
will be communicated to the patient and to 
the health care team. The nursing plan aims 
to prevent, solve or reduce a patient’s health 
problem and to achieve the patient’s expec-
tations relating to health [1]. 
During this step of the nursing process the 
first intention is to identify the expected out-
comes, which are individualised on the basis 
of the patient’s characteristics and condition. 
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When identifying the anticipated outcomes, 
the first partner is the patient and then the 
family, who can subjectively formulate their 
expectations. Starting from the diagnosis, 
outcomes may be derived in order to re-
spond to the patient’s needs. The outcomes 
will be identified on the basis of clinical ex-
pertise, scientific and medical evidence, 
associated risks, costs and benefits, the pa-
tient’s values and ethical considerations. The 
time points by which these outcomes should 
be met are then established. The identified 
outcomes may be modified if this is necessi-
tated by changes in the status of the patient. 
All the above will be documented [1]. 
In order to meet the expected outcomes, the 
patient will need professional help. Nursing 
interventions must be established that are 
appropriate in the context of the nursing 
diagnosis. These interventions must take 
account of nursing abilities, available time 
and resources and must be safe, efficient, re-
alistic, in accordance with research findings 
and standards of care, compatible with all 
the patient’s values and beliefs, acceptable 
to the patient and compatible with other 
therapeutic activities. Nursing interventions 
may be nurse initiated, when no physician’s 
order is needed and the intervention is based 
only on the nursing diagnosis, or physician 
initiated, when the nursing personnel imple-
ment interventions ordered by the physician 
in response to the medical diagnosis. 
The nursing plan should be documented 
in written form, which will help the nursing 
team to deliver goal-oriented, pertinent 
nursing care and will assist in standardisation 
of the activities requested to help the patient.
Implementing
In this step of the nursing plan, all the activi-
ties planned on the basis of the information 
gathered in the previous steps should be 
implemented by the nursing team (Fig. 1). 
The nurse will have the role of health care 
coordinator. Patients are seen by various spe-
cialists during the provision of medical care 
and each of them focusses on different as-
pects. The nurse needs to summarise all the 
findings and recommendations from all the 
healthcare professionals and to prepare pa-
tients and their families to participate maxi-
mally in the plan of care. The nurse may also 
have an important role in liaising between 
the members of the medical team. When im-
plementing the nursing plan, critical thinking 
is necessary: nursing personnel should iden-
tify the best means of implementation and 
assess whether the interventions are indeed 
supported by research findings in the field of 
interest. If, during monitoring, new evidence 
arises relating to the patient’s response, the 
plan should be modified accordingly [1].
Evaluating
Evaluation of the achieved outcomes estab-
lished within the nursing plan is very impor-
tant since this step assesses the success of 
nursing care and the need to correct, change, 
improve or continue the nursing care activi-
ties (Fig. 1). It is important that evaluation is 
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performed as early as possible; postponing 
it until just before patient discharge can lead 
to failure to implement modifications in a 
timely manner. The evaluation is based on 
various criteria and standards designed to 
assess the accomplishment of desired out-
comes. Final data are collected by nursing 
personnel in order to evaluate the success 
of the nursing plan. If all the outcomes have 
been achieved and no additional nursing di-
agnostics are identified, the nursing process 
may be closed. Very often, however, the pro-
cess must be continued owing to failure to 
achieve the established outcomes. The nurs-
ing plan then needs to be reviewed and re-
vised as necessary; this revision may include 
the deletion or modification of nursing diag-
noses, alteration of the expected outcomes 
so that they are more realistic, adjustment of 
the time points for achievement of specified 
outcomes and alteration of nursing interven-
tions [1].
Neurological care
In this section we shall review those neuro-
logical disorders more often addressed in 
diagnostic nuclear medicine departments 
using specific radiotracers described earlier 
in the guide. The main clinical characteristics 
of each disorder and the appropriate nursing 
interventions will be summarised.
Alzheimer’s disease
Alzheimer’s disease is a common neurologi-
cal disorder that affects a high percentage of 
elderly persons and accounts for more than 
half of cases of dementia. The prognosis is 
very poor. Initial signs and symptoms are in-
sidious and include memory loss. There may 
also be difficulty in learning and memorising 
new information, difficulty in concentrating 
and impaired hygiene. Gradually, progression 
to severe signs and symptoms occurs, with 
impairments of linguistic and spatial abili-
ties and appearance of complex symptoms. 
These include difficulty in abstract thinking, 
difficulty in performing activities that require 
judgment, deterioration in motor function 
and coordination, impaired ability to read 
and write, disorientation and performance of 
repetitive actions [3, 4].
The nursing personnel will focus on support-
ing the patient to maintain present abilities 
and to compensate for those abilities that 
have been lost. The patient and his or her 
family will be assisted in establishing an ef-
fective communication system according 
to the altered cognitive abilities. Emotional 
support will be offered. The patient will be 
protected from injuries by providing a safe 
environment. The patient will be encouraged 
and taught to perform physical exercises to 
maintain physical abilities. Appropriate infor-
mation about the disease will be provided to 
the patient and to the family [4].
Parkinson’s disease
The early symptoms of Parkinson’s disease 
are non-specific and include slower walk-
ing and dressing and non-motor symptoms 
such as disturbed sleep, anxiety and depres-
sion. The most obvious symptoms are bra-
dykinesia (lack of spontaneous movements, 
Chapter 10     Health Care in Patients with Neurological Disorders
EA
NM
121
lack of facial expression, reduced arm swing), 
rigidity and rest tremor; although the last-
mentioned symptom is the most frequent, 
still 20% of patients do not display it [3]. 
Parkinson’s disease is often accompanied by 
dementia.
The nursing personnel should initiate ap-
propriate interventions to help the patient 
to cope with these symptoms. An efficient 
communication system should be estab-
lished that will enable patients to adjust 
communication in accordance with their al-
tered cognitive abilities. Emotional support 
should be provided. The patient should be 
protected from potential injuries by creation 
of a safe environment and should be encour-
aged to perform physical activities so as to 
maintain mobility and physical performance. 
Physiological support will be provided: the 
patient and the family will be taught about 
the disease and any concerns should be lis-
tened to and addressed through appropriate 
advice [4].
Epilepsy
The symptoms of epilepsy differ mainly 
due to variations in the origin of pathologi-
cal electrical discharges in the brain. There 
are two main forms of epilepsy: generalised 
epilepsy, in which the abnormal electric dis-
charge arises in the deep structures of the 
brain and spreads throughout the entire cor-
tex, and focal epilepsy, in which a localised 
area of the brain is involved. The typical major 
symptom of an epileptic patient is the tonic-
clonic seizure, formerly known as grand mal 
seizure [3, 4]. Depending on the localisation 
and duration of the abnormal electrical dis-
charge, the symptoms may be: severe stress, 
nausea, a sinking sensation in the stomach, 
a dreamy feeling, visual sensations, unusual 
taste, unintelligible speech, confusion, a loud 
cry (before generalised tonic-clonic seizure), 
tongue-biting, loss of consciousness, inconti-
nence and apnoea. After the seizure the pa-
tient may complain of fatigue, headache and 
weakness and may fall into a sleep [4].
Given this variety of symptoms, the nursing 
personnel should have good knowledge of 
this complex disease so that they can sup-
port the patient in dealing with, and teach 
the family how to react during, the epileptic 
attack. First, the patient should be encour-
aged to express his or her feelings about the 
condition; support will be offered to enable 
the patient to understand the disease. The 
importance of compliance with the pre-
scribed medication must be underlined and 
the safety and efficacy of the medication 
should be stressed. The drug blood levels 
should be checked regularly [4].
The family will be instructed to avoid restrain-
ing the patient during an epileptic seizure, to 
lie the patient down, to place something soft 
under the head, to remove hard objects from 
the vicinity of the patient, to ensure an open 
airway by turning the patient’s head appro-
priately, and, if the mouth is open, to place 
a soft object between the teeth so as to pro-
tect the tongue [4].
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Cerebral ischaemia and stroke
Cerebral stroke is the irreversible interruption 
of blood supply to the brain tissue caused by 
two main pathological events: occlusion of 
arteries, termed cerebral ischaemia, and ce-
rebral haemorrhage, the latter being much 
more destructive than the former [3]. When 
the blood flow to the brain is reduced, isch-
aemia occurs, which is a reversible condition; 
if the condition is severe or prolonged, cell 
death ensues, which is termed infarction. If 
complete recovery from ischaemia occurs 
within minutes or hours, the episode is re-
ferred to as a transient ischaemic attack. If 
the ischaemic condition lasts more than 24 
hours, neurologically one speaks of stroke [3]. 
The associated symptomatology varies 
greatly depending on the involved arterial 
branch (and the location and size of the af-
fected brain territory) and the length of time 
for which the ischaemia persists. The main 
neurological symptoms and signs in brain 
ischaemia are as follows: In middle cerebral 
artery ischaemia there may be loss of use of 
and feeling in the contralateral face and arm, 
dyslexia, dysphasia, dysgraphia and dyscal-
culia. Anterior cerebral artery ischaemia pro-
duces loss of use of and feeling in the con-
tralateral lower limb. Contralateral homony-
mous hemianopia is suggestive of posterior 
cerebral artery ischaemia. Internal carotid ar-
tery ischaemia involves the face, arms or legs 
with or without homonymous hemianopia. 
Monocular loss of vision indicates ophthal-
mic artery occlusion. Vertebrobasilar artery 
ischaemia produces double vision, facial 
numbness or weakness, vertigo, ataxia, bilat-
eral loss of use or feeling of arms and legs, 
dysphagia or dysarthria, depending on the 
affected cranial nerve. Finally, small vessel 
ischaemia may produce pure loss of use of 
or feeling in the contralateral arm and leg [3].
Nursing interventions are complex and dif-
fer according to the type and localisation 
of ischaemia. The airway and oxygenation 
should be maintained and constricting 
clothes should be removed. In unconscious 
patients the lateral position should be ad-
opted, and mechanical ventilation or oxy-
gen should be provided if necessary. The 
vital signs and neurological status should be 
monitored, including blood pressure, heart 
rate, respiratory movements, pain, pupillary 
changes, sensory function and speech. The 
nursing personnel must pay attention to 
the electrolyte and fluid balance and ensure 
adequate nutrition (in terms of quantity and 
quality). Gastrointestinal activity should also 
be monitored, with attention to the diet in 
order to ensure efficient digestion and elimi-
nation. Adequate hygiene is to be ensured 
through specific care actions to ensure that 
the body, eyes and mouth remain clean. 
The nurse must pay special attention to the 
patient’s position, and this is especially im-
portant in unconscious patients. The body 
is to be aligned in the correct position, and 
special attention is required to avoid pressure 
sores and to prevent pneumonia by chang-
ing the patient’s position regularly. Patients 
will be taught and encouraged to perform 
exercises. Communication with the patient 
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is to be established and maintained accord-
ing to the patient’s abilities; the family will 
be instructed how to communicate with the 
patient and psychological support will be of-
fered [4].
Multiprofessional aspects of nuclear 
medicine practice related to neurological 
diseases
Healthcare systems are becoming more 
complex owing primarily to scientific and 
technical progress, but also because of so-
cial and economic factors related to health 
insurance systems, societal factors such as 
patients’ expectations and society’s demands 
on the medical system. It is impossible for 
one individual to cover all necessary aspects 
of healthcare, especially in the age of ultra-
specialisation. Collaborative multidisciplinary 
work is essential and will provide benefits 
to patients on the basis of the expertise of 
different professions, including physicians, 
nurses, therapists, technologists, social 
workers, etc. [5]. Effective nuclear medicine 
practice in relation to neurological diseases 
presupposes efficient interdisciplinary work 
between the referral team, the neurologist, 
the nursing personnel specialised in neurol-
ogy, the nuclear medicine team (in which 
the nuclear medicine physician will have an 
in-depth knowledge of neurology) and other 
specialist personnel, among whom the tech-
nologists have an essential role. Neurological 
patients are patients with special needs and 
the technologist, as the person in the medi-
cal team who has the most interaction with 
the patients, should therefore have a strong 
knowledge of the field and possess the skills 
to deal with this category of patient. In re-
cent decades a change towards overlapping 
of competencies or responsibilities has been 
noted in medical professions, and this trend 
may be regarded as normal in such a dy-
namic and challenging profession as nuclear 
medicine [6].
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Figure 1: Schematic r
Evaluating
- measuring how the patient has achieved 
the established outcomes
- identifying the factors that contributed to 
the success or failure of the nursing plan
- modifying the plan as needed
The nursing process is CLOSED and 
the patient has recovered his or 
her previous state of health 
The established outcomes are met
Reassessing
The established outcomes are not met
Changing the 
outcomes
Deletion or changing  
of nursing diagnoses
Assessing
- identify priorities for assessing the process
- systematic collection of data:  
nursing history, nursing findings
- continuous updating of database
- data validation and communication to 
medical team
Additional data input occurs
Implementing
- applying the established plan of nursing interventions according 
to and/or based on available resources, nurses’ abilities, standards 
of nursing, research findings and ethical and legal influences
- data are continuously collected and the nursing plan is  
modified as needed 
- all actions and decisions are documented and communicated to 
the patient/family and to the medical team
Diagnosing
- interpretation of collected data
- identification of health problems
- formulation and validation of nursing 
diagnoses
- prioritisation of nursing diagnoses
Outcome Identification and 
Planning
- the patient/family and the nursing 
personnel work together to establish 
priorities
- identification of expected patient outcomes
- establishment of evidence-based nursing 
interventions according to nursing plans 
and in congruence with other therapies
- recording and communication of nursing 
plan
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